This O
clock O
will O
be O
instrumental O
for O
understanding O
the O
biology O
of O
ageing O
and O
will O
allow O
modulation O
of O
its O
ticking O
rate O
and O
resetting O
the O
clock O
in O
vivo O
to O
study O
the O
impact O
on O
biological O
age O

About O
30% O
of O
newly O
diagnosed O
PCa O
patients O
receive O
RT O
with O
a O
curative O
intent O

Specifically O
, O
we O
focus O
on O
the O
role O
epigenetics O
may O
play O
in O
multigenerational O
and O
transgenerational O
transmission O
of O
environmentally O
induced O
health O
effects O

Specifically O
, O
they O
do O
not O
permit O
the O
unbiased O
characterization O
of O
non-linear O
epigenetic O
ageing O
trends O
across O
entire O
life O
spans O
, O
a O
critical O
question O
underlying O
this O
field O
of O
research O

From O
cytoplasmic O
inheritance O
to O
the O
epigenetics O
mechanisms O

268 O
: O
Epigenetics O
has O
been O
a O
buzzword O
in O
science O
for O
many O
years O
, O
but O
20 O
years O
ago O
, O
the O
idea O
that O
epigenetic O
gene O
regulation O
could O
be O
a O
driver O
in O
evolutionary O
processes O
was O
only O
a O
mischievous O
glint O
in O
a O
Lamarckian O
eye O

15 O
(SD O
2 O

743 O
: O
Cellular O
processes O
that O
control O
transcription O
of O
genetic O
information O
are O
critical O
for O
cellular O
function O
, O
and O
are O
often O
implicated O
in O
psychiatric B-Disease
and O
neurological O
disease B-Disease
states O

A O
plethora O
of O
novel O
strategies O
for O
addressing O
epigenetics O
in O
cancer B-Disease
therapy O
for O
immuno-oncological O
complications O
are O
currently O
available O
- O
ranging O
from O
basic O
treatment O
to O
epigenetic O
editing O

In O
this O
study O
, O
target O
site O
prediction O
tools O
for O
two O
major O
epigenetic O
mechanisms O
comprising O
histone O
modification O
and O
DNA O
methylation O
are O
reviewed O

There O
is O
an O
association O
between O
adverse O
environmental O
stimuli O
, O
such O
as O
early O
life O
stress O
, O
and O
epigenetic O
modification O
of O
gene O
expression O

The O
article O
also O
points O
out O
incorrect O
perceptions O
and O
media O
hypes O
among O
biological O
epigeneticists O
and O
calls O
attention O
to O
an O
apparent O
bias O
among O
scientific O
journals O
that O
prefer O
papers O
that O
promote O
transgenerational O
epigenetic O
inheritance O
over O
articles O
that O
critique O
it O


602 O
: O
Multiple O
genes O
and O
pathways O
are O
involved O
in O
the O
pathogenesis O
of O
hypertension B-Disease

Finally O
, O
we O
examine O
in O
vitro O
studies O
that O
model O
the O
impact O
of O
asthma-associated O
exposures O
on O
the O
epigenome O

We O
then O
review O
the O
short-comings O
of O
MS-AFLP O
and O
suggest O
alternative O
techniques O
that O
might O
address O
some O
of O
these O
limitations O

Areas O
covered O
: O
In O
this O
article O
, O
the O
authors O
briefly O
review O
genetic O
models O
of O
schizophrenia B-Disease
, O
focusing O
on O
examples O
of O
how O
new O
therapeutic O
strategies O
have O
been O
developed O
from O
them O

Recent O
progress O
in O
molecular O
biology O
, O
including O
next-generation O
sequencing O
( O
NGS O
) O
- O
based O
analyses O
, O
enables O
the O
analysis O
of O
gene O
expression O
profiles O
at O
a O
single O
cell O
level O

Such O
insight O
is O
crucial O
to O
enable O
development O
of O
evidence-based O
therapeutic O
options O

Recent O
research O
in O
this O
area O
has O
led O
to O
excitement O
and O
questions O
about O
medical O
applications O
of O
epigenetics O

In O
the O
beginning O
, O
epigenetics O
was O
viewed O
as O
a O
phenomenon O
above O
and O
beyond O
genetics O

In O
this O
chapter O
, O
we O
discuss O
relevant O
aspects O
for O
the O
design O
of O
DNA O
methylation O
studies O
and O
delineate O
essential O
steps O
for O
their O
analysis O

514 O
: O
Background O
: O
Modulating O
the O
epigenome O
has O
long O
been O
considered O
a O
potential O
opportunity O
for O
therapeutic O
intervention O
in O
numerous O
disease B-Disease
areas O
with O
several O
approved O
therapies O
marketed O
, O
primarily O
for O
cancer B-Disease

I'm O

In O
particular O
, O
his O
research O
focuses O
on O
developmental O
origins O
of O
health O
and O
disease B-Disease
with O
an O
emphasis O
on O
environmental O
exposures O
and O
epigenetic O
mechanisms O

Conclusion O
: O
These O
results O
point O
toward O
a O
crucial O
role O
of O
criticality O
to O
enhance O
the O
system O
responsivity O
, O
resulting O
in O
both O
energy O
transitions O
and O
structural O
rearrangements O

Many O
of O
these O
phenomena O
have O
involved O
cases O
of O
non-Mendelian O
inheritance O
and O
have O
often O
been O
dismissed O
as O
mere O
curiosities O
prior O
to O
the O
elucidation O
of O
their O
molecular O
mechanisms O

The O
cell-specific O
epigenomics O
and O
transcriptional O
patterns O
identified O
serve O
as O
a O
foundation O
for O
future O
studies O
on O
immune O
dysregulation O
in O
diseases O
and O
aging O

Most O
surprisingly O
, O
some O
epigenetic O
modifications O
may O
also O
be O
heritable O
via O
germ O
cells O
across O
generations O

This O
is O
poised O
to O
change O
with O
the O
development O
of O
new O
tools O
and O
concerted O
efforts O
by O
researchers O
across O
disciplines O
that O
have O
led O
to O
a O
better O
understanding O
of O
epigenetic O
mechanisms O
and O
comprehensive O
maps O
of O
epigenomic O
variation O

520 O
: O
Aydan O
Bulut-Karslioglu O
is O
a O
Group O
Leader O
at O
the O
Max O
Planck O
Institute O
for O
Molecular O
Genetics O
, O
Germany O
, O
where O
her O
research O
focuses O
on O
the O
epigenetic O
and O
metabolic O
mechanisms O
regulating O
embryonic O
development O

Epigenetic O
changes O
are O
reversible O
and O
include O
key O
processes O
of O
DNA O
methylation O
, O
chromatin B-Disease
modifications I-Disease
, O
nucleosome O
positioning O
, O
and O
alterations O
in O
noncoding O
RNA O
profiles O

We O
used O
linear O
regression O
to O
assess O
the O
relationship O
between O
these O
two O
estimates O
of O
biological O
age O
and O
average O
daily O
time O
spent O
sedentary O
, O
number O
of O
sit-to-stand O
transitions O
, O
and O
step O
count O

Fitting O
the O
mixture O
with O
expectation-maximization O
algorithm O
finally O
provides O
inferred O
composition O
of O
subclones O

While O
there O
are O
a O
variety O
of O
methods O
to O
perform O
genome-wide O
analyses O
of O
DNA O
methylation O
in O
model O
organisms O
, O
this O
is O
still O
a O
challenging O
task O
for O
non-model O
organisms O
without O
a O
reference O
genome O

246 O
: O
Epigenetic O
inheritance O
refers O
to O
changes O
in O
gene O
expression O
that O
are O
heritable O
across O
generations O
but O
are O
not O
caused O
by O
changes O
in O
the O
DNA O
sequence O

Owing O
to O
extensive O
mutations O
acquired O
over O
repeated O
cell O
divisions O
, O
tumor B-Disease
cells O
selectively O
accumulate O
metabolites O
that O
regulate O
the O
activity O
of O
key O
epigenetic O
enzymes O
to O
mediate O
activation/suppression O
of O
genes O
associated O
with O
T-cell O
function O
and O
macrophage O
polarization O

Epigenetic O
modifications O
are O
crucial O
for O
packaging O
and O
interpreting O
the O
genome O
, O
and O
they O
have O
fundamental O
functions O
in O
regulating O
gene O
expression O
and O
activity O
under O
the O
influence O
of O
physiologic O
and O
environmental O
factors O

Dietary O
intake O
has O
also O
presented O
significant O
influence O
on O
human O
health O
and O
disease B-Disease
development O
and O
nutritional O
modifications O
have O
proven O
important O
in O
prevention O
, O
but O
also O
the O
treatment O
of O
disease B-Disease

247 O
: O
Cancer B-Disease
arises O
through O
the O
accumulation O
of O
both O
genetic O
and O
epigenetic O
alterations O

) O
research O
approaches O
are O
vital O
for O
understanding O
the O
hierarchical O
complexity O
of O
human O
biology O
and O
have O
proven O
to O
be O
extremely O
valuable O
in O
cancer B-Disease
research O
and O
precision O
medicine O

We O
then O
describe O
the O
techniques O
that O
have O
been O
used O
to O
investigate O
DNA O
methylation O
in O
marine O
fishes O
to O
date O
and O
highlight O
some O
new O
techniques O
that O
hold O
great O
promise O
for O
future O
studies O

Fluorescence O
microscopy O
represents O
an O
attractive O
complementary O
approach O
to O
characterize O
epigenetics O

In O
some O
circumstances O
, O
self-templating O
can O
fuel O
disease B-Disease
, O
but O
it O
also O
permits O
access O
to O
multiple O
activity O
states O
from O
the O
same O
polypeptide O
and O
transmission O
of O
that O
information O
across O
generations O

Today O
, O
this O
concept O
has O
been O
so O
thoroughly O
assimilated O
that O
we O
struggle O
to O
still O
see O
how O
surprising O
this O
finding O
actually O
was O
: O
all O
cellular O
phenotypes O
naturally O
occurring O
in O
one O
person O
are O
generated O
from O
genetic O
uniformity O
, O
and O
thus O
are O
per O
definition O
epigenetic O

A O
statistical O
interaction O
between O
marijuana-years O
and O
alcohol O
consumption O
on O
GAA O
was O
observed O
( O
P O
= O
0 O

Although O
it O
has O
long O
been O
known O
that O
in O
vitro O
conditions O
induce O
variation O
at O
several O
levels O
, O
most O
studies O
using O
such O
conditions O
rely O
on O
the O
assumption O
that O
in O
vitro O
cultured O
plant O
cells/tissues O
mostly O
conform O
genotypically O
and O
phenotypically O

Another O
interesting O
finding O
that O
resulted O
from O
the O
genome O
project O
was O
that O
the O
perceived O
level O
of O
complexity O
of O
humans O
was O
not O
accompanied O
with O
a O
relative O
increase O
in O
the O
number O
of O
genes O
when O
compared O
to O
' O
lower O
species O
' O

Well O
thought O
out O
experimental O
designs O
that O
include O
complementary O
gene O
expression O
studies O
, O
and O
the O
improvement O
of O
genomics O
resources O
for O
the O
target O
group O
, O
promise O
to O
maximize O
the O
effect O
of O
future O
RRBS O
studies O

The O
aim O
of O
this O
article O
is O
to O
review O
the O
major O
epigenetic O
findings O
in O
motor O
neuron O
diseases O
and O
major O
hereditary B-Disease
muscular I-Disease
dystrophies I-Disease

Trichostatin O
A O
, O
a O
histone O
deacetyltransferase O
inhibitor O
( O
HDACi O
) O
, O
leads O
to O
AMP O
β-defensin O
2 O
( O
HBD2 O
) O
gene O
up-regulation O
in O
human O
epithelial O
cells O
suggesting O
a O
useful O
' O
epi-therapy O
' O
for O
Escherichia O
coli-induced O
intestinal O
diseases O

We O
found O
that O
some O
computed O
scores O
, O
unlike O
all O
6 O
experimental O
features O
, O
significantly O
contribute O
to O
the O
predictions O
of O
both O
models O

417 O
: O
Background O
: O
Premature O
infants O
are O
highly O
vulnerable O
to O
infection B-Disease

The O
history O
of O
epigenetics O
is O
briefly O
reviewed O
, O
together O
with O
the O
key O
issues O
in O
the O
field O
today O

Highly O
resistant O
to O
conventional O
chemo- O
and O
radiotherapy O
, O
CSCs O
have O
heterogeneity B-Disease
and O
can O
migrate O
to O
different O
organs O
and O
metastasize O

However O
, O
the O
up-to-date O
results O
can O
help O
us O
to O
better O
understand O
acupuncture O
's O
clinical O
applications O
and O
laboratory O
research O

Secondly O
, O
we O
explore O
how O
epigenetics O
narrows O
definitions O
of O
colonial O
harm O
through O
the O
optic O
of O
molecular O
trauma B-Disease
, O
reproducing O
conditions O
in O
which O
Indigenous O
people O
are O
made O
intelligible O
through O
a O
lens O
of O
" O
damaged O
" O
bodies O

Epigenetic O
studies O
accomplished O
in O
the O
last O
few O
years O
have O
exposed O
a O
very O
complex O
multilayered O
regulatory O
mechanism O
that O
is O
able O
to O
answer O
previously O
puzzling O
questions O
in O
biology O

Results O
from O
in O
vitro O
experiments O
showed O
that O
two O
clocks O
( O
Levine O
and O
Lin O
) O
were O
accelerated O
in O
accordance O
with O
two O
hallmarks O
of O
aging-cellular O
senescence B-Disease
and O
mitochondrial O
dysfunction O

While O
key O
genes O
and O
signaling O
pathways O
that O
lead O
to O
the O
onset O
of O
sexual O
maturation O
are O
known O
, O
the O
molecular O
mechanisms O
that O
determine O
when O
an O
individual O
enters O
puberty O
are O
only O
beginning O
to O
be O
understood O

Moreover O
, O
additional O
research O
on O
non-genetic O
inheritance O
draws O
attention O
to O
a O
variety O
of O
means O
whereby O
differences O
can O
be O
inherited O
in O
offspring O
generations O
that O
do O
not O
rely O
on O
differences O
in O
germline O
structures O

In O
this O
review O
, O
the O
early O
history O
has O
also O
been O
emphasized O
in O
order O
to O
underscore O
the O
transformation O
of O
the O
science O
of O
epigenetics O
from O
a O
phenomenon O
to O
a O
modern O
field O
of O
intense O
research O

This O
provides O
a O
rationale O
for O
the O
conservation O
of O
epigenotypes O
of O
interest O
, O
thus O
contributing O
to O
agrobiodiversity O
preservation O
through O
conservation O
and O
(epi)genetic O
monitoring O

This O
will O
provide O
much-needed O
information O
which O
will O
prepare O
health O
professionals O
for O
the O
introduction O
of O
epigenetic O
testing O
into O
future O
healthcare O

Genetic O
factors O
are O
important O
in O
determining O
bone O
mass O
and O
structure O
, O
as O
well O
as O
any O
predisposition O
for O
bone O
degradation O
and O
OVF O

Despite O
significant O
advancements O
towards O
epigenomic O
profiling O
, O
it O
is O
challenging O
to O
understand O
how O
various O
epigenetic O
modifications O
such O
as O
chromatin B-Disease
modifications I-Disease
and O
DNA O
methylation O
regulate O
gene O
expression O

733 O
: O
Advances O
in O
genomic O
technology O
have O
enabled O
a O
greater O
understanding O
of O
the O
genetics O
of O
common O
immune-mediated O
diseases O
such O
as O
ankylosing O
spondylitis O
( O
AS O
) O
, O
inflammatory O
bowel O
disease B-Disease
( O
IBD O
) O
and O
psoriasis B-Disease

Several O
studies O
have O
demonstrated O
that O
Epigenetics O
plays O
a O
key O
role O
in O
Aging O
and O
Aging-associated O
diseases O
through O
methylation O
of O
DNA O
, O
histone O
modification O
and O
non-coding O
RNA O
( O
ncRNA O
) O

Remarkably O
, O
epigenetic-sensitive O
drugs O
may O
aid O
to O
counteract O
MDR O
in O
clinical O
setting O


Differences O
in O
the O
genome-wide O
expression O
profile O
of O
microRNAs O
were O
found O
among O
multiple O
tissues O
, O
indicating O
the O
involvement O
of O
distinct O
processes O
in O
fibromyalgia O
pathogenesis O

Ovarian O
aging O
may O
be O
best O
viewed O
as O
a O
safeguard O
against O
pathologic O
overgrowth O
, O
where O
senescence B-Disease
operates O
as O
an O
evolved O
tumor-suppression O
response O

The O
aberrant O
expression O
of O
miRNAs O
has O
also O
gradually O
become O
a O
diagnostic O
biomarker O

Comparing O
age-related O
DMCs O
and O
DHMRs O
, O
1,854 O
annotated O
genes O
showed O
both O
differential O
5mC O
and O
5hmC O
, O
including O
one O
gene O
- O
Nfic O
- O
at O
five O
CpGs O
in O
the O
same O
250 O
bp O
chromosomal O
region O

1289/EHP8793 O

While O
we O
cannot O
provide O
a O
step-by-step O
guide O
that O
fits O
all O
experimental O
setups O
and O
questions O
addressed O
, O
we O
explain O
frequent O
misconceptions O
and O
often O
overlooked O
pitfalls O

383 O
: O
Combinatorial O
patterns O
of O
epigenetic O
features O
reflect O
transcriptional O
states O
and O
functions O
of O
genomic O
regions O

Here O
, O
we O
summarize O
the O
recent O
developments O
in O
comparative O
epigenomic O
analyses O
into O
three O
major O
directions O
, O
namely O
the O
comparisons O
across O
species O
, O
the O
time-course O
of O
a O
biological O
process O
, O
and O
individuals O

51 O
for O
the O
pan-tissue O
clock O
) O

621 O
: O
The O
development O
of O
new O
blood O
vessels O
from O
pre-existing O
vasculature O
is O
called O
angiogenesis O

218 O
: O
Genetic O
background O
of O
coeliac O
disease B-Disease
has O
been O
subjects O
to O
intensive O
research O
since O
decades O

Genetic O
predisposition O
- O
prenatal O
, O
perinatal O
and O
pediatric O
environmental O
influences O
- O
microbiome O
aberration O
( O
dysbiosis O
) O
and O
immune O
dysregulation O
appear O
to O
be O
important O
elements O
in O
disease B-Disease
development O
, O
progression O
and O
maintenance O

Behavioral O
epigenetics O
shows O
that O
our O
behavior O
could O
have O
long-term O
effects O
on O
the O
regulation O
of O
the O
genome O
function O

© O
2016 O
AACR O

492 O
: O
Convincing O
evidence O
accumulated O
over O
the O
last O
decades O
demonstrates O
the O
crucial O
role O
of O
epigenetic O
modifications O
for O
mammalian O
genome O
regulation O
and O
its O
flexibility O

The O
special O
section O
is O
both O
an O
acknowledgment O
of O
the O
increasing O
prominence O
of O
genetic O
factors O
in O
family O
models O
as O
well O
as O
an O
effort O
to O
highlight O
different O
approaches O
and O
foster O
greater O
cross-pollination O
between O
approaches O

This O
could O
have O
important O
implications O
for O
the O
development O
and O
application O
of O
both O
epigenetic O
therapies O
and O
cancer B-Disease
immunotherapies O
, O
and O
combinations O
thereof O

Additionally O
, O
an O
update O
on O
the O
detection O
of O
epigenetic O
variation O
in O
plant O
cell O
cultures O
will O
be O
provided O
and O
discussed O
in O
the O
light O
of O
recent O
progress O
in O
the O
plant O
epigenetics O
field O

By O
modifying O
the O
SunTag O
framework O
of O
dCas9 O
tagged O
with O
five O
GCN4 O
moieties O
, O
each O
epigenetic O
writer O
is O
bound O
to O
scFv O
and O
target-specific O
sgRNA O
, O
and O
this O
system O
is O
able O
to O
modify O
multiple O
epigenetic O
marks O
in O
a O
target-specific O
manner O

In O
this O
review O
, O
we O
summarize O
the O
current O
evidence O
for O
epigenetic O
regulation O
of O
immune-related O
pathways O
in O
cancer B-Disease
and O
describe O
bioinformatics O
tools O
, O
informative O
visualization O
techniques O
, O
and O
resources O
to O
help O
decipher O
the O
cancer B-Disease
epigenome O

Here O
we O
discuss O
asthma O
epigenetics O
within O
a O
developmental O
perspective O
based O
on O
our O
recent O
demonstration O
that O
the O
epigenetic O
trajectory O
to O
childhood O
asthma O
begins O
at O
birth O

However O
, O
new O
studies O
show O
novel O
genomic O
imprinting O
effects O
that O
are O
brain-region- O
, O
cell-type- O
and O
age-dependent O

In O
total O
, O
124 O
samples O
were O
collected O
, O
and O
bisulfite O
modified O
to O
convert O
unmethylated O
DNA O
to O
uracil O

Areas O
covered O
: O
We O
present O
an O
overview O
of O
the O
major O
epigenetic O
mechanisms O
and O
their O
effects O
on O
the O
expression O
of O
drug O
metabolizing O
enzymes O
and O
drug O
transporters O
, O
as O
well O
as O
the O
epigenetic O
status O
of O
drug O
protein O
targets O
affecting O
therapy O
response O

This O
emerging O
evidence O
may O
have O
substantial O
biological O
and O
clinical O
implications O

Please O

Using O
selected O
examples O
, O
we O
first O
recapitulate O
key O
findings O
supporting O
the O
role O
of O
adverse O
life O
events O
, O
alone O
or O
in O
combination O
with O
genetic O
risk O
, O
in O
epigenetic O
programming O
of O
neuropsychiatric O
systems O

It O
has O
been O
shown O
that O
multiple O
histone O
modifications O
can O
predict O
gene O
expression O
and O
reflect O
future O
responses O
of O
bulk O
cells O
to O
extracellular O
cues O

Together O
with O
genetic O
prediction O
of O
appearance O
and O
biogeographic O
ancestry O
, O
epigenomic O
lifestyle O
prediction O
is O
expected O
to O
increase O
the O
ability O
of O
police O
to O
find O
unknown O
perpetrators O
of O
crime O
who O
are O
not O
identifiable O
using O
current O
forensic O
DNA O
profiling O

We O
will O
herein O
discuss O
the O
available O
data O
in O
the O
epigenetic O
differences O
leading O
to O
disease B-Disease
discordance O
in O
MZ O
twins O
for O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
, O
rheumatoid B-Disease
arthritis I-Disease
, O
and O
systemic B-Disease
sclerosis I-Disease

g O

475 O
: O
Site-specific O
nucleases O
( O
SSNs O
) O
have O
drawn O
much O
attention O
in O
plant O
biotechnology O
due O
to O
their O
ability O
to O
drive O
precision O
mutagenesis O
, O
gene O
targeting O
or O
allele O
replacement O

We O
perform O
simulations O
and O
real O
data O
analysis O
to O
compare O
different O
approaches O
, O
and O
provide O
recommendations O
for O
data O
analysis O

We O
are O
confident O
that O
dbEM O
will O
be O
very O
useful O
in O
cancer B-Disease
research O
particularly O
in O
the O
field O
of O
epigenetic O
proteins O
based O
cancer B-Disease
therapeutics O

Many O
of O
these O
genomic O
events O
are O
being O
used O
in O
cancer B-Disease
diagnosis O
, O
whereas O
others O
are O
therapeutically O
targeted O
with O
small-molecule O
inhibitors O

The O
findings O
of O
this O
work O
encourage O
prospective O
applications O
of O
conformal O
prediction O
for O
other O
epigenetic O
target O
data O
sets O

500 O
) O
per O
each O
additional O
marijuana-year O

206 O
: O
This O
article O
considers O
the O
distinctive O
features O
of O
epigenetics O
and O
discusses O
whether O
, O
as O
a O
matter O
of O
ethics O
and O
law O
, O
epigenetics O
should O
be O
considered O
separate O
from O
genetics O

Although O
the O
evidence O
points O
towards O
a O
conserved O
role O
of O
epigenetics O
in O
responding O
to O
temperature O
change O
, O
there O
appears O
to O
be O
an O
element O
of O
temperature- O
and O
species-specificity O
in O
the O
specific O
effects O
of O
temperature O
change O
on O
epigenetic O
modifications O
and O
resulting O
phenotypic O
responses O

We O
propose O
that O
the O
combined O
DNA O
methylation O
levels O
of O
these O
imprinted O
genes O
can O
be O
used O
as O
a O
diagnostic O
tool O
to O
identify O
spermatozoa O
samples O
with O
epigenetic O
defects O
which O
could O
contribute O
to O
the O
pathophysiology O
of O
RPL O
and O
the O
couple O
could O
be O
counselled O
appropriately O

114 O
: O
The O
stage O
and O
molecular O
pathology-dependent O
prognosis O
of O
breast B-Disease
cancer I-Disease
, O
the O
limited O
treatment O
options O
for O
triple-negative O
carcinomas O
, O
as O
well O
as O
the O
development O
of O
resistance O
to O
therapies O
illustrate O
the O
need O
for O
improved O
early O
diagnosis O
and O
the O
development O
of O
new O
ther O

Contact O
: O
peter O

In O
this O
context O
and O
with O
multiple O
cancer B-Disease
immunotherapeutics O
already O
evaluated O
in O
the O
clinic O
and O
a O
large O
number O
in O
various O
stages O
of O
clinical O
trials O
, O
it O
is O
imperative O
to O
comprehensively O
examine O
genomics O
data O
to O
better O
comprehend O
the O
role O
of O
immunity O
in O
different O
cancers B-Disease
in O

484 O
: O
Methylation O
induces O
epigenetic O
silencing O
of O
tumor B-Disease
suppressor O
genes O
in O
human O
lung B-Disease
cancer I-Disease

It O
is O
argued O
that O
advances O
within O
these O
3 O
areas O
will O
make O
clearer O
the O
role O
of O
DNAm O
in O
the O
link O
between O
adversity O
and O
child O
and O
adolescent O
mental O
health O

This O
is O
partly O
attributable O
to O
the O
preterm O
immune O
system O
, O
which O
differs O
from O
that O
of O
the O
term B-Disease
neonate I-Disease
in O
cell O
composition O
and O
function O

Because O
epigenetic O
alterations O
can O
be O
reversed O
by O
chemicals O
and O
activate O
gene O
expression O
, O
epigenetic O
biomarkers O
potentially O
have O
numerous O
clinical O
applications O
in O
cancer B-Disease
intervention O
and O
treatment O
and O
significant O
implications O
in O
public O
health O

309 O
: O
DNA O
methylation O
is O
an O
epigenetic O
mark O
that O
is O
indispensable O
for O
mammalian O
development O
and O
occurs O
at O
cytosine O
residues O
throughout O
the O
genome O
( O
the O
" O
methylome O
" O
) O

In O
the O
present O
study O
, O
we O
applied O
linkage O
disequilibrium O
analysis O
to O
the O
DNA O
methylation O
data O
obtained O
from O
whole-genome O
bisulfite O
sequencing O
studies O
in O
mouse O
germline O
and O
other O
types O
of O
cells O

As O
nutrients O
like O
folic O
acid O
and O
vitamin O
B(12) O
can O
influence O
an O
individual's O
epigenome O
, O
especially O
early O
in O
life O
, O
abnormal O
intakes O
of O
such O
agents O
may O
be O
involved O
in O
the O
pathogenesis O
of O
the O
idiopathic O
mental B-Disease
disorders I-Disease

Through O
the O
analysis O
of O
such O
a O
model O
, O
we O
identified O
key O
genes O
and O
regulatory O
interactions O
driving O
the O
transition O
of O
cell O
states O

50 O
, O
respectively O
, O
the O
variance O
that O
should O
be O
attributed O
to O
genetic O
influences O
is O
instead O
attributed O
to O
nonshared O
environmental O
influences O
, O
thus O
deflating O
the O
estimates O
of O
genetic O
influences O
and O
inflating O
the O
estimates O
of O
nonshared O
environmental O
influences O


Here O
we O
review O
the O
findings O
to O
date O
and O
discuss O
how O
epigenetic O
investigation O
can O
further O
our O
understanding O
of O
this O
fundamental O
aspect O
of O
human O
development O

Detecting O
how O
natural O
selection O
has O
affected O
human O
genome O
variability O
has O
proven O
to O
be O
a O
powerful O
tool O
to O
delineate O
genes O
and O
biological O
functions O
having O
played O
a O
key O
role O
in O
human O
adaptation O
, O
a O
variation O
which O
can O
also O
be O
involved O
in O
phenotypes O
of O
medical O
relevance O

608 O
: O
There O
have O
been O
considerable O
advances O
in O
uncovering O
the O
complex O
genetic O
mechanisms O
that O
underlie O
nervous B-Disease
system I-Disease
disease B-Disease
pathogenesis O
, O
particularly O
with O
the O
advent O
of O
exome O
and O
whole O
genome O
sequencing O
techniques O

Epigenetic O
regulation O
includes O
histone O
modification O
and O
DNA O
methylation O
, O
of O
which O
CpG O
island O
methylation O
can O
be O
gene-specific O
; O
in O
several O
different O
cancers B-Disease
, O
CpG O
methylation O
inhibits O
binding O
of O
the O
transcription O
machinery O
, O
causing O
silencing O
of O
a O
specific O
oncogene O
, O
which O
leads O
to O

156 O
: O
Hundreds O
of O
distinct O
chemical O
modifications O
to O
DNA O
and O
histone O
amino O
acids O
have O
been O
described O

Among O
the O
most O
critical O
of O
these O
processes O
are O
epigenetic O
mechanisms O
, O
which O
serve O
to O
link O
the O
cellular O
environment O
with O
genomic O
material O

com O
/ O
NIGMS O
/ O
NIGMS O
- O
Sandbox O

Areas O
covered O
: O
This O
article O
focuses O
on O
the O
concepts O
and O
drug O
discovery O
aspects O
of O
epigenomics O

Psychotherapy O
could O
exert O
its O
therapeutic O
effect O
in O
idiopathic O
mental B-Disease
disorders I-Disease
through O
epigenetic O
mechanisms O

Moreover O
, O
they O
can O
be O
monitored O
not O
only O
in O
the O
affected O
tissue O
, O
but O
also O
in O
body O
fluids O

In O
the O
more O
complex O
herpersviruses B-Disease
transformation O
is O
a O
consequence O
of O
the O
expression O
of O
the O
viral O
latency O
proteins O
and O
RNAs O
which O
again O
can O
have O
either O
a O
direct O
or O
indirect O
effect O
on O
epigenetic O
regulation O
of O
cellular O
expression O

With O
progress O
of O
genome O
biology O
, O
the O
applicability O
of O
the O
nearly O
neutral O
theory O
has O
expanded O

The O
final O
product O
is O
a O
start-to-finish O
tutorial O
for O
the O
researchers O
with O
limited O
experience O
in O
multi-omics O
to O
integrate O
transcriptomics O
and O
epigenetics O
data O
analysis O
into O
a O
comprehensive O
pipeline O
to O
perform O
their O
own O
biological O
research O

Thirteen O
papers O
were O
included O
in O
the O
review O

Among O
molecular O
mechanisms O
linking O
stress O
and O
aging O
, O
the O
present O
article O
reviews O
evidence O
on O
the O
role O
of O
epigenetics O
, O
biochemical O
processes O
that O
can O
be O
set O
into O
motion O
by O
stressors O
and O
in O
turn O
influence O
genomic O
function O
and O
complex O
phenotypes O
, O
including O
aging-related O
outcomes O

In O
addition O
, O
we O
take O
the O
opportunity O
to O
describe O
the O
aims O
of O
EPI-CATCH O
, O
an O
international O
COST O
action O
consortium O
composed O
by O
researchers O
from O
28 O
countries O

The O
development O
of O
epigenetic O
drugs O
requires O
a O
detailed O
knowledge O
of O
the O
processes O
that O
govern O
chromatin O
regulation O

414 O
: O
Epigenetics O
has O
become O
one O
of O
the O
major O
areas O
of O
biological O
research O

Thus O
, O
using O
binned O
libraries O
, O
based O
on O
a O
common O
set O
of O
responses O
to O
known O
drugs O
, O
a O
cost-effective O
high-throughput O
screening O
strategy O
for O
epigenetically O
active O
compounds O
from O
plants O
or O
other O
sources O
is O
described O

A O
promising O
new O
approach O
is O
to O
introduce O
Deep O
Learning O
(DL) O
for O
the O
generation O
and O
simultaneous O
computation O
of O
novel O
genomic O
features O
tuned O
to O
the O
classification O
task O

Therefore O
, O
our O
method O
has O
the O
potential O
to O
generate O
fundamental O
insights O
into O
cell O
fate O
regulation O

In O
this O
article O
, O
we O
describe O
and O
evaluate O
a O
number O
of O
techniques O
, O
and O
discuss O
possible O
future O
prospects O
of O
DNA O
amplification O
in O
the O
fields O
of O
pharmacogenetics O
and O
pharmacogenomics O

438 O
: O
The O
study O
of O
epigenetics O
, O
or O
chemical O
modifications O
to O
the O
genome O
that O
may O
alter O
gene O
expression O
, O
is O
a O
growing O
area O
of O
interest O
for O
social O
scientists O

To O
this O
end O
, O
we O
have O
implemented O
a O
computational O
pipeline O
to O
systematically O
study O
epigenetic O
variability O
and O
uncover O
regulatory O
DNA O
sequences O

Generation O
of O
enormous O
amounts O
of O
data O
has O
driven O
the O
need O
for O
more O
advanced O
storage O
solutions O
and O
shared O
access O
through O
a O
range O
of O
public O
repositories O

The O
second O
contribution O
performed O
weighted O
gene O
coexpression O
network O
analysis O
and O
identified O
6 O
significant O
modules O
of O
at O
least O
30 O
CpG O
sites O
, O
including O
3 O
modules O
with O
topological O
differences O
pretreatment O
and O
posttreatment O

Systematic O
identification O
of O
the O
valleys O
provides O
novel O
information O
for O
delineating O
the O
annotation O
of O
regulatory O
elements O

Therefore O
, O
we O
posit O
that O
epigenetic O
alterations O
and O
genetic O
defects O
do O
not O
exclude O
each O
other O
as O
a O
disease-causing O
etiology O

holism O
, O
as O
well O
as O
simplicity O
vs O

The O
goal O
of O
this O
study O
is O
to O
develop O
and O
demonstrate O
a O
more O
detailed O
clonality O
approach O
by O
utilizing O
integrative O
genomics O

com O
/ O
guanjue O
/ O
S3V2_IDEAS_ESMP O

Furthermore O
, O
different O
predictors O
were O
often O
derived O
based O
on O
data O
from O
different O
types O
of O
arrays O
, O
where O
array O
differences O
and O
batch O
effects O
can O
make O
predictors O
difficult O
to O
compare O
across O
studies O

635 O
: O
There O
are O
four O
major O
hypotheses O
( O
H1 O
, O
H2 O
, O
H3 O
, O
and O
H4 O
) O
as O
to O
the O
source O
of O
missing O
heritability O

266 O
: O
This O
chapter O
describes O
resources O
and O
technologies O
generated O
by O
the O
NIH O
Roadmap O
Epigenomics O
Program O
that O
may O
be O
useful O
to O
epigenomics O
researchers O
investigating O
a O
variety O
of O
diseases O
including O
cancer B-Disease

In O
this O
review O
, O
we O
explore O
the O
recent O
refinements O
to O
bisulfite O
sequencing O
protocols O
that O
enable O
targeting O
genomic O
regions O
of O
interest O
, O
detecting O
derivatives O
of O
5-methylcytosine O
, O
and O
mapping O
single-cell O
methylomes O

The O
results O
were O
compiled O
, O
synthesized O
and O
discussed O
with O
an O
expert O
in O
genetics O
for O
critical O
input O
and O
validation O

We O
show O
the O
value O
of O
computer O
simulations O
to O
experiment O
with O
and O
propose O
generalizations O
of O
broader O
scope O
with O
novel O
testable O
predictions O

In O
turn O
, O
a O
specific O
subgroup O
of O
miRNAs O
, O
called O
epi-miRNAs O
, O
is O
able O
to O
directly O
target O
key O
enzymatic O
effectors O
of O
the O
epigenetic O
machinery O
( O
such O
as O
DNA O
methyltransferases O
, O
histone O
deacetylases O
, O
and O
polycomb O
genes O
) O
, O
therefore O
indirectly O
affecting O
the O

Although O
new O
antipsychotic O
medications O
have O
been O
launched O
in O
the O
past O
decades O
, O
there O
has O
been O
a O
general O
lack O
of O
significant O
innovation O
over O
the O
past O
60 O
years O

666 O
: O
The O
inheritance O
of O
characteristics O
induced O
by O
the O
environment O
has O
often O
been O
opposed O
to O
the O
theory O
of O
evolution O
by O
natural O
selection O

Since O
then O
, O
Aydan O
has O
been O
awarded O
Development O
's O
Outstanding O
Paper O
Prize O
for O
2022 O
and O
, O
most O
recently O
, O
a O
European O
Research O
Council O
Starting O
Grant O
Award O
for O
2023 O

517 O
: O
Platform O
technologies O
for O
measurement O
of O
CpG O
methylation O
at O
multiple O
loci O
across O
the O
genome O
have O
made O
ambitious O
epigenome-wide O
association O
studies O
affordable O
and O
practicable O

In O
this O
brief O
historical O
essay O
, O
we O
recall O
the O
novelties O
and O
relevance O
of O
the O
work O
from O
a O
retrospective O
stance O
, O
above O
all O
pointing O
out O
the O
crucial O
role O
played O
by O
it O
in O
the O
dawning O
of O
epigenetic O
standpoint O

First O
, O
from O
gene O
expression O
data O
, O
we O
derived O
a O
novel O
binary O
indicator O
to O
flag O
patients O
with O
a O
favorable O
immune O
state O

Collectively O
, O
our O
data O
indicate O
that O
aberrant O
DNMT1/3a/3b O
elevations O
and O
the O
resultant O
suppression O
of O
antiaging O
factors O
contribute O
significantly O
to O
epigenetic O
renal B-Disease
aging I-Disease
, O
which O
might O
be O
targeted O
for O
epigenetic O
intervention O
by O
synthetic O
or O
natural O
DNA-demethylating O
agents O

Here O
, O
we O
review O
key O
facts O
on O
the O
involvement O
of O
epigenetic O
modifications O
in O
allergic B-Disease
diseases I-Disease
and O
summarize O
and O
critically O
evaluate O
the O
lessons O
learned O
from O
epigenome-wide O
association O
studies O

The O
PubMed O
and O
EMBASE O
databases O
were O
searched O
up O
to O
30th O
April O
2020 O
; O
references O
of O
included O
articles O
and O
pertinent O
review O
articles O
were O
also O
screened O
to O
identify O
eligible O
studies O


Moreover O
, O
upregulated O
circulating O
miR-361-5p O
, O
miR-889 O
, O
miR-576-3p O
may O
be O
useful O
biomarkers O
to O
discriminate O
tuberculosis B-Disease
patients O

This O
review O
summarizes O
epigenetic O
mechanisms O
identified O
in O
ageing O
healthy O
tendon O

This O
eliminates O
tip O
costs O
and O
reduces O
the O
risk O
of O
reagent O
carryover O

This O
overview O
highlights O
the O
various O
presentations O
in O
this O
session O
, O
discussing O
integration O
of O
epigenetics O
end O
points O
in O
toxicologic O
pathology O
studies O
, O
investigating O
the O
role O
of O
epigenetics O
in O
product O
safety O
assessment O
, O
epigenetic O
changes O
in O
cancers B-Disease
, O
methodologies O
to O
detect O
them O
, O
and O
potential O

The O
results O
from O
the O
validation O
study O
indicated O
that O
97% O
of O
the O
control O
samples O
had O
probability O
scores O
below O
this O
threshold O
, O
whereas O
40% O
of O
the O
RPL O
samples O
were O
above O
this O
threshold O
with O
a O
post-hoc O
power O
of O
97 O

508 O
: O
Environmental O
epigenetics O
has O
become O
a O
site O
of O
growing O
attention O
related O
to O
the O
intergenerational O
effects O
of O
stress O
, O
trauma B-Disease
, O
and O
adversity O

Targeting O
epigenetic O
mechanisms O
in O
paediatric O
malignancy O
has O
in O
most O
circumstances O
yet O
to O
reach O
or O
extend O
beyond O
clinical O
proof O
of O
concept O
, O
as O
many O
targets O
do O
not O
yet O
have O
available O
investigational O
drugs O
developed O

This O
chapter O
focuses O
on O
the O
tight O
relationship O
between O
epigenetics O
and O
miRNAs O
and O
provides O
some O
insights O
on O
the O
translational O
implications O
of O
these O
findings O
, O
leading O
to O
the O
upcoming O
introduction O
of O
epigenetically O
related O
miRNAs O
in O
the O
treatment O
of O
cancer B-Disease

24 O
: O
Epigenetics O
is O
a O
term O
that O
encompasses O
a O
variety O
of O
regulatory O
processes O
that O
are O
able O
to O
crosstalk O
in O
order O
to O
influence O
gene O
expression O
and O
cell O
phenotype O
in O
response O
to O
environmental O
cues O

408 O
: O
By O
taking O
advantage O
of O
the O
natural O
variation O
in O
genetic O
relatedness O
among O
identical O
( O
monozygotic O
: O
MZ O
) O
and O
fraternal O
( O
dizygotic O
: O
DZ O
) O
twins O
, O
twin O
studies O
are O
able O
to O
estimate O
genetic O
and O
environmental O
contributions O
to O
complex O
human O
behaviors O

All O
contributions O
used O
the O
GAW20 O
real O
data O
set O
and O
employed O
either O
linear O
mixed O
effect O
(LME) O
models O
or O
marginal O
models O
through O
generalized O
estimating O
equations O
(GEE) O

Recent O
laboratory O
studies O
includes O
an O
interest O
in O
using O
newly O
developed O
DNA O
methylation O
biomarkers O
to O
probe O
immune O
profiles O
from O
archived O
blood O

Associations O
between O
greenness O
and O
biological O
aging O
measured O
by O
Horvath's O
and O
Hannum's O
DNAmAgeAC O
were O
less O
consistent O
, O
and O
depended O
on O
neighborhood O
socioeconomic O
status O

Furthermore O
, O
we O
show O
that O
epigenetic O
modules O
may O
act O
as O
a O
molecular O
readout O
of O
cumulative O
cardiovascular O
risk O
factor O
exposure O
, O
with O
implications O
for O
the O
improvement O
of O
clinical O
risk O
prediction O

Now O
, O
comparative O
epigenomics O
is O
a O
rapidly O
growing O
field O
that O
is O
uncovering O
mechanistic O
aspects O
of O
epigenetic O
modifications O
and O
chromatin O
organization O
in O
non-model O
invertebrates O
, O
ranging O
from O
octopus O
to O
sponges O

554 O
: O
The O
effect O
of O
environmental O
pollution O
on O
epigenetic O
changes O
and O
their O
heredity O
in O
affected O
organisms O
is O
of O
major O
concern O
as O
such O
changes O
can O
play O
a O
significant O
role O
in O
adaptation O
to O
changing O
environmental O
conditions O

Since O
then O
, O
the O
meaning O
of O
epigenetics O
changed O
over O
time O

In O
consequence O
, O
novel O
therapeutic O
strategies O
aimed O
at O
reversing O
aberrant O
epigenetic O
marks O
in O
cancer B-Disease
cells O
have O
been O
developed O
and O
used O
in O
recent O
molecular O
studies O
and O
clinical O
trials O

Regarding O
sequence O
dependency O
, O
charge O
localization O
, O
shown O
to O
favor O
guanines O
, O
could O
influence O
or O
even O
direct O
epigenetic O
changes O
, O
e O

Here O
, O
I O
present O
and O
review O
various O
algorithms O
that O
may O
be O
used O
for O
purposes O
of O
deconvolving O
epigenomic O
data O
from O
admixed O
samples O
to O
yield O
estimates O
that O
may O
be O
factored O
into O
downstream O
analyses O

Furthermore O
, O
the O
epigenome O
provides O
an O
interesting O
target O
for O
therapeutic O
intervention O
, O
with O
microRNA O
mimics O
, O
inhibitors O
, O
and O
antisense O
oligonucleotides O
being O
evaluated O
in O
clinical O
trials O
in O
patients O
with O
other O
diseases O

Altogether O
, O
functional O
work O
suggests O
that O
the O
effects O
of O
gbM O
, O
if O
any O
, O
must O
be O
relatively O
small O
, O
but O
there O
is O
nonetheless O
evidence O
that O
it O
is O
shaped O
by O
natural O
selection O

Epigenetic O
marks O
include O
DNA O
methylation O
, O
histone O
modifications O
and O
a O
variety O
of O
non-coding O
RNAs O

Research O
on O
early O
exposure O
has O
disrupted O
the O
previous O
thinking O
of O
avoidance O
of O
food B-Disease
allergies I-Disease
to O
prevent O
sensitization O
in O
children O
, O
instead O
leading O
to O
recommendations O
that O
early O
introduction O
to O
foods O
may O
, O
in O
fact O
, O
induce O
tolerance O

However O
, O
recognition O
of O
the O
importance O
of O
developmental O
plasticity O
as O
an O
important O
factor O
in O
influencing O
later O
life O
health-particularly O
within O
the O
medical O
and O
public O
health O
communities-is O
low O
, O
and O
we O
argue O
that O
this O
indifference O
cannot O
be O
sustained O
in O
light O
of O
the O
growing O
understanding O
of O
developmental O
processes O

DAC-activated O
FBW7 O
expression O
promoted O
Mcl-1 O
ubiquitination O
and O
degradation O
leading O
to O
a O
significant O
reduction O
in O
the O
half-life O
of O
Mcl-1 O
protein O

Although O
the O
field O
is O
still O
in O
its O
early O
days O
, O
this O
chapter O
will O
discuss O
the O
current O
standing O
of O
epigenetic O
research O
into O
ADHD O

The O
goal O
of O
this O
paper O
is O
to O
review O
studies O
of O
the O
genetics O
of O
these O
stress-related B-Disease
psychiatric I-Disease
disorders I-Disease

488 O
: O
Gene-nutrient O
interactions O
are O
important O
contributors O
to O
health O
management O
and O
disease B-Disease
prevention O

Conclusions O
: O
VAEs O
can O
distinguish O
the O
original O
subtypes O
from O
manually O
mixed O
methylation O
data O
frame O
with O
the O
encoded O
features O
of O
latent O
space O

Even O
so O
, O
our O
understanding O
of O
the O
underlying O
sources O
of O
epigenetic O
variability O
remains O
limited O

Evaluations O
in O
real O
datasets O
show O
that O
this O
approach O
improves O
estimate O
precision O
and O
comparability O
across O
studies O

Bioinformatics O
is O
an O
effective O
approach O
for O
epigenomic O
profiling O

95 O
: O
Epigenetic O
modification O
are O
heritable O
changes O
in O
gene O
expression O
not O
encoded O
by O
the O
DNA O
sequence O
therefore O
playing O
a O
significant O
role O
in O
a O
broad O
range O
of O
biological O
processes O
and O
diseases O

MethLAB O
features O
a O
graphical O
user O
interface O
(GUI) O
with O
a O
menu-driven O
format O
designed O
to O
efficiently O
read O
in O
and O
manipulate O
array-based O
methylation O
data O
in O
a O
user-friendly O
manner O

In O
this O
article O
, O
the O
properties O
of O
current O
single-molecule O
analyses O
of O
DNA O
modifications O
will O
be O
discussed O
and O
compared O

Not O
only O
can O
epigenetic O
status O
influence O
drug O
response O
, O
but O
it O
can O
also O
be O
modulated O
by O
drugs O

Here O
, O
we O
review O
recent O
developments O
in O
conventional O
active O
site O
and O
allosteric O
inhibitors O
, O
peptidomimetics O
, O
and O
novel O
proteolysis-targeted O
chimera O
( O
PROTAC O
) O
technology O
that O
have O
deepened O
our O
understanding O
of O
transcriptional O
processes O
and O
led O
to O
promising O
preclinical O
compounds O
for O
therapeutic O
translation O

Conversely O
, O
abnormal O
epigenetic O
regulation O
is O
a O
feature O
of O
complex O
diseases O
, O
including O
cancer B-Disease
, O
diabetes B-Disease
, O
heart O
disease B-Disease
and O
other O
pathologies O

Accordingly O
, O
much O
effort O
has O
been O
devoted O
to O
characterizing O
these O
states O
under O
normal O
and O
pathological O
conditions O

An O
increasing O
number O
of O
pathological O
situations O
are O
being O
attributed O
to O
abnormal O
establishment O
or O
maintenance O
of O
epigenetic O
patterns O

Alignment O
- O
free O
methods O
have O
been O
applied O
to O
identify O
distinct O
sequence O
features O
that O
are O
associated O
with O
epigenetic O
patterns O
and O
to O
predict O
epigenomic O
profiles O

DNA O
methylation O
data O
were O
obtained O
from O
genomic O
DNA O
extracted O
from O
the O
frontal O
cortex O
and O
blood O
samples O
of O
adult O
common O
marmosets O
as O
well O
as O
the O
frontal O
cortex O
of O
neonatal O
marmosets O

OMP O
was O
identified O
and O
defined O
, O
originally O
, O
as O
being O
more O
common O
among O
low O
birth O
weight O
individuals O
conceived O
in O
vitro O
but O
we O
have O
also O
identified O
OMP O
individuals O
among O
colon O
cancer B-Disease
patients O
profiled O
by O
us O
, O
as O
well O
as O
multiple O
types O
of O
cancer B-Disease
patients O
in O

Strong O
correlations O
existed O
between O
human O
and O
marmoset O
DNA O
methylation O
data O

Unfortunately O
, O
the O
moral O
and O
legal O
framework O
for O
the O
use O
of O
these O
epigenetic O
technologies O
, O
which O
can O
objectively O
determine O
the O
presence O
of O
medical O
illnesses O
such O
as O
diabetes B-Disease
or O
the O
consumption O
of O
substances O
of O
abuse O
, O
is O
not O
as O
well O
developed O

292 O
: O
The O
future O
of O
drug O
design O
and O
the O
development O
of O
new O
therapeutics O
will O
rely O
on O
our O
ability O
to O
unravel O
the O
complexities O
of O
the O
epigenome O
in O
normal O
and O
disease B-Disease
states O

Toward O
this O
goal O
, O
the O
Ecological O
Epigenetics O
symposium O
brought O
together O
researchers O
with O
diverse O
strengths O
in O
theory O
, O
developmental O
genetics O
, O
ecology O
, O
and O
evolution O
, O
and O
the O
proceedings O
from O
their O
talks O
are O
presented O
in O
this O
issue O

Thus O
, O
instead O
of O
targeting O
these O
expressed O
proteins O
, O
research O
towards O
angiogenesis O
inhibition O
had O
been O
focused O
on O
a O
deeper O
scale O
, O
epigenetic O
modifications O

5-hmC O
plays O
an O
important O
role O
in O
the O
epigenetic O
regulation O
of O
gene O
expression O
in O
animals O
, O
although O
its O
role O
in O
plants O
remains O
controversial O

The O
former O
enable O
accurate O
activation O
of O
developmental O
programs O
; O
the O
latter O
drive O
epigenetic O
responses O
to O
factors O
that O
directly O
or O
indirectly O
affect O
epigenetic O
biochemistry O
leading O
to O
alterations O
in O
genome O
regulation O
and O
mediating O
organism O
response O
to O
environmental O
transformations O

66 O
: O
Epigenetic O
mechanisms O
- O
including O
DNA O
methylation O
, O
histone O
post-translational O
modifications O
and O
changes O
in O
nucleosome O
positioning O
- O
regulate O
gene O
expression O
, O
cellular O
differentiation O
and O
development O
in O
almost O
all O
tissues O
, O
including O
the O
brain O

The O
precise O
mechanism O
of O
aggregation O
remains O
unknown O
, O
but O
increased O
expression O
of O
aggregation-prone O
proteins O
can O
lead O
to O
their O
aggregation O

With O
ten O
platform O
sessions O
and O
two O
sessions O
with O
over O
100 O
poster O
presentations O
, O
this O
conference O
featured O
cutting-edge O
epigenetic O
research O
, O
presented O
by O
Canadian O
and O
international O
principal O
investigators O
and O
their O
trainees O
in O
the O
field O
of O
epigenetics O
and O
chromatin O
dynamics O

Results O
: O
EWAS2 O

Given O
the O
dynamic O
and O
potentially O
reversible O
nature O
of O
the O
different O
types O
of O
epigenetic O
marks O
, O
environmental O
epigenetics O
constitutes O
a O
promising O
venue O
for O
developing O
fast O
and O
sensible O
biomonitoring O
programs O

ZIP10 O
deficiency O
was O
found O
to O
result O
in O
reduced O
HATs O
, O
confirming O
its O
involvement O
in O
histone O
acetylation O
for O
rigid O
skin O
barrier O
formation O

We O
review O
here O
the O
progress O
made O
in O
this O
field O
and O
discuss O
open O
questions O
in O
epigenetic O
regulation O
and O
its O
stability O
, O
methods O
to O
increase O
the O
specificity O
of O
epigenome O
editing O
, O
and O
improved O
delivery O
methods O
for O
targeted O
EpiEffectors O

Recent O
studies O
have O
demonstrated O
that O
the O
population O
of O
CSCs O
and O
the O
progression O
of O
cancer B-Disease
are O
increased O
by O
the O
deregulation O
of O
different O
epigenetic O
pathways O
having O
effects O
on O
gene O
expression O
patterns O
and O
key O
pathways O
connected O
with O
cell O
proliferation O
and O
survival O

Synthetic O
drugs O
targeting O
enzymes O
, O
e O

However O
, O
many O
existing O
epigenetic O
clocks O
are O
weakly O
correlated O
with O
each O
other O
, O
suggesting O
they O
may O
capture O
different O
biological O
processes O

, O
cancer B-Disease
modeling O
can O
be O
achieved O
by O
introducing O
aberrant O
epigenetic O
marks O
in O
normal O
cells O
, O
and O
cancer B-Disease
suppression O
can O
be O
achieved O
by O
correcting O
the O
epigenetic O
errors O
in O
cancer B-Disease
cells O

Variants O
in O
TET2 O
were O
significantly O
associated O
with O
overall B-Disease
breast I-Disease
, O
overall B-Disease
prostate I-Disease
, O
overall O
ovarian B-Disease
, O
and O
endometrioid B-Disease
ovarian I-Disease
cancer B-Disease
risk O
, O
with O
rs62331150 O
showing O
bidirectional O
effects O

com O
/ O
zfyuan O
/ O
EpiProfile2 O

This O
review O
provides O
a O
mechanism-based O
understanding O
and O
comparative O
overview O
of O
the O
most O
common O
techniques O
for O
detecting O
the O
status O
of O
epigenetic O
effects O
, O
including O
DNA O
methylation O
and O
histone O
modifications O
, O
for O
applicable O
approaches O
from O
low- O
to O
high-throughput O
scales O

Because O
epigenetic O
modifications O
are O
reversible O
many O
anticancer O
strategies O
targeting O
these O
mechanisms O
are O
currently O
under O
development O
and O
in O
clinical O
trials O

The O
overarching O
aim O
is O
to O
integrate O
the O
evidence O
which O
suggests O
epigenetic O
inheritance O
modulates O
lifespan/longevity O
with O
the O
main O
evolutionary O
theories O
of O
ageing O

In O
this O
article O
, O
we O
reviewed O
the O
literature O
investigating O
the O
involvement O
of O
epigenetic O
mechanisms O
, O
noncoding O
RNAs O
and O
metabolomic O
modifications O
in O
bipolar O
disorder B-Disease
and O
the O
mechanism O
of O
action O
and O
clinical O
efficacy O
of O
mood O
stabilizers O

High O
monozygotic O
twin O
discordance O
rates O
for O
common O
diseases O
suggest O
that O
unexplained O
environmental O
or O
epigenetic O
factors O
could O
be O
involved O

We O
have O
developed O
a O
Bayesian O
model O
to O
infer O
which O
epialleles O
are O
present O
in O
multiple O
regions O
of O
the O
same O
tumour B-Disease

Results O
: O
Early O
life O
trauma B-Disease
and O
earlier O
age O
at O
menarche O
independently O
predicted O
accelerated O
aging O
based O
on O
one O
of O
the O
four O
epigenetic O
clocks O
, O
DNAm O
GrimAge O
, O
though O
early O
life O
trauma B-Disease
was O
not O
associated O
with O
age O
of O
menarche O

ox O

These O
cumulative O
epigenetic O
alterations O
in O
stem O
cells O
might O
be O
the O
cause O
of O
the O
deregulation O
of O
developmental O
pathways O
seen O
during O
ageing O

This O
relationship O
reflects O
plastic O
responses O
made O
by O
the O
developing O
organism O
as O
an O
evolved O
strategy O
to O
cope O
with O
immediate O
or O
predicted O
circumstances O
, O
to O
maximize O
fitness O
in O
the O
context O
of O
the O
range O
of O
environments O
potentially O
faced O

Conclusions O
: O
The O
proportionality O
between O
the O
genetic O
and O
epigenetic O
variances O
of O
phenotypes O
implies O
the O
correlation O
between O
the O
robustness O
( O
or O
plasticity O
) O
against O
genetic O
changes O
and O
against O
noise O
in O
development O
, O
and O
also O
suggests O
that O
phenotypic O
traits O
that O
are O
more O
variable O
epigenetically O
have O

A O
few O
interesting O
talks O
on O
replication O
added O
some O
insightful O
information O
on O
the O
controversial O
issue O
of O
histone O
post-translational O
modifications O
as O
genuine O
epigenetic O
marks O
that O
are O
inherited O
through O
cell O
division O

This O
research O
provides O
a O
solid O
foundation O
for O
further O
detailed O
investigation O
of O
these O
themes O
, O
all O
of O
which O
will O
be O
important O
data O
to O
help O
inform O
future O
public O
health O
messages O
regarding O
epigenetic O
concepts O

Moreover O
, O
it O
has O
recently O
been O
demonstrated O
that O
epigenetic O
modifications O
are O
more O
susceptible O
to O
alterations O
induced O
by O
environmental O
factors O
than O
are O
DNA O
sequences O
, O
and O
that O
some O
drugs O
commonly O
used O
reverse O
mental-stress O
induced O
alterations O
to O
histone O
modifications O
in O
neural O
genes O

659 O
: O
Introduction O
: O
Schizophrenia B-Disease
is O
a O
major O
psychiatric B-Disease
disorder B-Disease
that O
afflicts O
about O
1% O
of O
the O
world O
's O
population O
, O
falling O
into O
the O
top O
10 O
medical O
disorders O
causing O
disability O

The O
mechanisms O
linking O
genetic O
factors O
and O
cellular O
stress O
to O
β-cell O
dedifferentiation O
remain O
largely O
unknown O

I'm O

com O
/ O
james O
- O
e O
- O
barrett O

We O
use O
the O
game O
to O
explore O
issues O
in O
symbiopoiesis O
and O
evo-devo O
, O
where O
we O
explore O
a O
fractal O
hypothesis O
: O
that O
self-similarity O
exists O
at O
different O
levels O
( O
cells O
, O
organisms O
, O
ecological O
communities O
) O
as O
a O
result O
of O
homologous O
interactions O
of O
two O
as O
processes O

991 O
years O

This O
does O
not O
come O
with O
alterations O
in O
the O
base O
sequence O
('genetic O
code') O

Furthermore O
, O
as O
exposures O
to O
the O
environment O
and O
individual O
habits O
do O
not O
affect O
all O
populations O
equally O
, O
the O
violation O
of O
the O
principle O
of O
distributive O
justice O
in O
the O
access O
to O
the O
benefits O
of O
clinical O
epigenetics O
is O
discussed O

Dysregulated O
epigenetic O
changes O
can O
alter O
gene O
expression O
and O
impair O
cellular O
functions O
in O
immune O
cells O
, O
resulting O
in O
autoreactive O
immune O
responses O

One O
of O
the O
reasons O
for O
this O
may O
be O
the O
extreme O
complexity O
and O
variability O
of O
clinical O
presentation O
of O
food B-Disease
allergy I-Disease
, O
ranging O
from O
less O
severe O
forms O
such O
as O
oral O
allergy O
syndrome O
to O
full-blown O
anaphylaxis O

Germline-dependent O
epigenetic O
change O
occurs O
when O
the O
epigenetic O
imprint O
is O
mediated O
through O
the O
germline O

Currently O
, O
we O
utilize O
mainly O
genetic O
biomarkers O
for O
optimization O
of O
drug O
therapy O
, O
although O
many O
rare O
genetic O
variants O
are O
not O
taken O
into O
consideration O

These O
epigenetic O
changes O
are O
induced O
by O
environmental O
stimuli O
; O
they O
alter O
gene O
expression O
and O
are O
potentially O
heritable O

To O
date O
, O
our O
knowledge O
about O
the O
role O
of O
epigenetic O
processes O
in O
schizophrenia B-Disease
is O
limited O
and O
based O
on O
analyses O
of O
small O
numbers O
of O
samples O
obtained O
from O
a O
range O
of O
different O
cell O
and O
tissue O
types O

Even O
when O
one O
only O
considers O
a O
single O
epigenetic O
modification O
such O
as O
DNA O
methylation O
, O
the O
last O
10 O
years O
have O
seen O
a O
wide O
array O
of O
technologies O
developed O

Here O
, O
we O
first O
develop O
uCoTarget O
, O
utilizing O
a O
split-pool O
barcoding O
strategy O
for O
realizing O
ultrahigh-throughput O
single-cell O
joint O
profiling O
of O
multiple O
epigenetic O
proteins O

Here O
, O
we O
review O
the O
current O
applications O
of O
these O
epigenetic O
editing O
tools O
in O
mammals O
and O
shed O
light O
on O
biochemical O
improvements O
that O
facilitate O
versatile O
applications O

195 O
: O
DNA O
methylation O
alterations O
have O
been O
widely O
studied O
as O
mediators O
of O
environmentally O
induced O
disease B-Disease
risks O

The O
activation O
of O
these O
immune-related O
pathways O
positively O
associated O
with O
prognosis O
in O
certain O
cancer B-Disease
types O
, O
most O
notably O
melanoma B-Disease
, O
head O
and O
neck O
, O
and O
cervical O
cancers B-Disease

g O

This O
contemporary O
neoliberal O
" O
regime O
of O
truth O
," O
to O
use O
a O
term O
from O
Michel O
Foucault O
, O
greatly O
influences O
the O
ways O
in O
which O
knowledge O
is O
being O
interpreted O
and O
implemented O

We O
then O
discuss O
a O
nonpathogenic O
role O
for O
epigenetics O
in O
the O
clinic O
: O
epigenetic O
biomarkers O

Recent O
advances O
in O
the O
field O
of O
epigenetics O
have O
uncovered O
highly O
dynamic O
mechanisms O
of O
chromatin O
remodelling O
occurring O
during O
cell O
dedifferentiation O
and O
differentiation O
processes O
on O
which O
in O
vitro O
adventitious O
plant O
regeneration O
systems O
are O
based O

Computational O
approaches O
have O
enabled O
us O
to O
analyze O
mass O
data O
produced O
by O
these O
methods O

With O
the O
advances O
of O
high-throughput O
technologies O
and O
the O
accumulation O
of O
enormous O
amount O
of O
data O
, O
method O
development O
for O
analyzing O
these O
data O
has O
gained O
tremendous O
interests O
in O
the O
fields O
of O
computational O
biology O
and O
bioinformatics O

We O
argue O
that O
attention O
to O
phenotype O
nuance O
, O
progressing O
to O
association O
with O
epigenetic O
marks O
and O
then O
causal O
analyses O
of O
the O
epigenetic O
mechanism O
, O
will O
enable O
clearer O
evaluation O
of O
the O
evolutionary O
path O

Recently O
, O
epigenetic O
mechanisms O
were O
shown O
to O
be O
involved O
in O
endocrine O
cell O
differentiation O
and O
islet O
function O

20 O
: O
Epigenetics O
is O
a O
field O
of O
biological O
sciences O
focused O
on O
the O
study O
of O
reversible O
, O
heritable O
changes O
in O
gene O
function O
, O
not O
due O
to O
modifications O
of O
the O
genomic O
sequence O

Epigenetic O
modifications O
defined O
as O
' O
heritable O
changes O
to O
the O
genome O
that O
do O
not O
involve O
changes O
in O
DNA O
sequence O
' O
have O
emerged O
as O
a O
new O
layer O
of O
biological O
regulation O
in O
CVD O
and O
could O
advance O
individualized O
risk O
assessment O
as O
well O
as O
devising O
and O
deploying O
tailored O
therapies O


647 O
: O
Hydroxymethylcytosine O
( O
hmC O
or O
5-hmC O
) O
is O
a O
nitrogen O
base O
occurring O
as O
a O
result O
of O
cytosine B-Disease
methylation I-Disease
followed O
by O
replacing O
a O
methyl O
group O
with O
a O
hydroxyl O
group O
through O
active O
oxidation O

We O
utilize O
multi-omics O
data O
from O
diverse O
human O
tissue/cells O
to O
identify O
shared O
features O
across O
eleven O
existing O
epigenetic O
clocks O

The O
modern O
societies O
are O
characterised O
by O
an O
ageing O
population O
, O
which O
represents O
challenges O
for O
the O
healthcare O
system O

However O
, O
the O
large O
and O
diverse O
bioinformatic O
and O
statistical O
methods O
, O
referring O
to O
the O
confounders O
of O
the O
statistical O
models O
, O
application O
of O
multiple-testing O
adjustment O
methods O
, O
questions O
regarding O
the O
correlation O
of O
DNAm O
across O
tissues O
, O
and O
sex-dependent O
differences O
in O
results O
, O
have O
raised O
challenges O

By O
extension O
, O
this O
new O
perspective O
has O
implications O
for O
risk O
and O
risk O
management O
of O
antisocial O
behaviour O
where O
there O
is O
a O
biological O
component O
, O
such O
as O
psychopathy B-Disease

However O
, O
all O
analyses O
have O
been O
correlational O
in O
nature O
and O
, O
as O
these O
studies O
have O
focussed O
on O
children O
and O
adolescents O
, O
DNAm O
has O
been O
based O
on O
peripheral O
tissue O
( O
cord O
blood O
, O
whole O
blood O
, O
buccal O
cells O
) O

, O
disease B-Disease
susceptibility O
) O

The O
integration O
and O
analyses O
of O
these O
high-throughput O
data O
have O
unraveled O
many O
novel O
molecular O
aberrations O
and O
network O
alterations O
in O
tumors B-Disease

Then O
, O
the O
identification O
of O
epigenetic O
mechanisms O
underlying O
the O
environmental O
causes O
of O
cancers B-Disease
brings O
scientific O
legitimacy O
to O
products O
and O
services O
whose O
advertising O
promotes O
the O
ability O
of O
each O
person O
to O
protect O
herself O
from O
cancer B-Disease
by O
adapting O
her O
lifestyle O

It O
is O
crucial O
that O
the O
most O
appropriate O
tools O
are O
selected O
to O
ensure O
that O
the O
best O
possible O
results O
are O
achieved O

Conclusion O
: O
Overall O
, O
there O
seems O
to O
be O
a O
consistency O
in O
the O
literature O
, O
pointing O
to O
a O
link O
between O
early O
childhood O
adversity O
, O
attachment O
processes O
, O
and O
epigenetic O
changes O

250 O
: O
Jörg O
Tost O
received O
his O
PhD O
in O
genetics O
from O
the O
University O
of O
Saarbrücken O
( O
Germany O
) O
in O
2004 O
for O
devising O
novel O
methods O
for O
the O
analysis O
of O
haplotypes O
and O
DNA O
methylation O
patterns O

S O

This O
property O
gives O
rise O
to O
a O
dynamic O
dimension O
in O
phenotypic O
inheritance O

In O
addition O
, O
his O
laboratory O
is O
interested O
in O
tumor B-Disease
biology O
, O
investigating O
somatic O
alterations O
in O
tumor B-Disease
tissue O
from O
the O
patients O
who O
have O
developed O
exposure-related O
cancers B-Disease

( O
) O
review O
addresses O
one O
of O
the O
most O
fundamental O
questions O
in O
the O
fields O
of O
child O
psychology O
and O
psychiatry O
- O
How O
can O
adverse O
experiences O
shape O
development O
to O
a O
sufficient O
degree O
and O
in O
profound O
and O
enduring O
ways O
to O
create O
long O
term O
risk O
for O
later O
mental B-Disease
disorder I-Disease
and O
disability O

Nonetheless O
, O
the O
potential O
epigenetic O
vestiges O
of O
early O
care O
and O
protective O
interventions O
in O
NICU O
have O
not O
been O
investigated O
yet O
and O
this O
represents O
a O
fascinating O
challenge O
for O
future O
PBE O
research O

319 O
: O
The O
aim O
of O
this O
review O
is O
to O
summarize O
an O
evolution O
of O
thinking O
about O
the O
epigenetic O
basis O
of O
human O
cancer B-Disease
, O
from O
the O
earliest O
studies O
of O
altered O
DNA O
methylation O
in O
cancer B-Disease
to O
the O
modern O
comprehensive O
epigenomic O
era O

544 O
: O
In O
many O
eukaryotic O
organisms O
, O
methylation O
at O
the O
fifth O
carbon O
of O
cytosine O
( O
5mC O
) O
is O
a O
stable O
epigenetic O
mark O
crucial O
for O
many O
biological O
processes O
, O
including O
cell O
differentiation O
, O
X-chromosome O
inactivation O
, O
transposon O
silencing O
, O
and O
genomic O
imprinting O

g O

008 O
) O
compared O
to O
heavy O
drinkers O
( O
β O
= O
0 O

We O
have O
also O
reported O
the O
sequence O
profiles O
, O
tertiary O
structures O
and O
post-translational O
modifications O
of O
these O
epigenetic O
proteins O
in O
cancer B-Disease

His O
research O
combines O
experimental O
model O
systems O
, O
computational O
and O
omics O
tools O
, O
and O
epidemiological O
studies O
to O
investigate O
the O
influence O
of O
environmental O
exposures O
on O
wildlife O
and O
human O
health O
, O
and O
underlying O
molecular O
mechanisms O

We O
describe O
how O
these O
enzymatic O
reactions O
have O
been O
combined O
and O
permuted O
to O
localize O
DNA O
modifications O
with O
high O
specificity O
and O
without O
the O
destructive O
limitations O
posed O
by O
chemical O
methods O
for O
epigenetic O
sequencing O

In O
this O
study O
, O
we O
introduce O
a O
novel O
epigenetic O
target O
identification O
strategy O
( O
ETI-Strategy O
) O
that O
integrates O
a O
multi-task O
graph O
convolutional O
neural O
network O
prior O
model O
and O
a O
protein-ligand O
interaction O
classification O
discriminating O
model O
using O
large-scale O
bioactivity O
data O
for O
a O
panel O
of O
55 O
epigenetic O
targets O

It O
leads O
to O
changes O
in O
gene O
expressions O
and O
the O
emergence O
of O
new O
traits O
in O
different O
organisms O
in O
many O
diseases O
such O
as O
cancer B-Disease

Following O
Breusch-Pagan O
test O
of O
heteroscedasticity O
, O
we O
showed O
that O
a O
linear O
regression O
model O
, O
where O
the O
residuals O
were O
used O
in O
a O
mixed O
effect O
model O
with O
a O
random O
intercept O
, O
properly O
estimated O
the O
change O
of O
interindividual O
variability O
over O
time O

Past O
research O
in O
the O
social O
sciences O
suggests O
that O
environmental O
experiences O
related O
to O
social O
status O
contribute O
to O
these O
disparities O
, O
but O
the O
underlying O
biological O
mechanisms O
are O
only O
partially O
understood O

In O
total O
, O
11 O
studies O
were O
included O

Implementation O
of O
a O
switched O
current O
integrator O
can O
potentially O
increase O
both O
accuracy O
and O
window O
for O
detection O
, O
within O
the O
frequency O
region O
of O
DNA O
reactions O

We O
show O
that O
the O
experimental O
data O
are O
compatible O
with O
the O
finite-size O
behavior O
of O
a O
self-attracting O
polymer O

Additionally O
, O
environmentally O
induced O
diabetic B-Disease
susceptibility O
could O
be O
transmitted O
to O
subsequent O
generations O

Availability O
and O
implementation O
: O
The O
EWAS O
software O
is O
freely O
available O
at O
http://www O

Understanding O
the O
capacity O
of O
freshwater O
species O
to O
tolerate O
the O
environmental O
fluctuations O
induced O
by O
climate O
change O
is O
critical O
to O
the O
development O
of O
effective O
conservation O
strategies O

Using O
this O
methodology O
, O
we O
observe O
a O
significant O
age-associated O
erosion O
of O
LINE-1 O
methylation O
in O
cfDNA O
suggesting O
that O
the O
threshold O
of O
hypomethylation O
sufficient O
for O
relevant O
LINE-1 O
activation O
and O
consequential O
harmful O
retrotransposition O
might O
be O
reached O
at O
higher O
age O

The O
newest O
version O
, O
HumanMethylationEPIC O
, O
quantifies O
the O
DNA O
methylation O
level O
of O
850,000 O
CpG O
sites O
, O
while O
the O
previous O
versions O
, O
HumanMethylation450 O
and O
HumanMethylation27 O
, O
measured O
>450,000 O
and O
27,000 O
loci O
, O
respectively O

, O
immediate O
early O
gene O
transcription O
) O
, O
and O
neural O
network O
function O
( O
e O

In O
the O
simulated O
populations O
, O
the O
results O
of O
the O
analysis O
provided O
marginal O
posterior O
distributions O
that O
included O
the O
population O
parameters O
in O
the O
regions O
of O
highest O
posterior O
density O


Also O
, O
several O
of O
the O
epigenetic O
drugs O
currently O
approved O
as O
anticancer O
agents O
affect O
the O
expression O
of O
miRNAs O
and O
this O
might O
explain O
part O
of O
their O
mechanism O
of O
action O

To O
address O
these O
problems O
, O
we O
developed O
DMF-ChIP-seq O
that O
builds O
on O
digital O
microfluidic O
( O
DMF O
) O
technology O
to O
profile O
genome-wide O
DPIs O
in O
a O
highly O
efficient O
, O
cost-effective O
, O
and O
user-friendly O
way O

Here O
we O
review O
recent O
studies O
that O
demonstrate O
shifts O
in O
metabolic O
state O
can O
orchestrate O
immune O
cell O
functions O
through O
its O
impact O
on O
epigenetic O
remodeling O
, O
and O
the O
microenvironment O
can O
exert O
its O
influence O
on O
immune O
cells O
through O
the O
metabolic O
regulation O
of O
epigenetics O

627 O
: O
Hematopoiesis O
is O
one O
of O
the O
best O
characterized O
biological O
systems O
but O
the O
connection O
between O
chromatin O
changes O
and O
lineage O
differentiation O
is O
not O
yet O
well O
understood O

This O
review O
highlights O
the O
potential O
of O
epigenetics O
as O
a O
tool O
for O
predicting O
treatment O
efficacy O
and O
personalizing O
medicine O
for O
psychiatric B-Disease
disorders I-Disease

Epigenetic O
mechanisms O
are O
essential O
for O
maintaining O
specific O
patterns O
of O
gene O
expression O
and O
normal O
development O
and O
growth O
of O
living O
individuals O

734 O
: O
Plants O
are O
continuously O
exposed O
to O
various O
environmental O
stresses O

373 O
: O
DNA O
methylation O
- O
based O
epigenetic O
signatures O
have O
become O
valuable O
cancer B-Disease
biomarkers O

These O
demethylating O
agents O
may O
induce O
T-cell O
attraction O
and O
enhance O
immune O
checkpoint O
inhibitor O
efficacy O
in O
mouse O
models O

Epigenome O
editing O
is O
a O
promising O
approach O
for O
durable O
gene O
regulation O
, O
with O
many O
applications O
in O
basic O
research O
including O
the O
investigation O
of O
the O
regulatory O
functions O
and O
logic O
of O
chromatin B-Disease
modifications I-Disease
and O
cellular O
reprogramming O

Moreover O
, O
negative O
definition O
casts O
the O
genetic-epigenetic O
relationship O
as O
an O
either/or O
binary O
, O
overshadowing O
continuities O
and O
connections O

14 O

Various O
methods O
are O
available O
for O
the O
detection O
of O
DNA O
methylation O
changes O

To O
translate O
research O
findings O
into O
clinical O
practice O
, O
interdisciplinary O
collaborations O
, O
technical O
and O
ethical O
considerations O
, O
and O
accessibility O
of O
resources O
and O
knowledge O
are O
crucial O

Using O
cell-type-specific O
data O
from O
two O
separate O
studies O
, O
we O
discover O
epigenetic O
mechanisms O
underlying O
childhood O
food B-Disease
allergy I-Disease
and O
survival-associated O
, O
methylation-driven O
ncRNAs O
in O
non-small O
cell O
lung B-Disease
cancer I-Disease

Epigenetics O
is O
emerging O
as O
an O
important O
piece O
of O
molecular O
data O
to O
include O
in O
these O
studies O
because O
it O
can O
provide O
mechanistic O
insights O
into O
genetic O
and O
environmental O
risk O
factors O
for O
disease B-Disease
, O
identify O
potential O
intervention O
targets O
, O
provide O
biomarkers O
of O
exposure O
, O
illuminate O
gene-environment O
interactions O
and O

Finally O
, O
we O
discuss O
the O
role O
neutrophils O
play O
in O
adaptive O
pathologies O
with O
a O
focus O
on O
tumour B-Disease
initiation O
and O
progression O

Archer O
and O
not O
the O
NIH/NIEHS O
or O
the O
US O
government O

We O
reviewed O
all O
articles O
and O
included O
a O
critical O
discussion O
of O
field-specific O
methodological O
considerations O

However O
, O
the O
original O
family O
longevity O
selection O
score O
( O
FLoSS O
) O
focuses O
on O
populations O
of O
elderly O
only O

Appropriate O
construct O
designs O
were O
used O
to O
demonstrate O
that O
the O
cis-spread O
of O
heterochromatin O
could O
be O
interfered O
with O
a O
stronger O
euchromatic O
barrier O
( O
TUB2 O
promoter O
) O

In O
fact O
, O
key O
alterations O
produced O
by O
methamphetamine O
involve O
dopamine O
neurotransmission O
in O
a O
way O
, O
which O
is O
reminiscent O
of O
spontaneous O
neurodegeneration B-Disease
and O
psychiatric B-Disease
schizophrenia B-Disease

9 O
are O
regularly O
reported O
using O
a O
single O
CpG O
site O
( O
cg05575921 O
; O
AHRR O
) O

Experiments O
were O
now O
designed O
to O
assess O
the O
epigenetic O
consequences O
of O
inserting O
a O
5 O

In O
addition O
, O
dietary O
factors O
have O
been O
suggested O
to O
have O
potential O
to O
reverse O
aberrant O
epigenetic O
patterns O

His O
lab O
currently O
works O
on O
epigenetic O
mechanisms O
of O
gene O
regulation O
in O
cancer B-Disease
and O
other O
diseases O

We O
can O
predict O
active O
signaling O
pathways O
in O
K562 O
single O
cells O
using O
the O
epigenetic O
data O
and O
confirm O
that O
the O
predicted O
results O
strongly O
correlate O
with O
actual O
active O
signaling O
pathways O
identified O
by O
RNA-seq O
results O

We O
methodically O
assessed O
the O
reprogramming O
efficiency O
of O
each O
DF O
line O
and O
then O
quantified O
the O
individual O
and O
demographic-specific O
variations O
in O
SWI/SNF O
chromatin O
remodeling O
proteins O
and O
mRNA O
expression O

443 O
: O
Background O
: O
The O
functional O
impact O
of O
genetic O
variation O
has O
been O
extensively O
surveyed O
, O
revealing O
that O
genetic O
changes O
correlated O
to O
phenotypes O
lie O
mostly O
in O
non-coding O
genomic O
regions O

Consequently O
, O
many O
human O
diseases O
are O
associated O
with O
aberrant O
DNA O
methylation O

124 O
: O
The O
genetic O
code O
cannot O
alone O
explain O
the O
diversity O
of O
cellular O
and O
individual O
phenotypes O

, O
risk O
to O
add O
an O
epigenetic O
determinism O
on O
top O
of O
the O
current O
genetic O
one O
) O


497 O
: O
Epilepsy O
affects O
over O
50 O
million O
individuals O
globally O
, O
making O
it O
the O
most O
prevalent O
chronic O
and O
serious O
neurological O
condition O

401 O
: O
Longitudinal O
cohort O
studies O
are O
ideal O
for O
investigating O
how O
epigenetic O
patterns O
change O
over O
time O
and O
relate O
to O
changing O
exposure O
patterns O
and O
the O
development O
of O
disease B-Disease

Specifically O
, O
we O
speculate O
that O
the O
" O
epigenetic O
landscapes O
" O
that O
define O
identity O
in O
adult O
tissues O
are O
dynamic O
, O
facilitating O
cellular O
de-differentiation O
and O
trans-differentiation O
in O
the O
setting O
of O
injury O

Drugs O
targeting O
DNA O
and O
histone O
modifications O
are O
under O
development O
with O
some O
such O
as O
5-azacytidine O
, O
decitabine O
, O
vorinostat O
, O
and O
panobinostat O
already O
approved O
by O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
and O
the O
European O
Medicines O
Agency O
( O
EMA O
) O

Epigenetic O
processes O
serve O
critical O
roles O
in O
development O
and O
operate O
as O
intermediaries O
that O
connect O
the O
genome O
to O
the O
rest O
of O
the O
world O

In O
particular O
, O
histone O
modifications O
have O
a O
role O
in O
the O
regulation O
of O
gene O
expression O
pertinent O
to O
activation O
of O
fibroblasts O
to O
myofibroblasts O
, O
governing O
their O
fate O

These O
few O
studies O
have O
reported O
significant O
epigenetic O
differences O
in O
various O
racial O
and O
ethnic O
groups O
that O
could O
account O
for O
the O
differences O
seen O
in O
tumor B-Disease
initiation O
, O
progression O
, O
aggressiveness O
, O
and O
outcome O
of O
these O
cancers B-Disease

We O
found O
that O
epigenetic O
features O
characterizing O
promoters O
and O
transcription O
elongation O
tend O
to O
be O
more O
consistent O
than O
regions O
characterizing O
enhancers O
or O
Polycomb-repressed O
regions O
and O
that O
epigenetically O
active O
genes O
consistent O
across O
all O
epigenomes O
tend O
to O
have O
higher O
expression O
than O
those O
not O
marked O
as O
epigenetically O
active O

The O
ability O
to O
identify O
patients O
with O
subclinical O
(asymptomatic) O
metastatic O
melanoma B-Disease
, O
combined O
with O
new O
, O
highly O
active O
targeted O
and O
immunomodulatory O
agents O
, O
may O
lead O
to O
further O
improvements O
in O
outcomes O
for O
this O
patient O
population O

However O
, O
the O
effect O
of O
the O
Sandwich O
Model O
in O
learning O
gain O
and O
student O
attitudes O
was O
not O
dependent O
on O
PRS O
incorporation O
per O
se O
and O
students O
seemed O
to O
favour O
non-PRS O
activities O
over O
PRS O
, O
as O
evidenced O
by O
their O
feedback O

52 O
: O
Cardiomyopathies O
( O
CMPs O
) O
are O
a O
heterogeneous O
group O
of O
myocardial O
diseases O
accountable O
for O
the O
majority O
of O
cases O
of O
heart B-Disease
failure I-Disease
( O
HF O
) O
and/or O
sudden O
cardiac O
death B-Disease
( O
SCD O
) O
worldwide O

26 O
among O
the O
selected O
CpGs O
) O
, O
affecting O
the O
empirical O
p-value O
distributions O
and O
the O
usual O
multiple O
testing O
control O

Of O
interest O
here O
is O
the O
recent O
shift O
in O
focus O
from O
genetic O
to O
epigenetic/epigenomic O
research O
and O
the O
emergence O
and O
extension O
of O
resource O
provision O
to O
support O
this O
both O
at O
local O
and O
global O
scale O

We O
then O
develop O
uCoTargetX O
, O
an O
expansion O
of O
uCoTarget O
to O
simultaneously O
measure O
transcriptome O
and O
multiple O
epigenome O
targets O

Lysenkoism O
was O
a O
neo-Lamarckian O
idea O
, O
claiming O
that O
in O
crop O
plants O
, O
such O
as O
wheat O
, O
environmental O
influences O
are O
heritable O
via O
all O
cells O
of O
the O
organism O

Such O
effects O
are O
independent O
of O
the O
causative O
agent O
and O
there O
is O
no O
evidence O
at O
present O
that O
a O
germline-dependent O
epigenetic O
state O
can O
be O
reversed O

Computer O
-aided O
drug O
design O
techniques O
( O
CADD O
) O
encompass O
a O
large O
variety O
of O
methods O
which O
are O
subdivided O
into O
structure-based O
( O
SBDD O
) O
and O
ligand-based O
drug O
design O
( O
LBDD O
) O
methods O

These O
constitute O
the O
core O
techniques O
that O
are O
used O
in O
our O
laboratory O
for O
accurately O
surveying O
the O
epigenetics O
of O
retrotransposable O
elements O

We O
explored O
the O
application O
of O
epigenetic O
clocks O
to O
measure O
the O
efficacy O
of O
interventions O
focusing O
on O
rejuvenation O

We O
have O
found O
three O
overlap O
genes O
that O
show O
significant O
DNA O
methylation O
changes O
, O
both O
in O
obesity B-Disease
and O
depression B-Disease

The O
incorporation O
of O
epigenomic O
assessments O
in O
cancer B-Disease
epidemiology O
studies O
has O
and O
is O
likely O
to O
continue O
to O
provide O
important O
insights O
into O
the O
field O
of O
cancer B-Disease
research O

The O
theories O
discussed O
are O
divided O
into O
epigenetic O
and O
genetic O
ones O
, O
with O
the O
latter O
further O
classified O
into O
gene-based O
and O
genome-based O
hypotheses O

ucla O

Such O
strategies O
may O
distort O
relationships O
between O
functionally O
correlated O
epigenetic O
features O
and O
hinder O
biological O
interpretation O

05 O
) O
were O
considered O
statistically O
significant O

486 O
: O
Epigenetics O
refers O
to O
a O
heritable O
change O
in O
the O
pattern O
of O
gene O
expression O
that O
is O
mediated O
by O
a O
mechanism O
specifically O
not O
due O
to O
alterations O
in O
the O
primary O
nucleotide O
sequence O

We O
also O
trained O
a O
prediction O
model O
that O
uses O
the O
average O
methylation O
level O
over O
genomic O
regions O

Conclusion O
: O
Epigenetic O
therapies O
are O
emerging O
as O
an O
attractive O
add-on O
to O
traditional O
chemotherapy O
and O
immunotherapy O
regimens O

g O

This O
indicated O
a O
possible O
commonality O
in O
their O
mode O
of O
action O
, O
unlike O
curcumin O
which O
might O
have O
a O
different O
mechanism O

HTS O
robots O
capable O
of O
low-volume O
dispensing O
reduce O
assay O
setup O
times O
and O
provide O
highly O
accurate O
and O
reproducible O
dispensing O
, O
minimizing O
variation O
between O
sample O
replicates O
and O
eliminating O
the O
potential O
for O
manual O
error O

466 O
: O
Epigenetics O
is O
the O
study O
of O
biochemical O
modifications O
carrying O
information O
independent O
of O
DNA O
sequence O
, O
which O
are O
heritable O
through O
cell O
division O

discuss O
available O
evidence O
suggesting O
that O
postnatal O
environmental O
risk O
factors O
contribute O
to O
psychotic B-Disease
disorders O
via O
epigenetic O
mechanisms O

Clarification O
of O
these O
issues O
is O
an O
important O
prerequisite O
for O
any O
experimental O
design O
with O
the O
aim O
to O
(dis)prove O
Kammerer O
and O
to O
establish O
a O
(potential) O
epigenetic O
basis O
of O
his O
observations O
about O
the O
mating O
behavior O
in O
midwife O
toads O

There O
is O
emerging O
evidence O
that O
epigenetic O
variants O
of O
functional O
and/or O
agronomic O
importance O
exist O
in O
CWR O
gene O
pools O

93 O
; O
95 O
% O
CI O
= O
0 O

those O
due O
to O
mutations O
to O
the O
gene O
regulation O
network O
and O
those O
due O
to O
noise O
in O
gene O
expression O
dynamics O
were O
found O
to O
be O
proportional O
over O
a O
number O
of O
genes O

We O
considered O
573 O
cases O
of O
low-grade O
glioma O
( O
LGG O
) O
and O
glioblastoma O
( O
GBM O
) O
from O
The O
Cancer B-Disease
Genome O
Atlas O
( O
TCGA O
) O

Here O
we O
introduce O
recent O
studies O
that O
have O
utilized O
this O
property O
for O
cancer B-Disease
research O

The O
epigenetic O
model O
of O
aging O
postulates O
that O
there O
are O
epigenetic O
marks O
of O
aging O
that O
increase O
with O
age O
, O
leading O
to O
a O
progressive O
derepression O
of O
DNA O
which O
in O
turn O
causes O
deregulated O
expression O
of O
genes O
that O
disrupt O
cell O
function O

While O
participants O
' O
recognition O
of O
epigenetic O
terms O
and O
phrases O
was O
high O
, O
their O
understanding O
was O
limited O

, O
due O
to O
mutations O
in O
genes O
in O
the O
population O
, O
or O
epigenetic O
, O
i O

A O
total O
of O
22 O
different O
epigenetic O
and O
transcriptional O
regulators O
of O
OCG O
were O
identified O
; O
key O
epigenetic O
regulators O
included O
DNA O
methylation O
, O
histone O
methylation O
, O
histone O
acetylation O
, O
miRNAs O
and O
lncRNAs O

At O
this O
region O
, O
5mC O
and O
5hmC O
levels O
both O
decreased O
with O
age O

669 O
: O
Aging O
is O
one O
of O
the O
most O
complex O
and O
irreversible O
health O
conditions O
characterized O
by O
continuous O
decline O
in O
physical/mental O
activities O
that O
eventually O
poses O
an O
increased O
risk O
of O
several O
diseases O
and O
ultimately O
death B-Disease

DNA O
methyltransferase O
and O
histone O
deacetylase O
, O
that O
regulate O
epigenetic O
patterns O
are O
active O
in O
clinical O
settings O

17: O
Epigenetics O
is O
likely O
to O
play O
a O
role O
in O
the O
mediation O
of O
the O
effects O
of O
genes O
and O
environment O
in O
risk O
for O
many O
non-communicable O
diseases O
( O
NCDs O
) O

Dr O
Pfeifer O
received O
a O
PhD O
degree O
from O
the O
University O
of O
Frankfurt O
, O
Germany O

61 O
was O
selected O
with O
a O
specificity O
of O
90 O

Thus O
, O
epigenetic O
marks O
may O
play O
roles O
in O
short-term O
( O
within O
an O
organism O
's O
lifetime O
or O
to O
the O
next O
generation O
) O
adaptation O
and O
phenotypic O
plasticity O

149 O
: O
Background O
: O
One O
of O
the O
fundamental O
assumptions O
of O
DNA O
methylation O
in O
clinical O
epigenetics O
is O
that O
DNA O
methylation O
status O
can O
change O
over O
time O
with O
or O
without O
interplay O
with O
environmental O
and O
clinical O
conditions O

We O
show O
that O
postgenomic O
research O
on O
health O
disparities O
in O
Latin O
America O
reintroduces O
old O
colonial O
views O
about O
the O
relations O
between O
race O
, O
environment O
, O
and O
social O
status O

Recent O
significant O
technological O
advancement O
in O
the O
study O
of O
epigenetics O
could O
break O
through O
the O
barrier O
of O
the O
mysterious O
black O
box O
of O
epigenetic O
toxicity O

This O
review O
offers O
a O
comprehensive O
overview O
of O
the O
current O
state O
of O
knowledge O
on O
epigenetic O
processes O
implicated O
in O
cardiovascular O
and O
metabolic B-Disease
diseases I-Disease
, O
highlighting O
the O
potential O
of O
DNA O
methylation O
as O
a O
precision O
medicine O
biomarker O
and O
examining O
the O
impact O
of O
social O
determinants O
of O
health O
, O
gut O


This O
protocol O
has O
been O
specifically O
optimized O
for O
detecting O
histone O
modifications O
in O
fluorescence-activated O
cell O
sorting O
(FACS)-isolated O
epidermal O
stem O
cells O
from O
adult O
mice O

With O
the O
advance O
in O
high-throughput O
sequencing O
and O
the O
availability O
of O
genome O
sequences O
, O
mapping O
the O
methylome O
for O
species O
with O
complex O
genomes O
has O
become O
increasingly O
feasible O

Such O
multi-samples O
experimental O
designs O
introduced O
analytical O
and O
computational O
challenges O

In O
addition O
, O
several O
significant O
brain-development O
related O
pathways O
, O
e O

This O
review O
will O
introduce O
and O
discuss O
the O
currently O
most O
popular O
pipelines O
and O
packages O
and O
is O
particularly O
aimed O
at O
new O
450k O
users O

Epigenetic O
abnormalities O
have O
been O
found O
to O
be O
causative O
factors O
in O
cancer B-Disease
, O
genetic O
disorders O
, O
and O
pediatric O
syndromes B-Disease

The O
same O
generic O
polymer O
model O
leads O
to O
quantitative O
differences O
between O
active O
, O
inactive O
and O
repressed O
domains O

Induced O
proximity O
strategies O
involve O
bringing O
molecular O
effectors O
into O
spatial O
proximity O
with O
specific O
genomic O
regions O
to O
achieve O
the O
probing O
or O
manipulation O
of O
local O
epigenetic O
environments O
with O
increased O
proximity O

Recent O
advances O
suggest O
that O
these O
2 O
distinct O
schools O
of O
thought O
could O
be O
united O

270 O
: O
As O
a O
mechanism O
of O
epigenetic O
gene O
regulation O
, O
DNA O
methylation O
has O
crucial O
roles O
in O
developmental O
and O
differentiation O
programs O

Candidate O
gene O
association O
studies O
( O
CGASs O
) O
along O
with O
genome-wide O
association O
studies O
( O
GWASs O
) O
and O
genome-wide O
linkage O
analyses O
( O
GWLAs O
) O
have O
found O
numerous O
genes O
and O
loci O
with O
susceptible O
DDH O
association O

To O
facilitate O
the O
uptake O
of O
the O
socio-exposome O
in O
multiomics O
oral B-Disease
health I-Disease
studies O
and O
subsequent O
interventions O
, O
3 O
pertinent O
facets O
are O
discussed O


The O
purpose O
of O
this O
perspective O
is O
to O
consider O
the O
placement O
of O
epigenetic O
and O
epigenomic O
insights O
within O
a O
population O
health O
framework O
to O
strengthen O
the O
physical O
therapy O
profession's O
understanding O
of O
variations O
in O
health O
, O
inform O
integrated O
action O
, O
and O
further O
justify O
our O
role O
in O
reducing O
health-related O
disparities O

, O
schizophrenia B-Disease
, O
Williams O
syndrome O
, O
and O
autism B-Disease
spectrum O
disorders O
(comparison O
2 O
) O

As O
new O
methylation O
microarrays O
are O
developed O
and O
older O
models O
discontinued O
, O
existing O
epigenetic O
clocks O
might O
become O
obsolete O

Epigenetic O
changes O
and O
metabolic O
rewiring O
are O
intertwined O
in O
cancer B-Disease

These O
CpG O
sites O
with O
sex O
differences O
in O
DNA O
methylation O
should O
be O
further O
investigated O
for O
their O
possible O
contribution O
to O
various O
physiological O
and O
pathological O
functions O
in O
the O
human O
body O

Is O
it O
possible O
that O
epigenetic O
variants O
modify O
temperament O
and O
human O
behavior O
? O
May O
abused O
or O
neglected O
children O
develop O
long-lasting O
epigenetic O
marks O
in O
their O
DNA O
? O
May O
bipolar O
states O
correlate O
with O
different O
epigenetic O
signatures O
? O
Studying O
these O
subjects O
in O
not O
an O
easy O
task O
, O
but O

) O
are O
of O
great O
importance O
in O
determining O
the O
functional O
state O
of O
chromatin O

A O
major O
problem O
is O
the O
fact O
that O
the O
brain O
is O
inaccessible O
to O
epigenetic O
studies O
in O
humans O
and O
the O
relevance O
of O
DNA O
methylation O
in O
peripheral O
tissues O
to O
behavioral O
phenotypes O
has O
been O
questioned O

Finally O
, O
the O
current O
hot O
topic O
of O
cancer B-Disease
stem O
cells O
is O
presented O

org O
) O
, O
a O
web O
- O
based O
platform O

Advancing O
paternal O
age O
is O
a O
subtle O
and O
varying O
phenotype O

An O
evolutionary O
explanation O
of O
why O
randomness O
exists O
in O
the O
development O
of O
organisms O
has O
long O
been O
articulated O
, O
in O
terms O
of O
offering O
a O
survival O
advantage O
in O
changing O
environments O

, O
adipose O
tissue O
, O
skeletal O
muscle O
, O
pancreatic O
islets O
, O
liver O
, O
and O
blood O
- O
in O
relation O
to O
obesity B-Disease
and O
T2D O

Among O
many O
epigenetic O
mechanisms O
, O
covalent O
modifications O
such O
as O
acetylation O
and O
methylation O
of O
lysine O
residues O
on O
core O
histones O
emerged O
as O
a O
major O
mechanism O
in O
epigenetic O
regulation O

Whereas O
CIMP O
is O
defined O
on O
the O
basis O
of O
hyper-methylation O
in O
tumor B-Disease
genomes O
, O
OMP O
is O
defined O
on O
the O
basis O
of O
highly O
variant O
( O
either O
or O
both O
hyper- O
and O
hypo-methylation O
) O
methylation O
at O
many O
sites O
in O
normal O
tissues O

In O
sum O
, O
integration O
into O
life O
science O
investigation O
of O
social O
experiences O
such O
as O
exposure O
to O
risk O
, O
nutritional O
habits O
, O
prejudice O
and O
stigma O
, O
is O
imperative O
to O
understand O
epigenetic O
variation O
in O
disease B-Disease

Here O
we O
review O
experimental O
evidence O
for O
the O
presence O
of O
noncytosine O
epigenetic O
modifications O
in O
metazoans O
and O
plants O
focusing O
on O
two O
" O
unusual O
" O
DNA O
bases O
, O
5-hydroxymethyluracil O
( O
5hmU O
) O
and O
N6-methyladenine O
( O
6mA O
) O
, O
and O
suggest O
potential O
explanations O
for O

The O
magnitude O
of O
rejuvenation O
instigated O
by O
MPTR O
appears O
substantially O
greater O
than O
that O
achieved O
in O
previous O
transient O
reprogramming O
protocols O

The O
new O
procedure O
was O
used O
with O
two O
simulated O
data O
sets O
and O
with O
a O
beef O
cattle O
database O

We O
used O
information O
on O
age-associated O
DNA O
methylation O
in O
human O
and O
mouse O
genes O
to O
identify O
homologous O
gene O
regions O
in O
humpbacks O

Future O
research O
should O
address O
these O
challenges O
, O
advance O
public O
health O
initiatives O
to O
reduce O
teratogen O
exposure O
and O
consider O
ethical O
implications O
of O
epigenetic O
profiling O

We O
argue O
that O
this O
situation O
might O
improve O
upon O
understanding O
the O
coinfluence O
between O
epigenetic O
pathways O
and O
tissue O
architecture O

Data O
analysis O
was O
performed O
using O
R O
via O
generalized O
regression O
models O

This O
study O
identifies O
a O
potential O
correlate O
or O
determinant O
of O
accelerated O
epigenetic O
aging-menarcheal O
age O

This O
review O
further O
outlines O
exciting O
future O
avenues O
of O
research O
to O
address O
the O
significance O
of O
epigenetic O
heterogeneity B-Disease
and O
the O
contributions O
of O
microfluidics O
technologies O
to O
single-cell O
isolation O
and O
analysis O

Supplementary O
information O
: O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

He O
joined O
the O
faculty O
at O
the O
University O
of O
Southern O
California O
in O
1996 O
, O
where O
he O
served O
as O
the O
Founding O
Director O
of O
the O
USC O
Epigenome O
Center O
and O
also O
as O
the O
Leader O
of O
the O
Epigenetics O
and O
Regulation O
Program O
of O
the O
Norris O
Comprehensive O
Cancer B-Disease
Center O

Targeting O
epigenetic O
reprogramming O
or O
plasticity O
represents O
a O
new O
strategy O
to O
prevent O
the O
emergence O
of O
drug-refractory O
populations O
and O
to O
enable O
more O
consistent O
clinical O
responses O

readthedocs O

In O
addition O
, O
the O
evolutionary O
role O
of O
epigenetically O
inherited O
phenotypes O
is O
a O
relatively O
recent O
but O
promising O
field O

298 O
: O
DNA O
methylation O
constitutes O
the O
most O
studied O
epigenetic O
mechanism O
, O
regulating O
gene O
expression O
in O
several O
physiological O
and O
pathological O
states O

312 O
: O
Background O
: O
Ageing O
is O
associated O
with O
DNA O
methylation O
changes O
in O
all O
human O
tissues O
, O
and O
epigenetic O
markers O
can O
estimate O
chronological O
age O
based O
on O
DNA O
methylation O
patterns O
across O
tissues O

345 O
: O
DNA O
methylation O
and O
gene O
expression O
are O
two O
critical O
aspects O
of O
the O
epigenetic O
landscape O
that O
contribute O
significantly O
to O
cancer B-Disease
pathogenesis O

Different O
epigenetic O
modifications O
, O
such O
as O
mutations O
in O
DNA O
methyltransferase O
and O
somatic B-Disease
mutations I-Disease
in O
core O
histone O
genes O
that O
lead O
to O
a O
global O
loss O
of O
the O
histone O
modifications O
, O
have O
innumerable O
relationships O

We O
observed O
widely O
aberrant O
methylation O
in O
the O
promoters O
of O
ncRNAs O
, O
and O
this O
abnormal O
methylation O
was O
more O
frequent O
than O
that O
in O
protein-coding O
genes O

provides O
evidence O
for O
this O
mode O
of O
inheritance O
in O
mice O
by O
using O
a O
CRISPR/Cas9-based O
epigenetic O
editing O
technique O
to O
modify O
DNA O
methylation O
levels O
at O
specific O
promoters O
and O
then O
demonstrating O
the O
inheritance O
of O
the O
gain O
in O
methylation O
in O
offspring O

286 O
: O
Gene O
regulatory O
pathways O
comprise O
an O
emerging O
and O
active O
area O
of O
chemical O
probe O
discovery O
and O
investigational O
drug O
development O

Second O
, O
we O
show O
on O
this O
basis O
that O
epigenetics O
has O
progressively O
turned O
its O
main O
focus O
from O
biological O
problems O
regarding O
development O
, O
toward O
issues O
concerning O
evolution O

While O
there O
is O
some O
degree O
of O
similarity O
between O
the O
nature O
and O
content O
of O
these O
areas O
and O
the O
abundant O
literature O
on O
ethical O
, O
legal O
and O
social O
issues O
in O
genetics O
, O
the O
potential O
implications O
of O
epigenetics O
ought O
not O
be O
conflated O
with O
the O
latter O

The O
present O
work O
highlights O
substantial O
scopes O
and O
relevant O
discoveries O
related O
to O
the O
development O
of O
the O
term O
from O
its O
first O
notions O

Consequently O
, O
targeting O
the O
enzymatic O
machinery O
that O
controls O
the O
epigenetic O
regulation O
of O
the O
genome O
has O
emerged O
as O
an O
attractive O
new O
strategy O
for O
therapeutic O
intervention O

303 O
: O
The O
aim O
of O
this O
article O
is O
to O
put O
the O
growing O
interest O
in O
epigenetics O
in O
the O
field O
of O
evolutionary O
theory O
into O
a O
historical O
context O

100 O
: O
Emerging O
ethical O
, O
legal O
, O
and O
social O
implications O
( O
ELSI O
) O
scholarship O
in O
epigenetics O
has O
focused O
largely O
on O
hypothetical O
issues O
involving O
institutional O
racism O
, O
discrimination O
, O
and O
eugenics O

, O
heavy O
metals O
, O
particulate O
air O
pollution O
, O
bisphenol O
A O
, O
hydroquinone O
, O
and O
pentachlorophenol O
metabolites O
) O

Finally O
, O
the O
authors O
provide O
some O
suggestions O
for O
future O
directions O

We O
anticipate O
that O
JMnorm O
will O
enhance O
integrative O
and O
comparative O
epigenomics O

442 O
: O
Motivation O
: O
DNA O
methylation-based O
predictors O
of O
various O
biological O
metrics O
have O
been O
widely O
published O
and O
are O
becoming O
valuable O
tools O
in O
epidemiologic O
studies O
of O
epigenetics O
and O
personalized O
medicine O

Suicidal O
behavior O
is O
the O
product O
of O
the O
interaction O
of O
many O
risk O
factors O
, O
such O
as O
genetics O
and O
environmental O
factors O

There O
is O
an O
urgent O
need O
for O
appropriate O
analytical O
methods O
for O
EWAS O
mediation O
analysis O

However O
, O
the O
interplay O
between O
these O
factors O
has O
only O
recently O
been O
started O
to O
be O
unraveled O

The O
talks O
were O
mainly O
focused O
on O
questions O
of O
the O
generation O
, O
maintenance O
, O
flexibility O
and O
erasure O
of O
DNA O
methylation O
patterns O
in O
context O
of O
other O
epigenetic O
signals O
like O
histone O
tail O
modifications O
and O
ncRNAs O

This O
revealed O
that O
matrix O
factorization O
, O
latent O
variable O
analysis O
, O
and O
deep O
learning O
are O
potent O
strategies O

Nearly O
any O
brain O
region O
of O
interest O
can O
be O
targeted O
in O
rodents O
at O
every O
stage O
of O
postnatal O
life O

We O
focus O
our O
review O
on O
DNA O
methylation O
and O
histone O
PTMs O
, O
the O
two O
most O
important O
aspects O
of O
epigenetic O
mechanisms O

In O
addition O
, O
Epi-MSA O
has O
a O
good O
interpretability O
, O
this O
is O
confirmed O
by O
referring O
its O
attention O
weight O
matrix O
with O
existing O
biological O
knowledge O

Within O
the O
European O
Network O
for O
Human O
Congenital O
Imprinting O
Disorders O
we O
have O
discussed O
these O
issues O
and O
designed O
a O
nomenclature O
for O
naming O
imprinted O
DMRs O
as O
well O
as O
for O
reporting O
methylation O
values O

As O
a O
result O
, O
interest O
in O
placental O
epigenetics O
generally O
, O
and O
changes O
occurring O
in O
placenta-associated O
disease B-Disease
, O
has O
intensified O
over O
recent O
years O

Finally O
, O
we O
discuss O
DNA O
methylation O
profiling O
technologies O
and O
the O
most O
recent O
advances O
in O
single-cell O
methods O
, O
bisulfite-free O
approaches O
and O
ultra-long O
read O
sequencing O
techniques O

271 O
: O
Epigenetics O
is O
the O
study O
of O
the O
heritable O
changes O
on O
gene O
expression O
that O
are O
responsible O
for O
the O
regulation O
of O
development O
and O
that O
have O
an O
impact O
on O
several O
diseases O

638 O
: O
Somatic O
mutations O
accumulating O
over O
a O
patient O
's O
lifetime O
are O
well-defined O
causative O
factors O
that O
fuel O
carcinogenesis O

Patterned O
action O
potential O
activity O
activates O
intracellular O
signaling O
networks O
selectively O
in O
accordance O
with O
the O
kinetics O
of O
activation O
and O
inactivation O
of O
second O
messengers O
, O
phosphorylation O
and O
dephosphorylation O
of O
protein O
kinases O
, O
and O
cytoplasmic O
and O
nuclear O
calcium O
dynamics O
, O
which O
differentially O
activate O
specific O
transcription O

Availability O
and O
implementation O
: O
The O
function O
was O
included O
in O
software O
package O
ENmix O
, O
and O
is O
freely O
available O
from O
Bioconductor O
website O
( O
https://www O

The O
growth O
of O
tumors B-Disease
depends O
on O
a O
network O
of O
supplying O
vessels O
that O
provide O
them O
with O
oxygen O
and O
nutrients O

Because O
of O
the O
inherent O
flexibility O
of O
epigenetic O
regulation O
, O
a O
variety O
of O
biological O
phenomena O
can O
be O
traced O
back O
to O
evolutionary O
adaptations O
of O
few O
conserved O
molecular O
pathways O
that O
converge O
on O
chromatin O

Importantly O
, O
as O
the O
first O
point O
of O
contact O
for O
many O
of O
such O
environmental O
factors O
including O
nutrition O
, O
the O
digestive O
system O
is O
being O
increasingly O
linked O
to O
a O
number O
of O
" O
modern O
" O
pathologies O

Gene O
expression O
is O
known O
to O
change O
in O
characteristic O
ways O
with O
age O
, O
and O
in O
particular O
DNA O
methylation O
changes O
in O
age-related O
ways O

Systemic O
autoimmune O
diseases O
include O
rheumatoid B-Disease
arthritis I-Disease
, O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
, O
systemic B-Disease
sclerosis I-Disease
, O
Sjogren B-Disease
syndrome I-Disease
, O
polymyositis O
, O
and O
dermatomyositis O

However O
, O
a O
group O
of O
small O
molecules O
called O
polyamines O
also O
require O
SAM O
for O
their O
synthesis O

This O
paragraph O
will O
discuss O
all O
conceived O
technologies O
and O
new O
perspectives O
that O
can O
be O
applied O
in O
treating O
some O
associated O
genetic O
disorders O
, O
such O
as O
cardiovascular B-Disease
diseases I-Disease
, O
metabolic B-Disease
diseases I-Disease
, O
inflammatory O
diseases O
, O
and O
tumors B-Disease
by O
means O
of O
reversible O
and O

632 O
: O
The O
sequence O
of O
the O
human O
genome O
represents O
our O
genetic O
blueprint O

FBW7 O
is O
a O
tumor B-Disease
suppressor O
that O
functions O
as O
an O
Mcl-1 O
E3 O
ligase O
to O
degrade O
Mcl-1 O
by O
ubiquitination O

mpg O

In O
a O
subset O
of O
patients O
with O
congenital B-Disease
neurodevelopmental I-Disease
disorders I-Disease
, O
clear O
diagnosis O
can O
be O
achieved O
using O
DNA O
sequence-based O
analysis O
to O
identify O
changes O
in O
the O
DNA O
sequence O
( O
genetic O
variation O
) O

405 O
: O
Epigenetic O
testing O
is O
one O
of O
the O
most O
significant O
new O
technologies O
to O
provide O
insight O
into O
the O
behavioral O
and O
environmental O
factors O
that O
influence O
the O
development O
and O
reconfiguration O
of O
the O
human O
genetic O
code O

746 O
: O
Environmental O
stress O
is O
one O
of O
the O
most O
important O
factors O
affecting O
plant O
growth O
and O
development O

Recent O
findings O
: O
There O
are O
several O
methods O
established O
with O
the O
collaborative O
efforts O
from O
different O
consortiums O
, O
such O
as O
ENCODE O
, O
Human O
Cell O
Atlas O
, O
and O
exRNA O
consortium O
to O
study O
role O
of O
epigenetics O
in O
human O
health O

Moreover O
, O
we O
explore O
how O
epigenetic O
factors O
alter O
cellular O
pathways O
and O
associated O
biological O
networks O
, O
contributing O
to O
the O
MSC O
aging O
phenotype O

The O
next O
challenge O
is O
to O
leverage O
these O
tools O
for O
improved O
patient O
outcomes O

Plant O
studies O
have O
provided O
numerous O
important O
contributions O
to O
the O
epigenetic O
research O

45 O
: O
The O
prevalence O
of O
obesity B-Disease
and O
associated O
diseases O
has O
reached O
pandemic O
levels O

Moreover O
, O
the O
interplay O
between O
epigenome O
and O
cell O
growth O
pathways O
is O
extensively O
described O
in O
published O
literature O

Epi-drugs O
include O
histone O
methylation O
inhibitors O
, O
histone O
demethylation O
inhibitors O
, O
histone O
deacetylation O
inhibitors O
, O
and O
DNA O
methylation O
inhibitors O

619 O
: O
The O
epigenetic O
trajectory O
of O
DNA O
methylation O
profiles O
has O
a O
nonlinear O
relationship O
with O
time O
, O
reflecting O
rapid O
changes O
in O
DNA O
methylation O
early O
in O
life O
that O
progressively O
slow O
with O
age O

As O
a O
result O
, O
minimal O
DNA O
methylation O
changes O
during O
developmental O
stages O
drive O
severe O
phenotypes O
, O
as O
observed O
in O
germ-line O
imprinting O
disorders O
, O
while O
genome-wide O
alterations O
occurring O
in O
somatic O
cells O
are O
linked O
to O
cancer B-Disease
onset O
and O
progression O

86 O
) O
and O
high O
repeatability O
( O
PCC O
> O
0 O

In O
this O
review O
, O
we O
summarize O
the O
existing O
literature O
on O
dietary O
micronutrients O
, O
bioactive O
compounds O
, O
and O
food-borne O
mycotoxins O
that O
affect O
DNA O
methylation O
patterns O
and O
identify O
their O
potential O
in O
the O
onset O
and O
treatment O
of O
cancer B-Disease

However O
, O
data O
about O
the O
relationship O
between O
drug O
response O
and O
the O
epigenomic O
variations O
is O
still O
scarce O
mainly O
because O
the O
epigenome O
is O
highly O
variable O
between O
individuals O

However O
, O
each O
assay O
comes O
with O
its O
own O
specific O
set O
of O
analytical O
needs O
if O
enhancer O
prediction O
is O
to O
be O
optimal O

In O
addition O
, O
we O
applied O
this O
analysis O
to O
the O
transitional O
zone O
between O
methylated O
and O
unmethylated O
regions O
and O
to O
the O
cells O
undergoing O
epigenetic O
reprogramming O

This O
allows O
users O
to O
analyse O
data O
from O
the O
Infinium O
Human O
Methylation O
BeadChip O
in O
the O
easiest O
possible O
way O

464 O
: O
Simian O
virus B-Disease
40 O
( O
SV40 O
) O
is O
one O
of O
the O
best-characterized O
members O
of O
the O
polyomavirus O
family O
of O
small O
DNA O
tumor B-Disease
viruses B-Disease

Investigators O
commonly O
superimpose O
separate O
ChIP-seq O
or O
BS-seq O
datasets O
, O
and O
then O
infer O
where O
chromatin O
features O
are O
found O
together O

Here O
we O
describe O
in O
detail O
protocols O
for O
three O
methods O
to O
measure O
DNA O
methylation O
and O
hydroxymethylation O
at O
specific O
genomic O
targets O
: O
glucMS-qPCR O
, O
and O
two O
sequencing O
approaches O
( O
pyrosequencing O
and O
high-throughput O
sequencing O
) O
for O
analyzing O
bisulfite- O
and O
oxidative O
bisulfite-modified O
DNA O

Several O
lines O
of O
evidence O
suggest O
that O
largely O
chance O
events O
, O
from O
the O
biographical O
down O
to O
the O
sub-cellular O
, O
contribute O
an O
important O
stochastic O
element O
to O
disease B-Disease
risk O
that O
is O
not O
epidemiologically O
tractable O
at O
the O
individual O
level O

394 O
: O
Based O
on O
epidemiological O
and O
genomic O
characteristics O
, O
lung B-Disease
cancer I-Disease
in O
never O
smokers O
( O
LCNS O
) O
is O
a O
different O
disease B-Disease
from O
lung B-Disease
cancer I-Disease
in O
smokers O

The O
Developmental O
Origins O
of O
Health O
and O
Disease O
(DOHaD) O
theory O
presents O
unique O
opportunities O
regarding O
the O
possibility O
of O
early O
life O
interventions O
to O
alter O
the O
epigenetic O
makeup O
of O
an O
individual O
, O
thereby O
modifying O
their O
risk O
for O
a O
variety O
of O
NCDs O

Epigenetic O
alterations O
can O
arise O
from O
downstream O
activation O
of O
cellular O
pathways O
through O
both O
extracellular O
stimulation O
and O
genetic-associated O
changes O
, O
impacting O
epigenetic O
enzymes O
or O
their O
interactors O

197 O
: O
Epigenetic O
modifications O
are O
responsible O
for O
the O
stable O
maintenance O
of O
cellular O
phenotypes O
and O
consist O
of O
DNA O
methylation O
and O
histone O
modifications O

To O
address O
this O
question O
, O
epigenetic O
mechanisms O
have O
emerged O
as O
the O
potential O
link O
between O
genetic O
and O
environmental O
factors O
of O
health O
and O
disease B-Disease

601 O
: O
Cellular O
automatons O
and O
computer O
simulation O
games O
are O
widely O
used O
as O
heuristic O
devices O
in O
biology O
, O
to O
explore O
implications O
and O
consequences O
of O
specific O
theories O

This O
Review O
summarizes O
epigenetic O
signatures O
obtained O
from O
human O
tissues O
of O
relevance O
for O
metabolism-i O

Several O
approaches O
have O
been O
successfully O
used O
over O
the O
last O
three O
decades O
in O
different O
fields O

We O
also O
provide O
insights O
into O
the O
mechanism O
of O
action O
of O
the O
drugs O
under O
investigation O
and O
their O
potential O
impact O
on O
disease-modifying O
pathways O

102 O
: O
The O
regulation O
of O
gene O
expression O
plays O
a O
pivotal O
role O
in O
complex O
phenotypes O
, O
and O
epigenetic O
mechanisms O
such O
as O
DNA O
methylation O
are O
essential O
to O
this O
process O

A O
combination O
of O
Active O
Learning O
(ACL) O
and O
Imbalanced O
Class O
Learning O
(ICL) O
was O
used O
to O
address O
past O
problems O
with O
ML O
to O
develop O
a O
more O
efficient O
feature O
selection O
process O
and O
address O
the O
imbalance O
problem O
in O
all O
genomic O
data O
sets O

The O
current O
limitations O
associated O
with O
epigenetic O
profiling O
and O
therapeutics O
in O
liver O
disease B-Disease
are O
discussed O
, O
as O
is O
the O
intriguing O
possibility O
that O
environmental-induced O
epigenetic O
changes O
may O
become O
stable O
and O
heritable O

6 O
kbp O
plasmid O
into O
the O
human O
genome O

The O
identified O
evidence O
gaps O
call O
for O
a O
joint O
endeavour O
by O
the O
medical O
community O
towards O
a O
deeper O
and O
more O
systematic O
study O
of O
HCN O
, O
aiming O
at O
defining O
epigenetic O
markers O
in O
early O
diagnose O
, O
allowing O
for O
accurate O
stratification O
of O
maligancy B-Disease
and O
disease B-Disease
risk O
and O
for O
effective O

7 O
% O
vs O

These O
insights O
have O
led O
to O
the O
introduction O
of O
novel O
targeted O
therapies O
, O
revolutionising O
the O
management O
of O
patients O
with O
advanced O
disease B-Disease

Both O
of O
these O
approaches O
require O
substantial O
investments O
and O
expertise O
in O
terms O
of O
instrumentation O
, O
experimental O
methodology O
, O
bioinformatics O
, O
and O
data O
interpretation O
and O
are O
, O
therefore O
, O
usually O
applied O
independently O
from O
each O
other O
by O
dedicated O
research O
groups O

172 O
: O
In O
many O
aspects O
of O
life O
, O
epigenetics O
, O
or O
the O
altering O
of O
phenotype O
without O
changes O
in O
sequences O
, O
play O
an O
essential O
role O
in O
biological O
function O

545 O
: O
Cancer B-Disease
epigenetics O
is O
one O
of O
the O
most O
important O
research O
subjects O
in O
dissecting O
cancer B-Disease
mechanisms O
and O
therapeutic O
targets O
because O
the O
emergence O
and O
malignant O
transformation O
of O
various O
cancers B-Disease
are O
caused O
by O
unnatural O
expression O
of O
cancer-related O
genes O
attributed O
to O
their O
epigenetic O
errors O

The O
Szyf O
lab O
proposed O
two O
decades O
ago O
that O
DNA O
methylation O
is O
a O
prime O
therapeutic O
target O
in O
cancer B-Disease
and O
other O
diseases O
and O
postulated O
and O
provided O
the O
first O
set O
of O
evidence O
that O
the O
social O
environment O
early O
in O
life O
can O
alter O
DNA O
methylation O
, O
launching O
the O
em O

Environmental O
factors O
, O
somatic B-Disease
mutations I-Disease
and O
ageing O
contribute O
to O
epigenetic O
changes O
that O
may O
constitute O
early O
hallmarks O
or O
causal O
factors O
of O
disease B-Disease

Chromatin O
immunoprecipitation O
followed O
by O
sequencing O
( O
ChIP-seq O
) O
is O
the O
most O
widely O
used O
method O
to O
characterize O
where O
in O
the O
genome O
transcription O
factors O
, O
modified O
histones O
, O
modified O
nucleotides O
and O
chromatin O
binding O
proteins O
are O
found O
; O
bisulfite O
sequencing O
( O
BS-seq O
) O
and O

Even O
if O
Lamarckism O
is O
not O
back O
, O
epigenetic O
inheritance O
might O
be O
appealing O
for O
evolutionary O
biologists O
because O
it O
could O
potentiate O
two O
neglected O
mechanisms O
: O
the O
Baldwin O
effect O
and O
genetic O
assimilation O

In O
this O
regard O
, O
epigenetics O
represents O
a O
great O
opportunity O
for O
the O
integration O
of O
public O
policy O
measures O
aimed O
to O
create O
healthier O
living O
environments O

When O
the O
scope O
of O
the O
analysis O
is O
to O
detect O
regions O
of O
the O
genome O
with O
different O
methylation O
patterns O
between O
two O
or O
more O
conditions O
, O
e O

This O
review O
will O
discuss O
experimental O
evidence O
so O
far O
showing O
a O
role O
for O
epigenetic O
regulation O
in O
models O
of O
peripheral O
and O
central O
nervous B-Disease
system I-Disease
axonal O
injury O

These O
important O
observations O
suggest O
that O
future O
epigenetic O
studies O
are O
necessary O
to O
better O
understand O
, O
classify O
, O
prevent O
, O
and O
treat O
epileptic O
disorders O

CTCF O
is O
involved O
in O
multiple O
aspects O
of O
epigenetic O
regulation O
including O
regulation O
of O
chromatin O
remodeling O
and O
genomic O
imprinting O

Maternal O
factors O
, O
including O
nutrition O
, O
smoking O
and O
toxin O
exposure O
, O
can O
alter O
CB O
DNA O
methylation O
patterns O
, O
associated O
with O
conditions O
from O
obesity B-Disease
to O
neurodevelopmental O
disorders O

337 O
: O
The O
growth O
in O
epigenetics O
continues O
to O
attract O
considerable O
cross-disciplinary O
interest O
, O
apparently O
representing O
an O
opportunity O
to O
move O
beyond O
genomics O
towards O
the O
goal O
of O
understanding O
phenotypic O
variability O
from O
molecular O
through O
organismal O
to O
the O
societal O
level O

However O
, O
mapping O
efforts O
to O
determine O
an O
individual O
's O
cell-type-specific O
epigenome O
are O
constrained O
by O
experimental O
costs O
and O
tissue O
accessibility O

These O
computational O
models O
have O
been O
shown O
to O
possess O
properties O
typically O
found O
in O
the O
biological O
world O
, O
such O
as O
robustness O
and O
self O
organisation O

456 O
: O
DNA O
methylation O
is O
an O
epigenetic O
modification O
with O
a O
very O
long O
evolutionary O
history O

Larger O
sample O
sizes O
, O
replication O
, O
genetic-epigenetic O
analyses O
and O
longitudinal O
assays O
are O
now O
needed O
to O
establish O
the O
role O
of O
epigenetic O
variants O
in O
disease B-Disease

The O
package O
of O
Snapshot O
is O
available O
at O
GitHub O
: O
https://github O

Furthermore O
, O
we O
provide O
a O
large-scale O
performance O
comparison O
across O
different O
tissues O
and O
diseases O
in O
terms O
of O
age O
prediction O
accuracy O
and O
age O
acceleration O
, O
a O
measure O
of O
deviance O
from O
physiology O

Building O
on O
sociologist O
Thomas O
Lemke O
's O
Foucauldian O
" O
analytics O
of O
biopolitics O
" O
and O
on O
literature O
from O
the O
field O
of O
science O
and O
technology O
studies O
, O
we O
present O
two O
sociological O
trends O
that O
may O
impede O
the O
policy O
translation O
of O
epigenetics O
: O
molecularization O
and O
biomedicalization O

Of O
note O
, O
studies O
investigating O
the O
epigenetic O
control O
of O
the O
onset O
of O
puberty O
suggest O
that O
epigenetic O
repression O
of O
key O
inhibitory O
loci O
may O
play O
a O
fundamental O
role O
in O
the O
initiation O
of O
puberty O

We O
argue O
that O
, O
since O
Waddington O
, O
epigenetics O
, O
as O
an O
integrative O
research O
area O
, O
has O
been O
used O
to O
bridge O
the O
gap O
between O
different O
biological O
fields O

All O
genomic O
data O
from O
publicly O
funded O
projects O
are O
freely O
available O
in O
Internet-based O
databases O
, O
for O
download O
or O
searching O
via O
genome O
browsers O
such O
as O
Ensembl O
, O
Vega O
, O
NCBI's O
Map O
Viewer O
, O
and O
the O
UCSC O
Genome O
Browser O

05 O
[ O
95% O
CI O
- O
0 O

In O
particular O
, O
we O
examine O
whether O
we O
could O
identify O
separations O
between O
the O
female O
and O
male O
distributions O
of O
DNA O
methylation O
across O
hundred O
of O
thousands O
CpG O
sites O
in O
two O
independent O
cohorts O
, O
the O
Swedish O
Adoption O
Twin O
study O
and O
the O
Lamarck O
study O

Here O
we O
focused O
on O
DNA O
methylation O
and O
posttranslational O
histone O
modifications O

We O
conducted O
our O
study O
in O
canids O
, O
which O
prove O
to O
be O
an O
ideal O
species O
to O
assess O
epigenetic O
moderators O
due O
to O
their O
extreme O
variability O
in O
size O
and O
well-characterized O
genetic O
structure O

425 O
: O
This O
article O
compares O
two O
different O
bodies O
of O
theories O
concerning O
the O
role O
of O
the O
genome O
in O
life O
processes O

In O
recent O
years O
, O
the O
Waddington O
diagram O
has O
been O
repurposed O
to O
illustrate O
how O
cellular O
identity O
changes O
in O
the O
context O
of O
reprogramming O

Alterations O
in O
the O
normal O
methylation O
levels O
of O
DNA O
may O
contribute O
to O
the O
development O
of O
pathological O
conditions O
like O
cancer B-Disease

Furthermore O
, O
there O
is O
circumstantial O
evidence O
that O
a O
subset O
of O
antipsychotic O
drugs O
, O
including O
the O
atypical O
, O
Clozapine O
, O
interfere O
with O
chromatin O
remodeling O
mechanisms O

I'm O

For O
diagnostics O
, O
DNA O
methylation O
and O
miRNA O
biomarkers O
are O
well O
suited O
because O
of O
their O
relatively O
high O
stability O

This O
review O
will O
take O
a O
look O
back O
at O
the O
origins O
of O
this O
field O
and O
revisit O
the O
past O
early O
efforts O
to O
conduct O
EWAS O
using O
the O
27k O
Illumina O
methylation O
beadarrays O
, O
to O
the O
present O
where O
most O
investigators O
are O
using O
the O
450k O
Illumina O
beadarrays O
and O
finally O
to O

0 O

com O
/ O
NGS-lib O
/ O
NGSplusplus O

Often O
, O
each O
of O
these O
resulting O
datasets O
is O
large O
, O
heterogeneous O
, O
and O
noisy O

355 O
: O
The O
majority O
of O
methylome-wide O
association O
studies O
( O
MWAS O
) O
have O
been O
performed O
using O
commercially O
available O
array-based O
technologies O
such O
as O
the O
Infinium O
Human O
Methylation O
450K O
and O
the O
Infinium O
MethylationEPIC O
arrays O
( O
Illumina O
) O

Yet O
, O
the O
clinical O
use O
for O
solid O
tumors B-Disease
of O
approved O
epigenetic O
drugs O
is O
meager O

Finally O
, O
we O
conclude O
by O
presenting O
a O
typology O
of O
the O
different O
conceptions O
of O
epigenetics O
throughout O
time O
, O
and O
analyse O
the O
connections O
between O
them O

The O
interest O
in O
epigenetics O
is O
also O
true O
for O
studies O
of O
drug O
metabolism O
and O
transport O

These O
conditions O
cannot O
be O
ignored O
by O
anyone O
but O
there O
are O
evidences O
that O
suggest O
that O
exercise O
, O
healthy O
diet O
and O
good O
routines O
may O
delay O
the O
Aging O
process O
significantly O

By O
and O
large O
, O
these O
challenges O
have O
been O
successfully O
met O
by O
the O
introduction O
by O
statutes O
such O
as O
the O
Genetic O
Information O
Nondiscrimination O
Act O
( O
GINA O
) O

Concurrently O
, O
immune O
cells O
undergo O
significant O
metabolic O
reprogramming O
during O
immune O
response O

Functionally O
, O
epigenetics O
provides O
an O
extra O
layer O
of O
transcriptional O
control O
and O
plays O
a O
crucial O
role O
in O
normal O
physiological O
development O
, O
as O
well O
as O
in O
pathological O
conditions O

338 O
: O
Epigenetics O
, O
referring O
to O
genetic O
modifications O
that O
change O
gene O
expression O
, O
but O
which O
are O
not O
encoded O
in O
DNA O
, O
has O
been O
shown O
to O
be O
related O
to O
oncology O
, O
with O
the O
potential O
to O
influence O
associated O
treatments O

The O
structure O
of O
chromatin O
is O
subjected O
to O
a O
dynamic O
regulation O
through O
multiple O
epigenetic O
mechanisms O
, O
including O
DNA O
methylation O
, O
histone O
posttranslational O
modifications O
( O
PTMs O
) O
, O
chromatin O
remodeling O
and O
noncoding O
RNAs O

We O
describe O
EpiSAFARI O
, O
a O
computational O
method O
for O
sensitive O
detection O
of O
valleys O
from O
diverse O
types O
of O
epigenetic O
profiles O

We O
also O
identified O
a O
set O
of O
18 O
genes O
epigenetically O
active O
and O
consistently O
expressed O
in O
the O
thyroid O
that O
are O
likely O
highly O
relevant O
to O
thyroid O
function O

Integration O
of O
epigenetic O
information O
represents O
yet O
another O
challenging O
molecular O
frontier O

We O
hypothesized O
that O
the O
variation O
of O
SWI/SNF O
subunit O
expression O
in O
the O
human O
population O
would O
contribute O
to O
variability O
in O
the O
efficiency O
of O
induced O
pluripotent O
stem O
cells O
( O
iPSC O
) O
reprogramming O

As O
predicted O
, O
CSA O
, O
but O
not O
genetic O
load O
or O
later O
substance O
abuse O
, O
was O
associated O
with O
epigenetic O
change O

However O
, O
growing O
evidence O
shows O
that O
alterations O
in O
molecular O
mediators O
associated O
with O
the O
diagnosis O
of O
CMPs O
are O
not O
always O
correlated O
with O
genetic O
mutations O
, O
suggesting O
that O
additional O
mechanisms O
, O
such O
as O
epigenetics O
, O
may O
play O
a O
role O
in O
the O
onset O
or O
progression O
of O
CMPs O

zoom O
in O
on O
the O
late O
occurring O
, O
subclonal O
subset O
of O
such O
mutations O
and O
define O
the O
molecular O
mechanism O
behind O
their O
enrichment O
in O
cancer B-Disease

219 O
: O
A O
plethora O
of O
preclinical O
evidences O
suggests O
that O
pharmacological O
targeting O
of O
epigenetic O
dysregulation O
is O
a O
potent O
strategy O
to O
combat O
human O
diseases O

Recent O
studies O
show O
that O
epigenetic O
factors O
, O
such O
as O
DNA O
methylation O
affect O
gene O
expression O
and O
therefore O
could O
play O
an O
important O
role O
in O
DDH O
pathogenesis O

We O
developed O
a O
package O
that O
reduces O
noise O
while O
normalizing O
the O
epigenomic O
data O
by O
a O
novel O
normalization O
method O
, O
followed O
by O
integrative O
dimensional O
reduction O
by O
learning O
and O
assigning O
epigenetic O
states O

Nonetheless O
, O
the O
literature O
for O
researchers O
seeking O
guidance O
on O
which O
platform O
to O
choose O
is O
sparse O

For O
example O
, O
there O
is O
a O
high O
negative O
correlation O
between O
promoter O
CpG O
methylation O
and O
CD3D O
expression O
in O
renal O
and O
thyroid B-Disease
cancers I-Disease
, O
but O
not O
in O
brain O
tumors B-Disease

Conventional O
methods O
for O
detecting O
DNA O
methylation O
, O
ranging O
from O
paper O
chromatography O
to O
differential O
restriction O
enzyme O
digestion O
preference O
to O
dot O
blots O
, O
have O
more O
recently O
been O
supplemented O
by O
ultrahigh O
performance O
liquid O
chromatography O
coupled O
with O
mass O
spectrometry O
( O
UHPLC-MS/MS O
) O
to O
accurately O
quantify O

Understanding O
its O
role O
in O
the O
development O
of O
atherosclerosis O
holds O
the O
promise O
of O
identifying O
a O
new O
category O
of O
therapeutic O
targets O
, O
since O
epigenetic O
changes O
are O
amenable O
to O
reversal O

Third O
, O
the O
possibility O
of O
epigenetic O
effects O
( O
inherited O
changes O
in O
gene O
expression O
) O
as O
a O
result O
of O
Famine O
has O
been O
discussed O
as O
a O
possible O
mechanism O
whereby O
Famine O
survivors O
might O
have O
passed O
on O
experiences O
of O
physical O
and O
psychological O
trauma B-Disease
to O
their O
children O
and O
subsequent O
gener O

cfNOMe O
has O
the O
potential O
to O
advance O
biomarker O
discovery O
and O
diagnostic O
usage O
in O
diseases O
with O
systemic O
perturbations O
of O
cfDNA O
composition O

One O
method O
that O
permits O
methylome O
analysis O
is O
methylated O
DNA O
immunoprecipitation O
( O
MeDIP O
) O
combined O
with O
next-generation O
sequencing O
( O
MeDIP-seq O
) O

In O
this O
chapter O
, O
we O
provide O
an O
overview O
of O
recent O
advances O
on O
high-dimensional O
mediation O
analysis O
, O
with O
application O
to O
two O
DNA O
methylation O
data O

g O

87 O
× O
10-5 O
] O

664 O
: O
The O
Epigenomics O
resource O
at O
the O
National O
Center O
for O
Biotechnology O
Information O
( O
NCBI O
) O
has O
been O
created O
to O
serve O
as O
a O
comprehensive O
public O
repository O
for O
whole-genome O
epigenetic O
data O
sets O
( O
www O

In O
particular O
, O
starting O
with O
low-input O
DNA O
can O
result O
in O
low-diversity O
libraries O


Finally O
, O
we O
expect O
EWAS2 O

Due O
to O
its O
complex O
pathogenesis O
, O
the O
treatment O
means O
of O
DR O
are O
very O
limited O


This O
seems O
to O
be O
particularly O
the O
case O
during O
vulnerable O
periods O
of O
human O
development O
such O
as O
pregnancy O
and O
early O
life O

3 O
× O
10-7 O
) O

There O
are O
periods O
in O
an O
organism O
's O
life O
cycle O
in O
which O
the O
organism O
is O
particularly O
susceptible O
to O
epigenetic O
influences O
; O
these O
include O
fertilization O
, O
gametogenesis O
, O
and O
early O
embryo O
development O

Epigenome O
editing O
, O
the O
most O
promising O
derivative O
technology O
of O
genome O
editing O
, O
can O
modify O
the O
epigenetic O
states O
at O
the O
pre-defined O
genomic O
locus O
using O
the O
programmable O
effectors O
, O
consisting O
of O
various O
epigenetic O
factors O
combined O
with O
site-specific O
DNA-binding O
domains O

457 O
: O
Background O
: O
Epigenetic O
mechanisms O
are O
informational O
cellular O
processes O
instructing O
normal O
and O
diseased O
phenotypes O

As O
with O
the O
previous O
introduction O
of O
genetic O
research O
in O
psychiatry O
, O
there O
is O
also O
the O
problem O
of O
unrealistic O
expectations O
and O
new O
legal O
and O
ethical O
problems O

The O
total O
number O
of O
epialleles O
, O
the O
epiallele O
DNAm O
patterns O
, O
and O
a O
noise O
hyperparameter O
are O
all O
automatically O
inferred O
from O
the O
data O

Screening O
the O
DNA O
methylome O
offers O
an O
attractive O
alternative O
as O
methylation O
can O
be O
thought O
of O
as O
a O
proxy O
for O
the O
combined O
influences O
of O
genetics O
and O
environment O

These O
techniques O
for O
genome-wide O
profiling O
of O
chromatin O
provide O
powerful O
and O
efficient O
tools O
to O
study O
the O
epigenome O

His O
research O
interests O
include O
cellular O
biology O
and O
genetics O
of O
cancer B-Disease
, O
specifically O
epigenetics O
or O
genetic O
modifications O
other O
than O
those O
in O
DNA O
that O
can O
affect O
cell O
behavior O
, O
and O
silencing O
of O
tumor B-Disease
suppressor O
genes O
and O
tumor B-Disease
progression O

Genome O
wide O
association O
studies O
( O
GWAS O
) O
completed O
during O
the O
past O
few O
years O
have O
identified O
risk O
associated O
single O
nucleotide O
polymorphisms O
that O
can O
be O
used O
as O
screening O
tools O
in O
epidemiologic O
studies O
of O
a O
variety O
of O
tumor B-Disease
types O

edu O
/ O
conneely O
/ O
MethLAB O
) O
using O
R O
, O
an O
open O
source O
statistical O
language O
that O
can O
be O
edited O
to O
suit O
the O
needs O
of O
the O
user O

123 O
: O
Epigenetics O
provides O
the O
opportunity O
to O
revolutionize O
our O
understanding O
of O
the O
role O
of O
genetics O
and O
the O
environment O
in O
explaining O
human O
behavior O
, O
although O
the O
use O
of O
epigenetics O
to O
study O
human O
behavior O
is O
just O
beginning O

By O
viewing O
methylation O
maintenance O
as O
a O
communications O
system O
, O
we O
introduce O
methylation O
channels O
and O
show O
that O
higher-order O
chromatin O
organization O
can O
be O
predicted O
from O
their O
informational O
properties O

The O
field O
of O
epigenomics O
aims O
to O
detect O
and O
interpret O
epigenetic O
modifications O
at O
the O
whole O
genome O
level O

Eventually O
, O
harnessing O
epigenetic O
strategies O
presents O
a O
promising O
trajectory O
toward O
sustainable O
agriculture O
in O
the O
face O
of O
escalating O
environmental O
challenges O

Few O
methodologies O
integrate O
epigenetic O
based O
predictions O
of O
multiple O
approaches O
when O
combining O
profiles O
generated O
by O
different O
tools O

The O
here O
presented O
protocol O
shows O
a O
method O
to O
obtain O
DNA O
samples O
ready O
for O
NGS O
sequencing O
for O
genome-wide O
methylation O
analysis O

88 O
) O
with O
a O
threshold O
value O
of O
0 O

From O
memory O
formation O
to O
immune O
function O
, O
the O
experience-dependent O
plasticity O
of O
epigenetic O
modifications O
to O
micro- O
and O
macro-social O
environments O
may O
contribute O
to O
the O
process O
of O
learning O
from O
comfort O
, O
pain O
, O
and O
stress O
to O
better O
survive O
in O
whatever O
circumstances O
life O
has O
in O
store O

Probing O
the O
role O
of O
various O
epigenetic O
mechanisms O
that O
contribute O
to O
AF O
may O
improve O
our O
knowledge O
of O
this O
complex O
disease B-Disease
, O
identify O
potential O
therapeutic O
targets O
, O
and O
facilitate O
targeted O
therapies O

Technological O
advancements O
in O
high-throughput O
genome O
sequencing O
and O
functional O
genomics O
have O
unraveled O
the O
complexities O
of O
epigenetic O
regulation O
in O
response O
to O
heavy O
metal O
and O
metalloid O
contamination O

It O
is O
also O
unknown O
whether O
these O
changes O
represent O
protective O
mechanisms O
to O
function O
or O
predispose O
to O
pathology O

Here O
we O
review O
the O
impact O
that O
epigenetic O
changes O
, O
and O
specifically O
DNA O
methylation O
, O
have O
on O
these O
extraordinary O
sequences O
in O
driving O
cancer B-Disease
progression O

Mass O
spectrometry O
(MS) O
has O
emerged O
as O
a O
versatile O
technology O
for O
the O
analysis O
of O
histones O
, O
contributing O
to O
the O
dissection O
of O
hPTMs O
, O
with O
special O
strength O
in O
the O
identification O
of O
novel O
marks O
and O
in O
the O
assessment O
of O
modification O
cross O
talks O

Both O
implementations O
were O
tested O
with O
datasets O
from O
fluorescent O
qPCR O
reactions O
, O
as O
well O
as O
pH-LAMP O
experiments O
that O
have O
been O
optimized O
for O
on-chip O
amplifications O

This O
lack O
of O
significant O
progress O
in O
the O
pharmacotherapy O
of O
schizophrenia B-Disease
is O
a O
reflection O
of O
the O
complexity O
and O
heterogeneity B-Disease
of O
its O
etiopathogenetic O
mechanisms O

In O
this O
review O
, O
a O
cross O
section O
of O
current O
knowledge O
on O
these O
issues O
is O
presented O
with O
special O
interest O
regarding O
the O
future O
clinical O
applications O

Together O
, O
our O
methods O
enable O
generalizable O
, O
versatile O
multimodal O
profiles O
for O
reconstructing O
comprehensive O
epigenome O
and O
transcriptome O
landscapes O
and O
analyzing O
the O
regulatory O
interplay O
at O
single-cell O
level O

254 O
: O
Allergic O
disease B-Disease
development O
is O
affected O
by O
both O
genes O
and O
the O
environment O
, O
and O
epigenetic O
mechanisms O
are O
hypothesized O
to O
mediate O
these O
environmental O
effects O

Similarly O
, O
conditions O
affecting O
the O
local O
microenvironment O
of O
cells O
, O
such O
as O
chronic B-Disease
inflammation I-Disease
, O
worsen O
the O
prognosis O
in O
cardiovascular B-Disease
diseases I-Disease
and O
additionally O
induce O
further O
epigenetic O
modifications O
leading O
to O
the O
consolidation O
of O
unfavorable O
cardiovascular O
changes O

RNA O
and O
DNA O
methylation O
integration O
were O
not O
previously O
possible O
, O
by O
CloneViz O
( O
previous O
version O
) O
or O
any O
other O
clonality O
method O
to O
date O

0 O
can O
analyze O
EWAS O
data O
and O
identify O
the O
association O
between O
epigenetic O
variations O
and O
disease/phenotype O

org O

Here O
, O
my O
goal O
is O
to O
introduce O
some O
of O
the O
common O
goals O
and O
challenges O
shared O
by O
those O
pursuing O
this O
critical O
field O

The O
reproducibility O
of O
childhood O
trauma B-Disease
DNAm O
studies O
, O
and O
the O
field O
of O
social O
epigenetics O
in O
general O
, O
may O
be O
improved O
by O
increasing O
sample O
sizes O
, O
standardizing O
variables O
, O
making O
use O
of O
effect O
size O
thresholds O
, O
collecting O
longitudinal O
and O
intervention O
samples O
, O
appropriately O
accounting O
for O

Genetic O
studies O
have O
also O
shown O
that O
some O
recurrent O
mutations O
in O
genes O
involved O
in O
the O
epigenetic O
machinery O
, O
including O
TET2 O
, O
IDH2-R172 O
, O
DNMT3A O
, O
RHOA O
, O
CD28 O
, O
IDH2 O
, O
TET2 O
, O
MLL2 O
, O
KMT2A O
, O
KDM6A O
, O
CREBBP O

Here O
, O
using O
a O
comprehensive O
genome-wide O
analysis O
of O
H3K27ac O
mark O
and O
gene O
expression O
in O
mammary O
epithelial O
cells O
undergoing O
EMT O
, O
we O
found O
that O
ERK O
signalling O
is O
essential O
for O
the O
epigenetic O
reprogramming O
underlying O
hallmark O
gene O
expression O
and O
phenotypic O
changes O
of O
EMT O

This O
would O
enable O
them O
to O
address O
the O
questions O
of O
which O
features O
, O
where O
in O
the O
genome O
, O
and O
which O
circumstances O
are O
essential O
to O
shape O
development O
and O
trigger O
disease B-Disease
states O

Over O
the O
last O
two O
decades O
, O
great O
advances O
have O
been O
made O
in O
identifying O
these O
alterations O
and O
their O
importance O
in O
the O
initiation O
and O
progression O
of O
cancer B-Disease

They O
can O
be O
of O
use O
for O
validating O
methylation-based O
biomarkers O
to O
include O
in O
clinical O
practice O

ac O

The O
assay O
has O
an O
R(2) O
of O
0 O

experimental O
designs O
, O
settings O
, O
techniques O
) O
and O
' O
stereotypes O
' O
( O
i O

The O
recent O
discovery O
of O
the O
sex O
determining O
region O
( O
SDR O
) O
of O
balsam O
poplar O
, O
Populus O
balsamifera O
, O
pinpointed O
13 O
genes O
with O
differentiated O
X O
and O
Y O
copies O

46 O
: O
Background O
: O
Previous O
studies O
have O
traditionally O
attributed O
the O
initiation O
of O
cancer B-Disease
cells O
to O
genetic O
mutations O
, O
considering O
them O
as O
the O
fundamental O
drivers O
of O
carcinogenesis O

After O
a O
postdoctoral O
stay O
in O
the O
technology O
development O
department O
of O
the O
Centre O
National O
de O
Génotypage O
(Evry, O
France), O
he O
led O
the O
Epigenetics O
groups O
from O
2006 O
to O
2012, O
before O
becoming O
the O
Director O
of O
Laboratory O
for O
Epigenetics O
and O
Environment O
at O
the O
Centre O
National O
de O
Recherche O
en O
Génomique O

688 O
: O
Here O
we O
report O
epigenomic O
and O
transcriptomic O
changes O
in O
a O
prototypical O
J774 O
macrophage O
after O
engulfing O
talc O
or O
titanium O
dioxide O
particles O
in O
presence O
of O
estrogen O

Additionally O
, O
we O
provide O
a O
hypothesis O
to O
explain O
how O
signal-induced O
crosstalk O
between O
histone O
tail O
modifications O
and O
long O
non-coding O
RNAs O
triggers O
chromatin O
architectural O
remodeling O
and O
culminates O
in O
cardiac O
hypertrophy O
and O
fibrosis O

We O
illustrate O
the O
outputs O
and O
performance O
of O
S3V2-IDEAS O
using O
137 O
epigenomics O
datasets O
from O
the O
VISION O
project O
that O
provides O
ValIdated O
Systematic O
IntegratiON O
of O
epigenomic O
data O
in O
hematopoiesis B-Disease

Moreover O
, O
some O
unique O
epigenetic O
mechanisms O
have O
been O
evolved O
in O
plants O

257 O
: O
Our O
goal O
is O
to O
draw O
a O
line-hypothetical O
in O
its O
totality O
but O
experimentally O
supported O
at O
each O
individual O
step-connecting O
the O
ribosomal O
DNA O
and O
the O
phenomenon O
of O
transgenerational O
epigenetic O
inheritance O
of O
induced O
phenotypes O

This O
article O
draws O
on O
a O
multi-sited O
ethnography O
of O
epigenetic O
knowledge O
production O
in O
the O
United O
States O
and O
Canada O
to O
document O
how O
scientists O
conceptualize O
, O
model O
, O
and O
measure O
these O
experiences O
and O
their O
effects O
on O
children O
's O
neurodevelopmental O
and O
behavioral O
health O

Known O
imprinted O
regions O
are O
enriched O
among O
epigenetically O
regulated O
loci O
, O
but O
we O
also O
observe O
several O
novel O
genomic O
regions O
( O
e O

Genomic O
profiling O
of O
pancreatic O
islets O
in O
non-diabetic O
and O
diabetic B-Disease
states O
is O
needed O
in O
order O
to O
dissect O
the O
contribution O
of O
epigenetic O
mechanisms O
to O
the O
declining O
proliferation O
potential O
of O
β O
cells O
that O
we O
see O
with O
aging O
or O
the O
β-cell O
failure O
observed O
in O
diabetes B-Disease

04e-16 O
) O
and O
predicts O
age O
from O
skin O
samples O
with O
a O
standard O
deviation O
of O
2 O

719 O
: O
Epigenetic O
and O
genetic O
alterations O
contribute O
to O
cancer B-Disease
initiation O
and O
progression O

Atrial O
remodeling O
includes O
changes O
in O
ion O
channel O
expression O
and O
function O
, O
structural O
alterations O
, O
and O
neural O
remodeling O
, O
which O
create O
an O
arrhythmogenic O
milieu O
resulting O
in O
AF O
initiation O
and O
maintenance O

R2 O
for O
epigenetic O
clocks O
based O
on O
the O
HorvathMammalMethylChip4 O
was O
higher O
and O
the O
MAD O
scaled O
to O
age O
range O
lower O
, O
compared O
with O
other O
DNAm O
quantification O
approaches O

Computational O
analysis O
of O
differential O
DNA O
enrichment O
between O
conditions O
is O
important O
for O
identifying O
epigenetic O
alterations O
in O
disease B-Disease
compared O
to O
healthy O
controls O
and O
for O
revealing O
dynamic O
epigenetic O
modifications O
throughout O
normal O
and O
distorted O
cell O
differentiation O
and O
development O

Given O
the O
link O
between O
aging O
, O
genetic O
, O
and O
epigenetic O
alterations O
, O
and O
given O
the O
reversible O
nature O
of O
epigenetic O
mechanisms O
, O
the O
precisely O
understanding O
of O
these O
factors O
may O
provide O
a O
potential O
therapeutic O
approach O
for O
age-related O
decline O
and O
disease B-Disease

Such O
therapeutic O
failure O
could O
result O
from O
no O
response O
, O
drug O
resistance O
, O
disease B-Disease
relapse O
or O
severe O
side O
effect O
from O
improper O
drug O
delivery O

As O
epigenetic O
drugs O
implicated O
in O
lymphoma B-Disease
have O
been O
continually O
reported O
in O
recent O
years O
, O
many O
new O
ideas O
for O
the O
diagnosis O
, O
treatment O
, O
and O
prognosis O
of O
PTCL O
originate O
from O
epigenetics O
in O
recent O
years O

We O
demonstrate O
that O
JMnorm-normalized O
data O
can O
better O
preserve O
cross-epigenetic-feature O
correlations O
across O
different O
cell O
types O
and O
enhance O
consistency O
between O
biological O
replicates O
than O
data O
normalized O
by O
other O
methods O

The O
present O
review O
provides O
a O
contextual O
background O
to O
CCS O
research O
and O
a O
theoretical O
framework O
discussing O
the O
potential O
uses O
of O
this O
novel O
epigenomic O
biomarker O
within O
sport O
and O
exercise O
science O
and O
medicine O

745 O
: O
With O
the O
development O
and O
improvement O
of O
high-throughput O
sequencing O
technologies O
, O
the O
acquisition O
and O
processing O
approaches O
of O
various O
biological O
omics O
data O
on O
different O
levels O
are O
becoming O
more O
mature O

EpiProfile O
2 O

Increasingly O
, O
investigators O
are O
incorporating O
epigenetic O
analysis O
into O
the O
studies O
of O
etiology O
and O
outcomes O

The O
enormous O
information O
content O
that O
comes O
with O
the O
large O
variety O
of O
observed O
STR O
genotypes O
allows O
for O
genetic O
individualisation O
( O
with O
the O
exception O
of O
identical O
twins O
) O

There O
is O
, O
however O
, O
a O
third O
, O
and O
separate O
, O
school O
based O
on O
the O
historical O
literature O
and O
debates O
and O
regards O
epigenetics O
as O
more O
of O
a O
perspective O
than O
a O
phenomenon O

Aging O
is O
a O
complex O
process O
with O
wide O
intervariability O
among O
individuals O

Epigenetic O
mechanisms O
program O
cell-type-specific O
gene O
expression O
during O
development O
, O
enabling O
one O
genome O
to O
be O
programmed O
in O
many O
ways O
, O
resulting O
in O
diverse O
stable O
profiles O
of O
gene O
expression O
in O
different O
cells O
and O
organs O
in O
the O
body O

Within O
the O
viral O
genome O
nucleosomes O
are O
organized O
for O
the O
expression O
of O
appropriate O
genes O
with O
relevant O
histone O
modifications O
particularly O
histone O
acetylation O

The O
muscle O
clock O
outperformed O
the O
pan-tissue O
clock O
, O
with O
a O
median O
error O
of O
only O
4 O

0 O
) O
, O
for O
accurate O
quantification O
of O
histone O
peptides O
based O
on O
liquid O
chromatography-tandem O
mass O
spectrometry O
( O
LC-MS/MS O
) O
analysis O

These O
epigenetic O
marks O
include O
DNA O
methylation O
at O
CpG O
dinucleotides O
, O
covalent O
modifications O
of O
histone O
proteins O
, O
and O
noncoding O
RNAs O
( O
ncRNAs O
) O

DNA O
methylation O
, O
histone O
modification O
, O
and O
RNA O
regulation O
are O
some O
of O
the O
mechanisms O
involved O
in O
epigenetic O
modification O

In O
addition O
, O
resistance O
to O
contaminating O
cells O
makes O
DNA O
methylation O
useful O
in O
genome-wide O
screening O
of O
biomarkers O
for O
various O
clinicopathologic O
characteristics O

In O
fact O
, O
epitranscriptomics O
aims O
at O
identifying O
and O
characterizing O
all O
functionally O
relevant O
changes O
involving O
both O
non-substitutional O
chemical O
modifications O
and O
editing O
events O
made O
to O
the O
transcriptome O

, O
human O
and O
mouse O
) O

© O
2017 O
Wiley O
Periodicals O
, O
Inc O

008 O
, O
- O
0 O

In O
addition O
, O
human O
studies O
are O
usually O
confounded O
with O
genetic O
and O
environmental O
heterogeneity B-Disease
and O
it O
is O
very O
difficult O
to O
derive O
causality O

Defining O
the O
heritability O
of O
epigenetic O
states O
and O
the O
underlying O
chromatin-based O
mechanisms O
within O
a O
population O
of O
cells O
is O
complicated O
due O
to O
cell O
heterogeneity B-Disease
combined O
with O
varying O
levels O
of O
stability O
of O
these O
states O
; O
thus O
, O
efforts O
must O
be O
focused O
toward O
single-cell O
analyses O

The O
histone O
modification O
valleys O
detected O
by O
EpiSAFARI O
exhibit O
high O
conservation O
, O
transcription O
factor O
binding O
and O
they O
are O
enriched O
in O
nascent O
transcription O

ChIPseeker O
is O
a O
freely O
available O
open-source O
package O
that O
may O
be O
found O
at O
https://www O

Comprehension O
and O
relevant O
alterations O
in O
these O
epigenetic O
modifications O
can O
lead O
to O
new O
therapeutic O
avenues O
of O
age-delaying O
contrivances O

84 O
, O
P O
< O
0 O

We O
show O
that O
the O
field O
of O
epigenetics O
and O
epigenomics O
could O
serve O
to O
link O
molecular O
regulatory O
mechanisms O
with O
disease B-Disease
development O
and O
disease B-Disease
manifestation O
which O
could O
contribute O
to O
PCOS O
prevention O
and O
treatment O
and O
eventually O
promote O
reproductive O
health O
in O
fertile O
age O
women O

We O
close O
by O
considering O
various O
ethical O
, O
legal O
, O
and O
social O
issues O
posed O
by O
recent O
developments O
in O
public O
health O
genomics O
; O
these O
include O
policies O
to O
regulate O
access O
to O
personal O
genomic O
information O
, O
the O
need O
to O
enhance O
genetic O
literacy O
in O
both O
health O
professionals O
and O
the O
public O
, O
and O

Studies O
were O
included O
if O
they O
described O
epigenetic O
and/or O
transcriptional O
regulation O
of O
OCG O
in O
a O
specific O
skeletal O
disorder B-Disease
, O
and O
quantified O
alterations O
in O
OCG O
by O
any O
well-described O
experimental O
method O


122 O
: O
DNA O
methylation O
alterations O
play O
mechanistic O
roles O
in O
aging O
; O
however O
, O
the O
epigenetic O
regulators O
/ O
mediators O
causally O
involved O
in O
renal B-Disease
aging I-Disease
remain O
elusive O

The O
first O
epigenetic O
biomarkers O
correlating O
with O
the O
successful O
outcome O
of O
immunotherapy O
have O
been O
reported O
, O
and O
with O
personalized O
treatment O
options O
being O
rolled O
out O
, O
epigenetic O
modifications O
might O
well O
play O
a O
role O
in O
monitoring O
or O
even O
predicting O
the O
response O
to O
tailored O
therapy O

08 O
; O
q O
= O
0 O

Hallmarks O
of O
ageing O
include O
the O
accumulation O
of O
molecular O
damage O
, O
failure O
of O
quality O
control O
systems O
, O
metabolic O
changes O
and O
alterations O
in O
epigenome O
stability O

624 O
: O
Numerous O
preclinical O
and O
clinical O
trials O
, O
with O
older O
as O
well O
as O
some O
newer O
drugs O
, O
have O
demonstrated O
the O
targeting O
of O
aberrant O
epigenetic O
marks O
to O
be O
a O
viable O
means O
of O
preventing O
and O
treating O
certain O
human O
disorders O
, O
including O
myelodysplastic O
and O
leukemic O

He O
is O
known O
for O
his O
groundbreaking O
studies O
linking O
environmental O
exposures O
early O
in O
life O
to O
the O
development O
of O
adult O
diseases O
through O
changes O
in O
the O
epigenome O
and O
for O
determining O
the O
evolutionary O
origin O
of O
genomic O
imprinting O
in O
mammals O

Through O
the O
practice O
of O
this O
course O
, O
students O
have O
a O
deeper O
understanding O
of O
the O
important O
role O
of O
epigenetic O
modifications O
, O
their O
scientific O
research O
capabilities O
have O
been O
greatly O
improved O
, O
thereby O
strongly O
supporting O
the O
cultivation O
of O
top O
innovative O
talents O
among O
the O
students O

436 O
: O
Analogous O
to O
multicellular O
organisms O
, O
social O
insect O
colonies O
are O
characterized O
by O
division O
of O
labor O
with O
queens O
and O
workers O
reflecting O
germline O
and O
soma O
, O
respectively O

Several O
lines O
of O
evidence O
garnered O
over O
the O
past O
decades O
suggest O
that O
epigenetic O
alterations O
, O
mostly O
encompassing O
DNA O
methylation O
, O
histone O
tail O
modifications O
, O
and O
generation O
of O
microRNAs O
, O
play O
an O
important O
, O
though O
still O
incompletely O
explored O
, O
role O
in O
both O
primary O
and O
secondary O
hemostasis O

All O
epigenetic O
effects O
are O
considered O
in O
light O
of O
their O
persistent O
changes O
induced O
in O
the O
postsynaptic O
neurons O
including O
sensitization O
and O
desensitization O
, O
priming O
, O
and O
shift O
of O
neuronal O
phenotype O

This O
novel O
concept O
of O
methylation-specific O
reaction O
, O
based O
on O
a O
straightforward O
chemical O
process O
, O
expands O
the O
range O
of O
methods O
available O
for O
the O
analysis O
of O
epigenetic O
modifications O

Application O
of O
those O
techniques O
to O
transplantation O
research O
is O
still O
very O
limited O
because O
of O
technical O
limitations O

It O
has O
also O
been O
widely O
adapted O
to O
map O
chromatin B-Disease
modifications I-Disease
and O
TFs O
in O
different O
species O
, O
illustrating O
the O
association O
of O
these O
chromatin O
epitopes O
with O
various O
physiological O
and O
pathological O
processes O

A O
record O
of O
this O
paper O
's O
transparent O
peer O
review O
process O
is O
included O
in O
the O
Supplemental O
Information O

New O
technologies O
as O
detection O
of O
circulating O
nucleic O
acids O
including O
microRNAs O
to O
early O
detect O
breast B-Disease
cancer I-Disease
are O
emerging O

16/15 O

He O
is O
currently O
a O
full O
professor O
at O
the O
Van O
Andel O
Institute O
in O
Grand O
Rapids O
, O
MI O

They O
encode O
the O
four O
subunits O
and O
assembly O
factor O
of O
succinate O
dehydrogenase O
(SDH) O
, O
a O
mitochondrial O
enzyme O
involved O
both O
in O
the O
tricarboxylic O
acid O
cycle O
and O
electron O
transport O
chain O

279 O
: O
A O
key O
challenge O
in O
epigenetics O
is O
to O
determine O
the O
biological O
significance O
of O
epigenetic O
variation O
among O
individuals O

With O
advances O
in O
modern O
health O
care O
, O
the O
average O
age O
of O
the O
general O
population O
is O
ever O
increasing O

The O
intent O
of O
this O
review O
is O
to O
elaborate O
upon O
well-supported O
examples O
of O
epigenetic O
precision O
medicine O
and O
how O
the O
field O
is O
moving O
forward O
, O
primarily O
in O
the O
context O
of O
aberrant O
DNA O
methylation O

Original O
research O
articles O
published O
in O
English O
measuring O
life O
trauma B-Disease
, O
post-traumatic O
stress O
, O
experience O
of O
discrimination O
, O
and O
epigenetic O
clocks O
or O
aging O
were O
analyzed O
using O
PRISMA O
guidelines O

558 O
: O
Considerable O
epidemiological O
, O
experimental O
and O
clinical O
data O
have O
amassed O
showing O
that O
the O
risk O
of O
developing O
disease B-Disease
in O
later O
life O
is O
dependent O
on O
early O
life O
conditions O
, O
mainly O
operating O
within O
the O
normative O
range O
of O
developmental O
exposures O

The O
present O
review O
describes O
the O
current O
knowledge O
on O
epigenetic O
alterations O
in O
the O
course O
of O
various O
kidney O
disease B-Disease
states O

711: O
ageing O
is O
the O
gradual O
decline O
in O
organismal O
fitness O
that O
occurs O
over O
time O
leading O
to O
tissue O
dysfunction O
and O
disease B-Disease

Thus O
, O
understanding O
the O
molecular O
mechanisms O
operated O
by O
methamphetamine O
represents O
a O
wide O
window O
to O
understand O
both O
the O
addicted O
brain O
and O
a O
variety O
of O
neuropsychiatric O
disorders O

These O
advances O
include O
the O
identification O
of O
epipolymorphisms O
associated O
with O
clinical O
outcomes O
, O
DNA O
methylation O
as O
a O
contributor O
to O
disease B-Disease
susceptibility O
in O
rheumatic O
conditions O
, O
the O
discovery O
of O
novel O
epigenetic O
mechanisms O
that O
modulate O
disease B-Disease
susceptibility O
and O
the O
development O
of O
new O
epigenetic O
therapies O

By O
contrast O
, O
several O
epigenetic O
biomarkers O
and O
treatments O
are O
currently O
in O
use O
for O
personalized O
therapies O
in O
patients O
with O
cancer B-Disease

Moreover O
, O
oleuropein O
( O
OLP O
) O
, O
an O
olive-derived O
polyphenol O
, O
also O
displayed O
similar O
epigenetic O
modulation O
and O
antiaging O
effects O

We O
hope O
this O
review O
will O
trigger O
a O
discussion O
about O
epigenetic O
toxicity O
that O
will O
lead O
to O
encouraging O
research O
advancements O

A O
plethora O
of O
studies O
have O
emphasized O
the O
importance O
of O
analyzing O
epigenetics O
data O
through O
genome-wide O
studies O
and O
high-throughput O
approaches O
, O
thereby O
providing O
key O
insights O
towards O
epigenetics-based O
diseases O
such O
as O
cancer B-Disease

Despite O
the O
increase O
in O
use O
, O
marijuana O
's O
effect O
on O
aging O
remains O
understudied O
and O
understanding O
the O
effects O
of O
marijuana O
on O
molecular O
aging O
may O
provide O
novel O
insights O
into O
the O
role O
of O
marijuana O
in O
the O
aging O
process O

Epigenetics O
can O
be O
defined O
as O
reversible O
heritable O
changes O
to O
chromatin O
that O
can O
alter O
gene O
expression O
without O
altering O
the O
gene O
's O
DNA O
sequence O

These O
severely O
affect O
the O
levels O
and O
distribution O
of O
DNA O
methylation O
, O
histone O
modifications O
, O
chromatin O
accessibility O
, O
and O
three-dimensional O
genome O
interactions O

Methods O
: O
We O
derived O
Horvath O
's O
DNA O
methylation O
age O
( O
DNAmAge O
) O
, O
Hannum O
's O
DNAmAge O
, O
PhenoAge O
, O
and O
GrimAge O
based O
on O
DNA O
methylation O
measured O
in O
peripheral O
blood O
samples O
from O
479 O
Australian O
women O
in O
130 O
families O

Using O
the O
term O
epimutation O
as O
exemplar O
, O
we O
analyze O
the O
paradoxical O
like-but-unlike O
structure O
of O
a O
term O
that O
must O
simultaneously O
connect O
with O
but O
depart O
from O
genetic O
concepts O

64 O
: O
Purpose O
of O
review O
: O
The O
purpose O
of O
this O
review O
is O
to O
provide O
an O
update O
of O
recent O
advances O
in O
the O
established O
role O
of O
different O
layers O
of O
epigenetic O
control O
mechanism O
that O
are O
used O
by O
joint O
cells O
to O
ensure O
tissue O
homeostasis O
and O
cope O
with O
changing O
microenvironment O
( O
e O

CVDs O
such O
as O
congenital B-Disease
heart I-Disease
disease I-Disease
, O
cardiomyopathy O
, O
heart B-Disease
failure I-Disease
, O
cardiac B-Disease
fibrosis I-Disease
, O
hypertension B-Disease
, O
and O
atherosclerosis O
are O
now O
being O
viewed O
as O
much O
more O
complex O
and O
dynamic O
disorders O

Specifically O
, O
we O
incorporate O
heat O
shock O
treatment O
for O
increased O
transfection O
efficiency O
of O
the O
MCF-7 O
cell O
line O

Most O
such O
proteins O
are O
prions O
( O
e O

During O
ontogenesis O
, O
the O
DNA O
methylome O
undergoes O
both O
programmed O
changes O
and O
those O
induced O
by O
environmental O
and O
endogenous O
factors O

Epigenetics O
provides O
a O
way O
to O
think O
about O
traumatic O
events O
and O
sustained O
deprivation O
as O
biological O
"exposures" O
that O
contribute O
to O
ill-health O
across O
generations O

Such O
analyses O
can O
produce O
a O
large O
number O
of O
false O
positive O
predictions O
, O
suggesting O
that O
sites O
supported O
by O
multiple O
algorithms O
provide O
a O
stronger O
foundation O
for O
inferring O
and O
characterizing O
regulatory O
programs O
associated O
with O
the O
epigenetic O
data O

Thus O
, O
the O
variances O
of O
phenotypes O
due O
to O
genetic O
and O
epigenetic O
perturbations O
provide O
quantitative O
measures O
for O
such O
changeability O
during O
evolution O
and O
development O
, O
respectively O

Recent O
findings O
: O
The O
main O
current O
themes O
that O
will O
be O
addressed O
on O
the O
role O
of O
epigenetics O
in O
disease B-Disease
pathogenesis O
include O
current O
understanding O
of O
the O
nature O
and O
function O
of O
histone O
modifications O
and O
DNA O
methylation O
; O
the O
connection O
between O
epigenetics O
and O
metabolic O
pathways O
; O
new O
studies O
on O

Availability O
and O
implementation O
: O
http://sigseeker O

21 O
[ O
95% O
CI O
0 O

Maternal O
and O
paternal O
environment O
, O
during O
all O
the O
development O
of O
the O
individual O
from O
gametogenesis O
to O
weaning O
and O
beyond O
, O
as O
well O
as O
the O
psychosocial O
environment O
in O
childhood O
and O
teenage O
, O
can O
shape O
the O
adult O
and O
the O
elderly O
person O
's O
susceptibility O
to O
her O
/ O
his O
own O
environment O

Small O
molecules O
are O
promising O
therapeutic O
approaches O
to O
target O
the O
epigenetic-metabolomic O
crosstalk O
in O
cancer B-Disease

DNAm O
in O
preterm O
and O
term O
hematopoietic O
cells O
conformed O
to O
previously O
identified O
DNAm O
signatures O
of O
fetal O
liver O
and O
bone O
marrow O
, O
respectively O

Preterm O
infants O
are O
hospitalized O
in O
the O
Neonatal O
Intensive O
Care O
Unit O
( O
NICU O
) O
where O
they O
are O
exposed O
to O
life-saving O
yet O
pain-inducing O
procedures O
and O
to O
protective O
care O

A O
total O
of O
25,765 O
of O
these O
were O
differentially O
methylated O
( O
DMCs O
) O

598 O
: O
Swine O
performance O
in O
the O
face O
of O
disease B-Disease
challenge O
is O
becoming O
progressively O
more O
important O

We O
also O
discuss O
how O
"computational O
epigenetics" O
has O
complemented O
the O
fast O
growth O
in O
the O
generation O
of O
epigenetic O
data O
for O
uncovering O
the O
main O
differences O
and O
similarities O
at O
the O
epigenetic O
level O
between O
individuals O
and O
the O
mechanisms O
underlying O
disease B-Disease
onset O
and O
progression O

In O
isogenic O
lineages O
and O
asexually O
reproducing O
organisms O
, O
poor O
or O
absent O
genetic O
diversity O
can O
hence O
be O
tolerated O

Considering O
the O
growing O
interest O
in O
and O
availability O
of O
DNA O
methylation O
data O
, O
there O
is O
a O
great O
need O
for O
user-friendly O
open O
source O
analytical O
tools O

Given O
the O
complex O
pathophysiology O
of O
cardiovascular B-Disease
diseases I-Disease
, O
an O
experimental O
approach O
capable O
of O
identifying O
multiple O
signaling O
networks O
activated O
in O
the O
heart O
upon O
pathological O
conditions O
could O
be O
particularly O
effective O
to O
identify O
new O
diagnostic O
, O
prognostic O
or O
therapeutic O
targets O

Furthermore O
, O
we O
are O
currently O
limited O
in O
the O
number O
of O
neuronal O
subtypes O
whose O
induction O
is O
fully O
established O
, O
and O
different O
cultivation O
protocols O
for O
each O
subtype O
exist O
, O
making O
it O
challenging O
to O
increase O
the O
reproducibility O
and O
decrease O
the O
variances O
that O
are O
observed O
between O
different O
protocols O

532 O
: O
Motivation O
: O
Characterizing O
cancer B-Disease
subclones O
is O
crucial O
for O
the O
ultimate O
conquest O
of O
cancer B-Disease

The O
results O
obtained O
from O
these O
models O
were O
compared O
with O
each O
other O
and O
with O
the O
outcomes O
generated O
by O
other O
well-established O
epigenetic O
clocks O

In O
this O
review O
, O
we O
highlight O
the O
evidence O
that O
epigenetic O
modifications O
, O
specifically O
histone O
modifications O
, O
within O
key O
brain O
reward O
regions O
are O
correlated O
with O
addiction O

Epigenomic O
studies O
using O
high-throughput O
technologies O
will O
widen O
the O
understanding O
of O
mechanisms O
as O
well O
as O
functions O
of O
regulatory O
pathways O
in O
plant O
genomes O
, O
which O
will O
further O
help O
in O
manipulating O
these O
pathways O
using O
genetic O
and O
biochemical O
approaches O

The O
main O
epigenetic O
mechanisms O
reported O
are O
DNA O
methylation O
, O
histone O
post-translational O
modifications O
, O
and O
non-coding O
RNAs O

These O
regions O
harbor O
distant O
regulatory O
elements O
, O
enhancers O
, O
super-enhancers O
, O
insulators O
, O
alternative O
promoters O
, O
and O
sequences O
that O
transcribe O
as O
noncoding O
RNAs O
( O
ncRNAs O
) O
such O
as O
miRNAs O
and O
long O
ncRNAs O

Reanalysis O
of O
the O
same O
single O
cell O
is O
also O
useful O
to O
acquire O
multiple O
epigenetic O
marks O
from O
the O
same O
single O
cells O

Further O
analysis O
reduced O
the O
number O
of O
CpG O
sites O
required O
for O
optimal O
determination O
of O
body O
fluid O
type O
to O
five O

However O
, O
when O
large-scale O
clonal O
propagation O
is O
the O
aim O
, O
there O
has O
been O
a O
concern O
in O
confirming O
true-to-typeness O
using O
molecular O
markers O
for O
evaluating O
stability O

36 O

The O
most O
common O
variation O
in O
the O
human O
genome O
is O
the O
SNP O
, O
which O
occurs O
throughout O
the O
genome O
, O
both O
within O
coding O
and O
noncoding O
regions O

The O
article O
concludes O
by O
shedding O
light O
on O
some O
of O
the O
current O
and O
prospective O
opportunities O
for O
social O
epigenomics O
research O
applied O
to O
the O
study O
of O
life O
course O
oral O
epidemiology O

Dysregulation O
can O
occur O
at O
any O
stage O
; O
however O
, O
the O
formation O
of O
committed O
osteoclasts O
from O
preosteoclasts O
is O
the O
most O
common O
target O

Conclusions O
: O
Therapeutics O
targeting O
epigenetic O
mechanisms O
may O
be O
helpful O
to O
counter O
immune O
evasion O
and O
improve O
the O
effectiveness O
of O
immunotherapies O
Conclusion O
: O
The O
aim O
of O
the O
review O
is O
to O
inform O
hepatologists O
of O
the O
emerging O
key O
epigenetic O
ideas O
of O
relevance O
to O
liver O
diseases O

In O
order O
to O
provide O
new O
investigative O
leads O
in O
cases O
where O
such O
reference O
samples O
are O
absent O
, O
forensic O
scientists O
started O
to O
explore O
the O
prediction O
of O
phenotypic O
traits O
from O
the O
DNA O
of O
the O
evidentiary O
sample O

Epigenetic O
aberrations O
dynamically O
contribute O
to O
cancer B-Disease
pathogenesis O

248 O
: O
It O
has O
been O
widely O
described O
that O
cancer B-Disease
genomes O
have O
frequent O
alterations O
to O
the O
epigenome O
, O
including O
epigenetic O
silencing O
of O
various O
tumor B-Disease
suppressor O
genes O
with O
functions O
in O
almost O
all O
cancer-relevant O
signalling O
pathways O
, O
such O
as O
apoptosis O
, O
cell O
proliferation O

Here O
, O
we O
explored O
the O
epigenetic O
patterns O
of O
ncRNAs O
in O
breast O
cancers B-Disease
using O
published O
sequencing-based O
methylome O
data O
, O
primarily O
focusing O
on O
the O
two O
most O
commonly O
studied O
ncRNA O
biotypes O
, O
long O
ncRNAs O
and O
miRNAs O

These O
" O
persisters O
" O
represent O
a O
pool O
of O
slow-growing O
cells O
that O
can O
either O
re-expand O
when O
treatment O
is O
discontinued O
or O
acquire O
permanent O
resistance O

Unlike O
genetics O
, O
epigenetic O
mechanisms O
could O
be O
reversible O
and O
an O
understanding O
of O
their O
role O
may O
lead O
to O
better O
protection O
of O
susceptible O
populations O
and O
improved O
public O
health O

Despite O
the O
triumphs O
of O
modern O
genetics O
, O
and O
the O
disproval O
of O
Lysenkoism O
, O
recent O
years O
have O
seen O
a O
' O
re-thinking O
' O
of O
this O
doctrine O
in O
Russia O

By O
contrast O
, O
sites O
of O
lineage-specific O
hypermethylation O
were O
restricted O
mostly O
to O
adaptive O
immune O
cells O

Each O
cell O
type O
carries O
a O
unique O
DNA O
modification O
profile O
consisting O
mainly O
of O
patterns O
of O
5-methylcytosine O
in O
CpG O
dinucleotides O
, O
which O
are O
critical O
for O
establishing O
and O
maintaining O
cellular O
identity O
and O
which O
are O
frequently O
disturbed O
in O
cancer B-Disease

Knowledge O
of O
these O
factors O
is O
of O
great O
relevance O
for O
the O
interpretation O
of O
DNA-methylation O
data O
for O
the O
estimation O
of O
chronological O
age O
in O
forensic O
casework O

Here O
, O
we O
report O
our O
CRISPR/dCas9-based O
modular O
epigenetic O
toolkit O
that O
enables O
gene-specific O
modulation O
of O
epigenetic O
architecture O

The O
purpose O
of O
this O
study O
is O
to O
bring O
forth O
an O
overview O
of O
the O
relevant O
parameters O
that O
need O
to O
be O
collected O
to O
assess O
the O
long-term O
and O
transgenerational O
health O
outcomes O
of O
famine O

The O
study O
sample O
size O
ranged O
from O
96 O
to O
1163 O
and O
most O
study O
populations O
had O
a O
mean O
age O
under O
50 O
and O
included O
predominantly O
White O
male O
participants O

314 O
: O
Epigenetic O
alterations O
, O
including O
5-methylcytosine O
( O
5mC O
) O
, O
5-hydroxymethylcytosine O
( O
5hmC O
) O
and O
nucleosome O
positioning O
( O
NP O
) O
, O
in O
cell-free O
DNA O
( O
cfDNA O
) O
have O
been O
widely O
observed O
in O
human O
diseases O
, O
and O
many O
available O
cfDNA-based O

340 O
: O
The O
fifth O
multistakeholder O
Paediatric O
Strategy O
Forum O
focussed O
on O
epigenetic O
modifier O
therapies O
for O
children O
and O
adolescents O
with O
cancer B-Disease

He O
also O
holds O
faculty O
appointments O
at O
the O
Center O
for O
Computational O
Medicine O
and O
Bioinformatics O
and O
the O
Graduate O
Program O
in O
Immunology O
at O
the O
University O
of O
Michigan O

The O
role O
of O
epigenetic O
variation O
and O
inheritance O
in O
natural O
populations O
, O
however O
, O
remains O
poorly O
understood O

However O
, O
their O
co-transcriptional O
nature O
and O
uncertain O
heritability O
mean O
that O
they O
fall O
outside O
the O
current O
definition O
of O
epigenetics O
, O
sparking O
an O
ongoing O
debate O
in O
the O
field O

Some O
environmental O
changes O
that O
have O
been O
linked O
to O
epigenetic O
changes O
include O
starvation O
, O
folic O
acid O
, O
and O
various O
chemical O
exposures O

We O
argue O
that O
using O
epigenetic O
biomarkers O
could O
reveal O
a O
broad O
range O
of O
health O
and O
life-style O
related O
information O
, O
therefore O
it O
is O
necessary O
to O
develop O
adequate O
safeguards O
to O
protect O
the O
privacy O
of O
the O
individuals O
under O
scrutiny O

Genes O
encoding O
epigenetic O
regulators O
are O
often O
mutated O
in O
cancer B-Disease
, O
underscoring O
their O
central O
roles O
in O
carcinogenesis O

468 O
: O
Renal O
cell O
carcinoma O
( O
RCC O
) O
is O
characterized O
by O
an O
infrequent O
number O
of O
somatic B-Disease
mutations I-Disease

© O
2017 O
by O
John O
Wiley O
& O
Sons O
, O
Inc O

Next O
generation O
sequencing O
( O
NGS O
) O
provides O
accurate O
and O
parallel O
sequencing O
thereby O
allowing O
researchers O
to O
comprehend O
epigenomic O
profiling O

393 O
: O
Epigenetic O
enzymes O
regulate O
higher-order O
chromatin O
architecture O
and O
cell-type O
specific O
gene O
expression O

When O
we O
controlled O
for O
multiple O
statistical O
testing O
, O
neither O
of O
these O
associations O
survived O
correction O
( O
both O
P O
≥ O
0 O

In O
vitro O
and O
cell O
type-specific O
studies O
have O
demonstrated O
that O
epithelial O
and O
stromal O
cells O
undergo O
particular O
epigenetic O
changes O
that O
modulate O
their O
transcriptional O
networks O
to O
accomplish O
their O
function O
during O
decidualization O
and O
implantation O

Although O
much O
work O
has O
been O
done O
, O
much O
is O
still O
unknown O

The O
current O
review O
discusses O
how O
epigenetics O
can O
cooperate O
with O
genetics O
to O
regulate O
development O
and O
allow O
for O
greater O
plasticity O
in O
response O
to O
environmental O
influences O

Scope O
of O
review O
: O
To O
summarize O
how O
enzymatic O
rather O
than O
chemical O
approaches O
can O
be O
leveraged O
to O
localize O
and O
resolve O
different O
cytosine O
modifications O
in O
a O
non-destructive O
manner O

This O
review O
will O
discuss O
how O
the O
epigenetic O
toolbox O
can O
be O
applied O
to O
contextualize O
genetic O
findings O
in O
schizophrenia B-Disease

Finally O
, O
our O
results O
indicate O
that O
cellular O
composition O
and O
DNA O
sequence O
variation O
are O
the O
strongest O
predictors O
of O
DNA O
methylation O
, O
highlighting O
critical O
factors O
for O
medical O
epigenomics O
studies O

Drawing O
on O
Jablonka's O
and O
Lamb's O
considerable O
output O
, O
I O
identify O
several O
differences O
between O
modern O
epigenetics O
and O
what O
Lamarckism O
was O
in O
the O
history O
of O
science O

Such O
techniques O
now O
allow O
genome-wide O
analyses O
of O
epigenetic O
regulation O
and O
help O
to O
advance O
our O
understanding O
of O
how O
epigenetic O
regulatory O
mechanisms O
affect O
cellular O
and O
genome O
function O

Promising O
results O
are O
emerging O
from O
studies O
performed O
in O
peripheral O
blood O
DNA O
that O
could O
provide O
early O
biomarkers O
of O
the O
pathology O

342 O
: O
Determining O
genes O
that O
orchestrate O
cell O
differentiation O
in O
development O
and O
disease B-Disease
remains O
a O
fundamental O
goal O
of O
cell O
biology O

The O
mechanisms O
of O
inheritance O
are O
not O
, O
however O
, O
unconstrained O
, O
because O
they O
are O
themselves O
subject O
to O
natural O
selection O

1289/EHP6104 O

698 O
: O
Summary O
: O
GLINT O
is O
a O
user-friendly O
command-line O
toolset O
for O
fast O
analysis O
of O
genome-wide O
DNA O
methylation O
data O
generated O
using O
the O
Illumina O
human O
methylation O
arrays O

The O
excitement O
in O
modern O
molecular O
biology O
surrounding O
the O
impact O
exerted O
by O
the O
environment O
on O
development O
of O
the O
phenotype O
is O
focused O
largely O
on O
mechanism O
and O
has O
not O
incorporated O
questions O
asked O
(and O
answers O
provided O
) O
by O
early O
philosophers O
, O
biologists O
, O
and O
psychologists O

Both O
are O
bridges O
to O
link O
genotypes O
with O
phenotypes O
and O
important O
for O
understanding O
how O
weak O
selection O
and O
drift O
interact O
in O
the O
evolution O
of O
complex O
systems O

In O
the O
present O
review O
, O
recent O
studies O
are O
addressed O
in O
terms O
of O
the O
characteristics O
of O
CSCs O
, O
the O
resistance O
thereof O
, O
and O
the O
factors O
influencing O
the O
development O
thereof O
, O
with O
an O
emphasis O
on O
different O
types O
of O
epigenetic O
changes O
in O
genes O
and O
main O
signaling O
pathways O
involved O

For O
the O
other O
, O
we O
showed O
preliminary O
evidence O
for O
monocyte-specific O
effects O
and O
statistical O
links O
to O
cumulative O
exposure O
to O
traditional O
cardiovascular O
risk O
factors O

CFEA O
provides O
a O
comprehensive O
and O
timely O
resource O
to O
the O
scientific O
community O
and O
supports O
the O
development O
of O
liquid O
biopsy-based O
biomarkers O
for O
various O
human O
diseases O

We O
illustrate O
here O
the O
current O
status O
of O
epidemiologic O
studies O
that O
are O
evaluating O
epigenetic O
changes O
in O
large O
populations O

1 O
binding O
sites O
were O
associated O
with O
lineage-specific O
hypo- O
and O
hypermethylation O
in O
different O
cell O
types O
, O
suggesting O
that O
it O
regulates O
DNA O
methylation O
in O
a O
context-dependent O
manner O

285 O
: O
Epigenetics O
plays O
a O
key O
role O
in O
cancer B-Disease
development O

62 O
: O
Purpose O
of O
review O
: O
The O
purpose O
of O
review O
is O
to O
describe O
the O
recent O
advances O
in O
the O
field O
of O
human O
epigenetics O

While O
these O
inferences O
might O
be O
correct O
, O
they O
can O
be O
misleading O
when O
the O
chromatin O
source O
has O
distinct O
cell O
types O
, O
or O
when O
a O
given O
cell O
type O
exhibits O
any O
cell O
to O
cell O
variation O
in O
chromatin O
state O

Alterations O
to O
the O
phenotype O
, O
due O
to O
exposure O
to O
environmental O
insults O
during O
sensitive O
periods O
of O
development O
, O
are O
mediated O
through O
alterations O
in O
epigenetic O
programming O
in O
affected O
tissues O

These O
tools O
will O
be O
a O
critical O
addition O
to O
ex O
vivo O
methods O
to O
evaluate O
- O
and O
intervene O
- O
in O
CNS O
dysfunction O

snu O

In O
this O
issue O
of O
The O
EMBO O
Journal O
, O
van O
Steenwyk O
and O
colleagues O
( O
2020 O
) O
provide O
important O
new O
insights O
into O
how O
one O
form O
of O
paternal O
experience O
( O
early-life O
stress O
or O
trauma B-Disease
) O
may O
impact O
sperm O
epigenetics O
via O
circulating O
factors O
, O
presenting O
novel O
experimental O
e O

Although O
analysing O
epigenetic O
data O
from O
long-read O
platforms O
remains O
challenging O
, O
the O
ability O
to O
detect O
various O
modified O
bases O
from O
a O
universal O
sample O
preparation O
, O
in O
addition O
to O
the O
mapping O
and O
phasing O
advantages O
of O
the O
longer O
read O
lengths O
, O
provide O
long-read O
sequencing O
with O
a O
decisive O
edge O

The O
average O
pairwise O
correlation O
coefficients O
between O
CpGs O
were O
enhanced O
after O
selection O
for O
the O
replication O
( O
e O

In O
the O
imprinting O
loci O
where O
methylation O
of O
constituent O
alleles O
is O
known O
, O
our O
analysis O
detected O
the O
deviation O
toward O
the O
concordant O
linkage O
as O
expected O

We O
speculate O
that O
this O
process O
might O
contribute O
to O
making O
aging O
the O
main O
risk O
factor O
for O
many O
cancers B-Disease

41 O
: O
The O
inappropriate O
use O
of O
antibiotics O
in O
man O
is O
driving O
to O
insurgence O
of O
pathogenic O
bacteria O
resistant O
to O
multiple O
drugs O
( O
MDR O
) O
representing O
a O
challenge O
in O
critical O
illness B-Disease

Many O
environmental O
factors O
are O
now O
known O
to O
cause O
epigenetic O
changes O
, O
including O
the O
presence O
of O
pathogens O
, O
parasites O
, O
harmful O
chemicals O
and O
other O
stress O
factors O

Here O
, O
we O
report O
the O
adaptation O
of O
the O
recently O
developed O
oxidative O
bisulfite O
( O
oxBS O
) O
chemistry O
to O
specifically O
detect O
both O
5mC O
and O
5hmC O
in O
a O
single O
workflow O
using O
450K O
BeadChips O
, O
termed O
oxBS-450K O

This O
chapter O
briefly O
highlights O
different O
epigenetics O
databases O
( O
MethDB O
, O
REBASE O
, O
Pubmeth O
, O
MethPrimerDB O
, O
Histone O
Database O
, O
ChromDB O
, O
MeInfoText O
database O
, O
EpimiR O
, O
Methylome O
DB O
, O
and O
dbHiMo O
) O
, O
and O
tools O
( O
compEpiTools O
, O
CpGProD O
, O
MethBlAST O

The O
introduction O
of O
the O
CRISPR/Cas9 O
method O
as O
a O
genome-editing O
instrument O
represented O
an O
important O
step O
in O
the O
advancement O
of O
the O
genome-editing O
method O
thanks O
to O
the O
ease O
and O
effectiveness O
of O
use O
as O
well O
as O
the O
great O
adaptability O
to O
different O
biomedical O
areas O

The O
entire O
on-chip O
process O
of O
sonication O
and O
IP O
took O
only O
1 O
h O

A O
combination O
approach O
is O
critical O
for O
successful O
utilisation O
of O
any O
epigenetic O
modifiers O
( O
e O

To O
set O
the O
scene O
, O
we O
begin O
with O
a O
short O
background O
of O
how O
the O
field O
of O
epigenetics O
has O
evolved O
, O
with O
a O
particular O
focus O
on O
plant O
epigenetics O

Epigenomic O
research O
in O
marine O
fishes O
is O
in O
its O
early O
stages O
, O
so O
we O
first O
briefly O
discuss O
what O
has O
been O
learned O
about O
the O
establishment O
, O
maintenance O
, O
and O
function O
of O
DNA O
methylation O
in O
fishes O
from O
studies O
in O
zebrafish O
and O
then O
summarize O
the O
studies O
demonstr O

The O
purpose O
of O
this O
overview O
is O
to O
discuss O
the O
application O
of O
epigenetics O
to O
toxicologic O
pathology O
and O
its O
utility O
in O
preclinical O
or O
mechanistic O
based O
safety O
, O
efficacy O
, O
and O
carcinogenicity O
studies O

511 O
: O
Eating B-Disease
disorders I-Disease
are O
complex O
heritable O
conditions O
influenced O
by O
both O
genetic O
and O
environmental O
factors O

587 O
: O
Epigenetic O
modifications O
, O
including O
DNA O
methylation O
and O
histone O
modifications O
, O
determine O
the O
way O
DNA O
is O
packaged O
within O
the O
nucleus O
and O
regulate O
cell-specific O
gene O
expression O

628 O
: O
Interindividual O
differences O
in O
chromatin O
states O
at O
a O
locus O
( O
epialleles O
) O
can O
result O
in O
gene O
expression O
changes O
that O
are O
sometimes O
transmitted O
across O
generations O

, O
modification O
of O
cytosines O
in O
CpG O
dinucleotides O

In O
this O
review O
we O
discuss O
recent O
advances O
for O
low-input O
genome-wide O
analysis O
of O
chromatin O
immunoprecipitation O
, O
methylation O
, O
DNA O
accessibility O
, O
and O
chromatin O
conformation O

Novel O
, O
less O
toxic O
and O
more O
selective O
epigenetic O
drugs O
are O
designed O
and O
tested O
in O
animal O
and O
cell O
culture O
models O
of O
neuromuscular O
disorders O
, O
and O
non-coding O
RNAs O
are O
being O
investigated O
as O
either O
disease B-Disease
biomarkers O
or O
targets O
of O
therapeutic O
approaches O
to O
restore O
gene O
expression O

At O
present O
, O
only O
six O
agents O
in O
two O
epigenetic O
target O
classes O
have O
been O
approved O
by O
the O
US O
FDA O
, O
limited O
to O
treatment O
of O
hematological O
malignancies B-Disease

562 O
: O
Cancer B-Disease
is O
a O
complex O
disease B-Disease
caused O
by O
the O
malignant O
cellular O
proliferation O
and O
metastasis O

Most O
machine O
learning O
approaches O
developed O
so O
far O
aim O
at O
finding O
DNA O
sequences O
responsible O
for O
the O
CG O
methylation O
patterns O
and O
were O
not O
tailored O
for O
studying O
the O
epigenetic O
crosstalk O

We O
then O
discuss O
, O
noting O
the O
general O
themes O
, O
four O
studies O
across O
taxa O
that O
demonstrate O
characteristics O
that O
increase O
the O
inferences O
that O
can O
be O
made O
from O
MS-AFLP O
data O
; O
we O
suggest O
that O
future O
MS-AFLP O
studies O
should O
incorporate O
these O
methods O
and O
techniques O

However O
, O
BeadChip O
processing O
relies O
on O
traditional O
bisulfite O
( O
BS O
) O
based O
protocols O
which O
cannot O
discriminate O
between O
5-methylcytosine O
( O
5mC O
) O
and O
5-hydroxymethylcytosine O
( O
5hmC O
) O

Future O
molecular O
studies O
investigating O
the O
involvement O
of O
zinc O
and O
its O
transporters O
in O
epigenetics O
are O
warranted O

Based O
on O
these O
insights O
, O
we O
propose O
a O
method O
, O
EPISTRUCTURE O
, O
for O
the O
inference O
of O
ancestry O
from O
methylation O
data O
, O
without O
the O
need O
for O
genotype O
data O

Epigenetics O
has O
been O
considered O
the O
missing O
link O
between O
nature O
and O
nurture O

Epigenetic O
regulatory O
mechanisms O
are O
now O
implicated O
in O
orchestrating O
aspects O
of O
neural O
development O
( O
e O

The O
mapping O
of O
these O
processes O
in O
large O
scale O
by O
chromatin O
immunoprecipitation O
sequencing O
and O
other O
methodologies O
in O
both O
cancer B-Disease
and O
normal O
cells O
reveals O
novel O
therapeutic O
opportunities O
for O
anticancer O
intervention O

Gene O
regions O
of O
identified O
loci O
were O
enriched O
in O
nervous B-Disease
system I-Disease
development O
functions O

At O
age O
79 O
years O
, O
sedentary O
behavior O
and O
physical O
activity O
were O
measured O
over O
7 O
days O
using O
an O
activPAL O
activity O
monitor O

Because O
several O
epigenetic O
changes O
occur O
before O
histopathological O
changes O
, O
they O
can O
serve O
as O
biomarkers O
for O
cancer B-Disease
diagnosis O
and O
risk O
assessment O

This O
article O
examines O
these O
three O
issues O
, O
noting O
the O
rapid O
expansion O
of O
research O
based O
on O
EMR-sourced O
clinical O
data O
, O
the O
large O
number O
of O
data O
protection O
models O
that O
can O
apply O
to O
genetic O
data O
( O
including O
point-of-use O
prohibitions O
on O
discrimination O
and O
confidentiality O
) O
, O
and O
the O
increasing O

However O
, O
to O
develop O
effective O
strategies O
for O
engagement O
, O
it O
is O
important O
to O
understand O
the O
public O
's O
understanding O
of O
the O
relevant O
concepts O

miRNA O
genes O
can O
be O
epigenetically O
regulated O
by O
DNA O
methylation O
or O
specific O
histone O
modifications O

, O
rs9388766 O
: O
OR O
= O
1 O

Latest O
generation O
techniques O
now O
allow O
high-resolution O
investigations O
of O
the O
entire O
genome O
, O
the O
proteome O
and O
the O
cellular O
metabolome O
, O
as O
well O
as O
epigenetic O
modifications O
and O
associated O
gene O
expression O
profiles O

The O
ability O
to O
accurately O
dispense O
lower O
volumes O
provides O
the O
potential O
to O
achieve O
a O
greater O
amount O
of O
information O
than O
could O
be O
otherwise O
achieved O
using O
manual O
dispensing O
technology O

As O
proof O
of O
functional O
conservation O
, O
mammalian O
epigenetic O
drugs O
demonstrably O
interfered O
with O
stress-induced O
gene O
silencing O

Epigenetic O
modifications O
are O
likely O
to O
be O
important O
in O
both O
suicidal B-Disease
ideation I-Disease
and O
behavior O

If O
the O
aim O
of O
the O
analysis O
is O
to O
use O
DNA O
methylation O
measurements O
as O
a O
biomarker O
for O
diseases O
diagnosis O
and O
treatment O
( O
Laird O
, O
Nat O
Rev O
Cancer B-Disease
3:253-266 O
, O
2003 O
; O
Bock O
, O
Epigenomics O
1:99-110 O
, O
2009 O
) O
, O
it O
is O
instead O
recommended O
to O

Lastly O
, O
we O
argue O
that O
research O
in O
environmental O
epigenetics O
could O
open O
a O
new O
route O
for O
personalized O
medicine O
in O
oncology O
, O
where O
epigenetics O
contributes O
to O
an O
individualized O
assessment O
of O
patients O
' O
life O
paths O

I O
will O
outline O
the O
progress O
and O
highlight O
challenges O
and O
areas O
that O
can O
be O
further O
explored O
perfecting O
the O
personalized O
health O
care O

Highlights O
include O
reference O
epigenome O
maps O
for O
a O
wide O
variety O
of O
human O
cells O
and O
tissues O
, O
the O
development O
of O
new O
technologies O
for O
epigenetic O
assays O
and O
imaging O
, O
the O
identification O
of O
novel O
epigenetic O
modifications O
, O
and O
an O
improved O
understanding O
of O
the O
role O
of O
epigenetic O
processes O
in O

[Formula: O
: O
see O
text O

In O
addition O
, O
the O
possible O
biomedical O
and O
discovery O
research O
applications O
of O
single-molecule O
epigenomics O
will O
be O
highlighted O

69 O
: O
Background O
: O
The O
Encyclopedia O
of O
DNA O
Elements O
( O
ENCODE O
) O
project O
has O
advanced O
our O
knowledge O
of O
the O
functional O
elements O
in O
the O
genome O
and O
epigenome O

Here O
, O
we O
review O
a O
number O
of O
case O
studies O
that O
cover O
different O
aspects O
of O
epigenetic O
drug O
discovery O
spanning O
from O
sequencing O
of O
epigenetic O
modifications O
, O
assays O
development O
over O
screening O
to O
medicinal O
chemistry O
, O
in O
vivo O
testing O
and O
clinical O
application O

He O
received O
his O
medical O
degree O
from O
Jordan O
University O
of O
Science O
and O
Technology O
and O
completed O
his O
residency O
training O
in O
internal O
medicine O
at O
the O
University O
of O
Oklahoma O
Health O
Sciences O
Center O
, O
and O
his O
fellowship O
in O
rheumatology O
at O
the O
University O
of O
Michigan O

Our O
review O
describes O
associations O
between O
epigenetic O
clocks O
and O
multiple O
traits O
across O
the O
life O
and O
health O
span O

We O
suggest O
that O
future O
research O
in O
environmental O
epigenetics O
focus O
on O
establishing O
the O
reversibility O
of O
stress-induced O
epigenetic O
modifications O
, O
and O
also O
on O
identifying O
positive O
epigenetic O
effects O
of O
environmental O
enrichment O

224 O
: O
Just O
as O
genome-wide O
association O
studies O
( O
GWAS O
) O
grew O
from O
the O
field O
of O
genetic O
epidemiology O
, O
so O
too O
do O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
derive O
from O
the O
burgeoning O
field O
of O
epigenetic O
epidemiology O
, O
with O
both O
aiming O
to O
understand O
the O
m O

Understanding O
the O
effects O
of O
environmental O
control O
on O
phenotypes O
and O
fitness O
, O
via O
epigenetic O
mechanisms O
, O
is O
essential O
for O
understanding O
the O
ability O
of O
organisms O
to O
rapidly O
adapt O
to O
environmental O
change O

To O
provide O
a O
primer O
on O
epigenomic O
research O
for O
fish O
biologists O
, O
we O
start O
by O
describing O
fundamental O
aspects O
of O
epigenetics O
, O
focusing O
on O
the O
most O
widely O
studied O
and O
most O
well O
understood O
of O
the O
epigenetic O
marks O
: O
DNA O
methylation O

Emerging O
findings O
on O
epigenetic O
changes O
associated O
with O
adverse O
early O
experiences O
are O
also O
reviewed O

With O
the O
use O
of O
whole-genome O
methylation O
sequencing O
, O
the O
data O
described O
herein O
substantiate O
an O
increasingly O
compromised O
DNA O
methylation O
profile O
as O
sperm O
ages O
and O
, O
for O
the O
first O
time O
, O
also O
demonstrate O
a O
generational O
correlation O
in O
sperm O
and O
blastocyst O
of O
an O
altered O
methylome O

150 O
: O
Asthma B-Disease
and O
allergic B-Disease
diseases I-Disease
are O
among O
the O
most O
prevalent O
chronic O
noncommunicable O
diseases O
of O
childhood O
, O
but O
the O
underlying O
pathogenetic O
mechanisms O
are O
poorly O
understood O

A O
special O
emphasis O
in O
how O
they O
could O
be O
used O
as O
targets O
for O
the O
development O
and O
use O
of O
novel O
drugs O
in O
cancer B-Disease
therapy O
is O
delineated O


Whether O
the O
goal O
is O
the O
production O
of O
viral O
particles O
using O
human O
embryonic O
kidney O
( O
HEK O
) O
cells O
or O
the O
direct O
examination O
of O
epigenomic O
modifications O
in O
the O
target O
cell O
type O
, O
continuous O
refinement O
of O
transfection O
methods O
is O
crucial O

Antidepressant O
treatments O
appear O
to O
reverse O
or O
initiate O
compensatory O
epigenetic O
alterations O
that O
may O
be O
relevant O
to O
their O
mechanism O
of O
action O

We O
start O
by O
presenting O
the O
well-elucidated O
mechanisms O
of O
plant O
gbM O
establishment O
and O
maintenance O

13 O
: O
Background O
: O
Epigenetic O
mechanisms O
regulate O
chromatin O
accessibility O
patterns O
that O
govern O
interaction O
of O
transcription O
machinery O
with O
genes O
and O
their O
cis-regulatory O
elements O

574 O
: O
Osteoporosis O
is O
a O
complex O
multifactorial O
condition O
of O
the O
musculoskeletal O
system O

94 O
) O

Recent O
findings O
on O
DNA O
methylation O
and O
hydroxymethylation O
, O
histone O
modifications O
, O
noncoding O
RNAs O
, O
and O
other O
epigenetic O
mechanisms O
were O
presented O
and O
discussed O

Silencing O
of O
the O
genes O
by O
hypermethylation O
or O
induction O
of O
oncogenes O
by O
promoter O
hypomethylation O
is O
a O
frequent O
mechanism O
in O
head O
and O
neck O
cancer B-Disease
and O
achieves O
increasing O
diagnostic O
and O
therapeutic O
importance O

g O

org O
/ O
groups O
/ O
biolabs O
/ O
tools O
/ O
span O
- O
peak O
- O
analyzer O
and O
https O
: O
/ O
/ O
research O

67 O
: O
It O
is O
now O
appreciated O
that O
both O
genetic O
alteration O
, O
e O

We O
propose O
NGS++ O
, O
a O
programming O
library O
in O
C++11 O
specialized O
in O
manipulating O
both O
next-generation O
sequencing O
( O
NGS O
) O
datasets O
and O
genomic O
information O
files O

First O
, O
a O
summary O
of O
the O
epigenetic O
landscape O
of O
oral B-Disease
health I-Disease
is O
presented O

This O
knowledge O
can O
help O
developing O
'epigenetics O
drugs' O
for O
complex O
diseases O
like O
cancers B-Disease

In O
this O
review O
, O
we O
briefly O
outline O
some O
principles O
of O
epigenetics O
, O
focusing O
on O
highlighting O
important O
considerations O
unique O
to O
DNA O
methylation O
studies O
to O
guide O
psychologists O
in O
incorporating O
DNA O
methylation O
into O
a O
project O

They O
influence O
key O
physiological O
processes O
throughout O
life O
, O
and O
together O
with O
inherited O
DNA O
primary O
sequence O
, O
contribute O
to O
responsiveness O
to O
environmental O
stresses O
, O
diet O
and O
risk O
for O
age-related O
chronic O
disease B-Disease

To O
avoid O
such O
false O
positives O
we O
argue O
for O
more O
extensive O
QC O
and O
that O
reporting O
the O
test-statistic O
inflation O
parameter O
lambda O
become O
standard O
for O
all O
MWAS O
allowing O
readers O
to O
better O
assess O
the O
risk O
of O
false O
discoveries O

403 O
: O
Despite O
growing O
appreciation O
of O
the O
importance O
of O
epigenetics O
in O
breast B-Disease
cancer I-Disease
, O
our O
understanding O
of O
epigenetic O
alterations O
of O
non-coding O
RNAs O
( O
ncRNAs O
) O
in O
breast B-Disease
cancer I-Disease
remains O
limited O

By O
comparing O
Spanish O
chronicles O
of O
the O
New O
World O
with O
recent O
epidemiological O
narratives O
on O
Mexican O
populations O
in O
social O
epigenetics O
( O
especially O
on O
obesity B-Disease
) O
, O
we O
identify O
four O
characteristics O
that O
both O
share O
in O
distinguishing O
races O
, O
such O
as O
indigenous O
or O
mestizos O
from O
Spaniards O
or O

Here O
, O
we O
describe O
an O
improved O
procedure O
for O
WGBS O
and O
original O
bioinformatic O
workflows O
applied O
to O
unravel O
tissue-specific O
variations O
of O
the O
methylome O
in O
relation O
to O
gene O
expression O
and O
accumulation O
of O
secondary O
metabolites O
in O
the O
medicinal O
plant O
Catharanthus O
roseus O

Conclusions O
: O
A O
variety O
of O
epigenetic O
and O
transcriptional O
factors O
can O
result O
in O
dysregulated O
osteoclastogenesis O
in O
different O
skeletal O
disorders O

88 O
: O
Histone O
modifications O
are O
epigenetic O
marks O
that O
fundamentally O
impact O
the O
regulation O
of O
gene O
expression O

Here O
, O
we O
describe O
how O
insights O
into O
the O
natural O
reactivities O
of O
these O
DNA-modifying O
enzymes O
can O
be O
leveraged O
to O
convert O
them O
into O
powerful O
biotechnological O
tools O

80-1 O
) O
with O
95% O
sensitivity O
and O
98% O
specificity O

These O
functional O
genomics O
studies O
have O
also O
enabled O
a O
clearer O
understanding O
of O
the O
role O
of O
the O
3D O
structure O
of O
the O
genome O
in O
epigenetic O
regulation O

These O
drugs O
may O
fulfil O
the O
need O
for O
newer O
and O
more O
effective O
drugs O
for O
treating O
these O
disorders O

A O
substantial O
drop O
in O
promoter O
methylation O
signal O
of O
the O
follow-up/post-treatment O
patients O
was O
also O
noted O
(p-value O
< O
0 O

Elucidating O
the O
proteins O
that O
interact O
with O
chromatin-associated O
RNA O
or O
proteins O
is O
key O
to O
understanding O
fundamental O
epigenetic O
regulatory O
pathways O

We O
also O
observed O
main O
effects O
of O
CSA O
and O
genetic O
load O
on O
depression B-Disease
and O
on O
antisocial O
characteristics O

Contact O
: O
lichtenbergj@mail O

From O
the O
practical O
side O
, O
we O
describe O
characteristics O
of O
allergic O
phenotypes O
and O
contrast O
different O
epidemiologic O
study O
designs O
used O
in O
epigenetic O
research O

However O
, O
Waddington O
referred O
first O
to O
the O
notion O
in O
the O
late O
1930s O

Besides O
the O
widely O
used O
PCR O
technique O
, O
there O
are O
several O
alternative O
approaches O
for O
genomic O
DNA O
amplification O
suitable O
for O
supporting O
the O
detection O
of O
genomic O
variation O

Indeed O
, O
standard O
genomic O
approaches O
do O
not O
take O
into O
account O
the O
world O
of O
regulation O
of O
gene O
expression O
by O
modifications O
of O
the O
'epi'genome O

These O
modifications O
represent O
a O
rich O
source O
of O
biomarkers O
that O
have O
the O
potential O
to O
be O
implemented O
in O
clinical O
practice O

In O
the O
latter O
case O
, O
it O
would O
be O
especially O
relevant O
to O
consider O
epigenetic O
factors O
such O
as O
life O
adversities O
( O
trauma B-Disease
, O
disorganized O
attachment O
, O
etc O

Obesity O
is O
associated O
with O
extensive O
gene O
expression O
changes O
in O
tissues O
throughout O
the O
body O

The O
tight O
control O
of O
all O
these O
mechanisms O
defines O
the O
final O
cellular O
character O

Although O
this O
region-based O
model O
was O
relatively O
more O
efficient O
than O
the O
WSH-based O
model O
, O
the O
latter O
required O
the O
analysis O
of O
just O
a O
few O
short O
genomic O
regions O
and O
, O
therefore O
, O
could O
be O
a O
useful O
tool O
to O
design O
a O
reduced O
epigenetic O
clock O
that O
is O
analyzed O
by O
targeted O
next-generation O

005 O

The O
accurate O
recognition O
of O
key O
epigenetic O
mechanisms O
in O
hemostasis O
would O
then O
contribute O
to O
identify O
new O
putative O
therapeutic O
targets O
, O
and O
develop O
innovative O
agents O
that O
could O
be O
helpful O
for O
preventing O
or O
managing O
a O
vast O
array O
of O
hemostasis O
disturbances O

This O
review O
highlights O
the O
significance O
of O
environmental O
temperature O
on O
epigenetic O
control O
of O
phenotypic O
variation O
, O
with O
the O
aim O
of O
furthering O
our O
understanding O
of O
how O
epigenetics O
might O
help O
or O
hinder O
species O
' O
adaptation O
to O
climate O
change O

We O
conclude O
that O
DNA O
hydroxymethylation O
is O
a O
sensitive O
biosensor O
for O
many O
harmful O
environmental O
factors O
each O
of O
which O
specifically O
targets O
5hmC O
in O
different O
organs O
, O
cell O
types O
, O
and O
DNA O
sequences O
and O
induces O
its O
changes O
through O
a O
specific O
metabolic O
pathway O

However O
, O
dysregulation O
of O
epigenetic O
patterns O
causes O
diseases O
like O
cancer B-Disease
, O
diabetes B-Disease
, O
neurological B-Disease
disorder I-Disease
, O
infectious B-Disease
diseases I-Disease
, O
autoimmunity O
etc O

The O
major O
family O
of O
proteins O
that O
bind O
methylated O
DNA O
is O
the O
methyl-CpG O
binding O
domain O
proteins O
, O
or O
the O
MBDs O

Recently O
, O
new O
classes O
of O
epigenetic O
inhibitors O
have O
appeared O
in O
literatures O

The O
majority O
of O
signals O
involve O
noncoding O
genetic O
variation O
, O
of O
which O
a O
large O
part O
is O
related O
to O
gene O
expression O
changes O

In O
this O
review O
, O
we O
cover O
most O
of O
the O
advancements O
made O
in O
the O
field O
of O
targeting O
epigenetics O
with O
special O
emphasis O
on O
microbiology O
, O
plasma O
science O
, O
biophysics O
, O
pharmacology O
, O
molecular O
biology O
, O
phytochemistry O
, O
and O
nanoscience O

187 O
: O
Epigenetics O
researchers O
in O
developmental O
, O
cell O
, O
and O
molecular O
biology O
greatly O
diverge O
in O
their O
understanding O
and O
definitions O
of O
epigenetics O

DNA O
methylation O
and O
demethylation O
is O
a O
key O
mechanism O
of O
genome O
programming O
and O
reprogramming O

Except O
for O
ALK O
+ O
anaplastic O
large-cell O
lymphoma B-Disease
(ALCL) O
, O
most O
peripheral O
T-cell O
lymphomas B-Disease
are O
highly O
malignant O
and O
have O
an O
aggressive O
disease B-Disease
course O
and O
poor O
clinical O
outcomes O
, O
with O
a O
poor O
remission O
rate O
and O
frequent O
relapse O
after O
first-line O
treatment O

Human O
DNA O
methylation O
studies O
require O
careful O
considerations O
for O
design O
and O
analysis O
including O
population O
and O
tissue O
selection O
, O
population O
stratification O
, O
cell O
heterogeneity B-Disease
, O
confounding O
, O
temporality O
, O
sample O
size O
, O
appropriate O
statistical O
analysis O
, O
and O
validation O
of O
results O

The O
interaction O
of O
MDR O
bacteria O
with O
host O
cells O
can O
guide O
molecular O
perturbations O
of O
host O
transcriptional O
programmes O
involving O
epigenetic-sensitive O
mechanisms O
, O
mainly O
DNA O
methylation O
, O
histone O
modifications O
, O
and O
non-coding O
RNAs O
leading O
to O
pathogen O
survival O

Then O
, O
a O
comparison O
will O
be O
made O
between O
the O
principles O
of O
the O
cumulative O
DNA O
damage O
theory O
of O
aging O
and O
the O
basic O
facts O
underlying O
the O
epigenetic O
model O
of O
aging O
, O
including O
Horvath O
's O
epigenetic O
clock O

We O
hope O
this O
information O
will O
stimulate O
further O
discourse O
on O
the O
emerging O
field O
of O
redox O
epigenomics O

Therefore O
, O
deciphering O
the O
hallmarks O
of O
aging O
represents O
a O
possibility O
for O
identifying O
potential O
druggable O
targets O
to O
attenuate O
the O
aging O
process O
, O
and O
then O
the O
age-related O
comorbidities O

Common O
dysregulation O
of O
epigenetic O
modifications O
in O
cancer B-Disease
has O
driven O
substantial O
interest O
in O
the O
development O
of O
epigenetic O
modifying O
drugs O

Expert O
opinion O
: O
There O
is O
growing O
evidence O
that O
pharmacoepigenetics O
has O
the O
potential O
to O
become O
an O
important O
element O
of O
personalized O
medicine O

Since O
some O
epigenetic O
changes O
are O
significant O
in O
abnormalities O
such O
as O
cancers B-Disease
and O
neurodegenerative B-Disease
diseases I-Disease
, O
the O
initial O
changes O
, O
dynamic O
and O
reversible O
properties O
, O
and O
diagnostic O
potential O
of O
epigenomic O
phenomena O
are O
subject O
to O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
for O
therapeutic O

Uncovering O
the O
human O
epigenome O
can O
lead O
us O
to O
better O
understand O
the O
dynamics O
of O
DNA O
methylation O
in O
disease B-Disease
progression O
which O
can O
further O
assist O
in O
cancer B-Disease
prevention O

In O
particular O
, O
DNA O
changes O
caused O
by O
psychological O
trauma B-Disease
can O
be O
transmitted O
from O
generation O
to O
generation O
, O
validating O
the O
psychoanalytic O
concept O
of O
intergenerational O
transmission O
of O
trauma B-Disease

89 O
: O
Ecological O
Epigenetics O
studies O
the O
relationship O
between O
epigenetic O
variation O
and O
ecologically O
relevant O
phenotypic O
variation O

Integrating O
historical O
work O
, O
ethnographic O
observation O
, O
and O
insights O
from O
philosophical O
practice-oriented O
conceptual O
analysis O
, O
we O
detail O
the O
distinctive O
epistemic O
goals O
the O
epimutation O
concept O
fulfils O
in O
medicine O
, O
plant O
biology O
and O
toxicology O

101 O
: O
Analysis O
of O
transcription O
factors O
and O
chromatin B-Disease
modifications I-Disease
at O
the O
genome-wide O
level O
provides O
insights O
into O
gene O
regulatory O
processes O
, O
such O
as O
transcription O
, O
cell O
differentiation O
and O
cellular O
response O

Low O
- O
volume O
automated O
nanoliter O
dispensers O
ensure O
accuracy O
of O
pipetting O
within O
volume O
ranges O
that O
are O
difficult O
to O
achieve O
manually O

In O
this O
review O
, O
we O
detail O
the O
development O
of O
induced O
proximity O
methods O
and O
applications O
in O
shedding O
light O
on O
the O
intricacies O
of O
epigenetic O
regulation O

e O

001 O
), O
and O
greater O
intrinsic O
age O
acceleration O
was O
associated O
with O
making O
more O
sit-to-stand O
transitions O
(regression O
coefficient O
( O
95% O
CI O
) O
0 O

A O
growing O
number O
of O
epigenetic O
studies O
in O
gastric O
cancer B-Disease
have O
provided O
lots O
of O
potential O
diagnostic O
and O
prognostic O
markers O
and O
therapeutic O
targets O

Therefore O
, O
advanced O
epigenetic O
therapeutics O
are O
required O
to O
develop O
target-specific O
epigenetic O
modifications O
to O
reverse O
gene O
expression O
pattern O

Additionally O
, O
a O
cohort O
study O
showed O
that O
exposure O
to O
NO2 O
was O
associated O
with O
significant O
hypomethylation O

713 O
: O
The O
origin O
of O
epigenetics O
has O
been O
traditionally O
traced O
back O
to O
Conrad O
Hal O
Waddington O
's O
foundational O
work O
in O
1940s O

3 O
% O
of O
families O
, O
comparable O
to O
original O
FLoSS O
in O
elderly O

The O
way O
the O
DNA O
code O
is O
translated O
into O
function O
depends O
not O
only O
on O
its O
sequence O
but O
also O
on O
the O
interaction O
with O
environmental O
factors O

Methylation O
of O
DNA O
and O
histones O
are O
primary O
means O
of O
epigenetic O
control O

Recent O
studies O
have O
shed O
new O
light O
on O
the O
mechanisms O
underlying O
both O
promoter-specific O
hypermethylation O
and O
global O
hypomethylation O
in O
cancer B-Disease
cells O
and O
identified O
potential O
targets O
for O
biomarker O
discovery O
and O
therapeutic O
intervention O

This O
review O
first O
summarizes O
the O
epigenetic O
targets O
, O
including O
metastable O
epialleles O
and O
imprinting O
genes O
, O
by O
which O
the O
environmental O
factors O
can O
modify O
the O
epigenome O

The O
development O
and O
research O
of O
biomarkers O
for O
epi-drugs O
provide O
a O
promising O
direction O
for O
screening O
drug-sensitive O
patients O

Epigenetic O
diversity O
may O
provide O
an O
additional O
layer O
of O
variation O
within O
CWR O
and O
can O
contribute O
novel O
epialleles O
for O
key O
traits O
for O
crop O
improvement O

Recent O
use O
and O
each O
additional O
day O
of O
recent O
use O
were O
associated O
with O
a O
20-month O
( O
P O
< O
0 O

308 O
: O
Increased O
understanding O
about O
the O
functional O
complexity O
of O
the O
genome O
has O
led O
to O
growing O
recognition O
about O
the O
role O
of O
epigenetic O
variation O
in O
the O
etiology O
of O
schizophrenia B-Disease

Most O
of O
the O
studies O
to O
date O
have O
focused O
on O
the O
latter O
, O
and O
herein O
we O
discuss O
observations O
on O
epigenomic O
changes O
in O
human O
cardiovascular O
disease B-Disease
, O
examining O
the O
role O
of O
protein O
modifiers O
of O
chromatin O
, O
noncoding O
RNAs O
and O
DNA O
modification O

This O
is O
the O
first O
epigenetic O
age O
estimation O
method O
for O
a O
wild O
animal O
species O
and O
the O
approach O
we O
took O
for O
developing O
it O
can O
be O
applied O
to O
many O
other O
nonmodel O
organisms O

Finally O
, O
ten O
unique O
studies O
met O
our O
inclusion O
criteria O

However O
, O
assessment O
of O
abnormal O
thyroid O
function O
may O
be O
challenging O
suggesting O
a O
more O
fundamental O
understanding O
of O
normal O
function O
is O
needed O

Our O
results O
validate O
the O
use O
of O
the O
EpiDISH O
algorithm O
in O
estimating O
the O
effect O
of O
cellular O
heterogeneity B-Disease
in O
EWAS O
and O
showed O
DNA O
methylation O
generally O
underestimates O
the O
epithelial O
cell O
content O
obtained O
from O
cytology O

Main O
changes O
in O
the O
progeny O
were O
due O
to O
the O
high O
frequency O
of O
genetic O
mutations O
rather O
than O
epigenetic O
changes O
; O
the O
difference O
was O
primarily O
in O
single O
nucleotide O
substitutions O
and O
deletions O

g O

Whereas O
the O
underlying O
molecular O
sources O
of O
interindividual O
variability O
remain O
poorly O
understood O
, O
recent O
work O
by O
Ecker O
et O
al O

001 O
) O
and O
a O
2 O

These O
lines O
of O
evidence O
suggest O
that O
additional O
mechanisms O
are O
needed O
to O
link O
the O
individual O
susceptibility O
with O
the O
proposed O
chemical O
and O
infectious O
factors O
in O
the O
environment O

681 O
: O
Epigenetics O
is O
the O
field O
of O
science O
that O
deals O
with O
the O
study O
of O
changes O
in O
gene O
function O
that O
do O
not O
involve O
changes O
in O
DNA O
sequence O
and O
are O
heritable O
while O
epigenetics O
inheritance O
is O
the O
process O
of O
transmission O
of O
epigenetic O
modifications O
to O
the O
next O
generation O

Karlsson O
earned O
a O
PhD O
in O
toxicology O
at O
the O
Department O
of O
Pharmaceutical O
Bioscience O
, O
Uppsala O
University O
, O
and O
has O
also O
worked O
at O
Centre O
of O
Molecular O
Medicine O
, O
Karolinska O
Institute O
, O
as O
well O
as O
Harvard O
University O
School O
of O
Public O
Health O


There O
have O
been O
numerous O
diseases O
, O
exposures O
and O
lifestyle O
factors O
investigated O
with O
EWAS O
, O
with O
several O
significant O
associations O
now O
identified O

Genes O
associated O
with O
autism B-Disease
spectrum O
disorder B-Disease
, O
schizophrenia B-Disease
, O
and O
bipolar O
disorder B-Disease
are O
significantly O
enriched O
with O
causative O
methylation O
aberrations O
in O
both O
sperm O
and O
embryos O
from O
aged O
fathers O

The O
methodology O
is O
based O
on O
the O
development O
of O
a O
T: O
matrix O
of O
epigenetic O
relationships O
that O
depends O
on O
the O
reset O
coefficient O

Given O
the O
widespread O
distribution O
of O
epigenetic O
marks O
and O
miRNA O
target O
sites O
in O
the O
genome O
, O
the O
regulatory O
circuits O
linking O
both O
mechanisms O
are O
likely O
to O
have O
a O
major O
impact O
in O
genome O
transcription O
and O
cell O
physiology O

Many O
CpG O
sites O
show O
significant O
tissue-independent O
correlations O
with O
age O
which O
allowed O
us O
to O
develop O
a O
multi-tissue O
predictor O
of O
age O
in O
the O
mouse O

Data O
were O
analyzed O
using O
predominately O
descriptive O
statistics O
, O
with O
free-text O
responses O
scored O
based O
on O
concordance O
with O
predetermined O
definitions O

The O
model O
borrows O
information O
from O
all O
tumour B-Disease
regions O
to O
leverage O
greater O
statistical O
power O

Given O
that O
transposable O
elements O
( O
TEs O
) O
make O
up O
at O
least O
50% O
of O
the O
human O
genome O
and O
can O
be O
actively O
transcribed O
or O
act O
as O
regulatory O
elements O
either O
for O
their O
own O
purposes O
or O
be O
co-opted O
for O
the O
benefit O
of O
their O
host O
; O
we O
are O
interested O
in O
exploring O

The O
classical O
approach O
for O
sequencing O
cytosine O
modifications O
has O
involved O
differential O
deamination O
via O
the O
chemical O
sodium O
bisulfite O
; O
however O
, O
bisulfite O
is O
destructive O
, O
limiting O
its O
utility O
in O
important O
biological O
or O
clinical O
settings O
where O
detection O
of O
low O
frequency O
populations O
is O
critical O

The O
model O
projected O
that O
for O
a O
commercial O
insurer O
with O
one O
million O
members O
, O
full O
adoption O
of O
PrecisionCHD O
as O
the O
primary O
method O
of O
initial O
CHD O
assessment O
would O
save O
approximately O
$113 O

In O
this O
review O
, O
we O
will O
first O
summarize O
the O
epigenetic O
toxicity O
research O
field O
, O
with O
examples O
of O
epigenetic O
toxicities O
and O
technologies O
for O
epigenetic O
analysis O

700 O
: O
The O
prevalence O
of O
non-communicable O
diseases O
has O
been O
on O
an O
upward O
trajectory O
for O
some O
time O
and O
this O
puts O
an O
enormous O
burden O
on O
the O
healthcare O
expenditure O

Together O
, O
these O
techniques O
are O
rapidly O
becoming O
a O
powerful O
tool O
in O
studies O
of O
cellular O
plasticity O
and O
diversity O
, O
as O
seen O
in O
stem O
cells O
and O
cancer B-Disease

All O
these O
results O
demonstrate O
that O
adaptive O
SMCCA O
are O
well O
suited O
for O
detecting O
three-way O
or O
multiway O
correlations O
and O
thus O
can O
find O
widespread O
applications O
in O
multiple O
omics O
and O
imaging O
data O
integration O

329 O
: O
Significance O
: O
Methylation O
of O
cytosine O
in O
DNA O
is O
linked O
with O
gene O
regulation O
, O
and O
this O
has O
profound O
implications O
in O
development O
, O
normal O
biology O
, O
and O
disease B-Disease
conditions O
in O
many O
eukaryotic O
organisms O

It O
includes O
the O
way O
in O
which O
humans O
have O
had O
to O
genetically O
adapt O
to O
the O
different O
environments O
they O
have O
encountered-nutritional O
, O
climatic O
or O
pathogenic-as O
well O
as O
the O
different O
epigenetic O
responses O
elicited O
by O
such O
environmental O
cues O

Epigenetics O
has O
become O
a O
new O
strategy O
for O
the O
basic O
and O
clinical O
research O
of O
acupuncture O
in O
the O
last O
decade O

Conclusions O
: O
Four O
conclusions O
from O
this O
GAW20 O
working O
group O
are O
: O
( O
a O
) O
QC O
measures O
are O
an O
important O
consideration O
for O
EWAS O
studies O
that O
are O
investigating O
multiple O
time O
points O
or O
repeated O
measurements O
; O
( O
b O
) O
application O
of O
heritability O
estimates O
between O
time O
points O
for O
individual O
Cp O

Epigenetic O
profiling O
is O
likely O
to O
become O
a O
routine O
tool O
for O
the O
diagnosis O
of O
neurological O
and O
psychiatric B-Disease
disorders I-Disease
in O
the O
near O
future O

Systematical O
studies O
of O
clinical O
and O
pathological O
mechanisms O
and O
identification O
of O
optimal O
therapeutic O
targets O
through O
integrative O
analysis O
of O
multi-omics O
data O
from O
different O
levels O
and O
resources O
have O
become O
an O
important O
research O
direction O
of O
precision O
medicine O
, O
which O
would O
provide O
innovative O
perspectives O
on O
disease B-Disease
study O
and O
new O
theoretical O

Further O
computational O
analyses O
identified O
a O
distinct O
set O
of O
transcription O
factor O
motifs O
enriched O
at O
distal O
regulatory O
regions O
that O
are O
epigenetically O
remodelled O
by O
ERK O
signalling O

623 O
: O
Background O
: O
Epigenetic O
research O
has O
pointed O
to O
that O
the O
interaction O
between O
genetics O
and O
environmental O
factors O
may O
play O
a O
role O
in O
making O
some O
individuals O
more O
vulnerable O
than O
others O

Recent O
evidence O
suggests O
an O
important O
role O
for O
epigenetic O
regulation O
in O
the O
emergence O
of O
neuropsychiatric O
disease B-Disease

Our O
data O
suggest O
a O
contribution O
of O
epigenetics O
to O
the O
regulation O
and O
divergence O
of O
anatomical O
morphogenesis O
in O
the O
two O
subspecies O
relevant O
for O
cattle O
evolution O
and O
sub-species O
differentiation O
and O
adaptation O

Overall O
, O
a O
growing O
body O
of O
literature O
finds O
that O
gbM O
correlates O
with O
levels O
and O
patterns O
of O
gene O
expression O

Associated O
data O
tracks O
can O
be O
viewed O
using O
popular O
genome O
browsers O
or O
downloaded O
for O
local O
analysis O

In O
this O
study O
, O
we O
explored O
the O
feasibility O
of O
constructing O
a O
minimized O
epigenetic O
clock O
utilizing O
data O
acquired O
through O
the O
iPlex O
MassARRAY O
technology O

CSCs O
are O
a O
subpopulation O
of O
bulk O
tumors B-Disease
, O
with O
stem O
cell-like O
properties O
and O
tumorigenic O
capabilities O
, O
having O
the O
abilities O
of O
self-renewal O
and O
differentiation O
, O
thereby O
being O
able O
to O
generate O
heterogeneous O
lineages O
of O
cancer B-Disease
cells O
and O
lead O
to O
resistance O
toward O
anti-tumor O
treatments O

Herein O
we O
introduce O
a O
novel O
approach O
for O
epigenetic O
quantitative O
structure-activity O
relationship O
( O
QSAR O
) O
modelling O
using O
conformal O
prediction O

In O
this O
narrative O
review O
, O
we O
discuss O
the O
role O
of O
epigenetic O
factors O
in O
the O
pathogenesis O
of O
psoriasis B-Disease

Macrophages O
are O
the O
first O
immune O
cells O
to O
engage O
and O
clear O
particles O
of O
various O
nature O

A O
detail O
experimental O
protocol O
for O
MS-RAPD-PCR O
is O
described O
in O
this O
chapter O

These O
developments O
lay O
the O
foundation O
for O
understanding O
the O
growing O
significance O
of O
epigenetics O
in O
plant O
stress O
biology O
and O
its O
potential O
to O
mitigate O
the O
detrimental O
effects O
of O
heavy O
metal O
and O
metalloid O
pollution O
on O
global O
agriculture O

We O
also O
outline O
what O
is O
currently O
understood O
about O
the O
public's O
understanding O
and O
opinion O
of O
epigenetics O
, O
DOHaD O
, O
and O
their O
relation O
to O
NCDs O

While O
these O
arrays O
offer O
a O
convenient O
and O
relatively O
robust O
assessment O
of O
the O
probed O
sites O
they O
only O
allow O
interrogation O
of O
2-4% O
of O
all O
CpG O
sites O
in O
the O
human O
genome O

Conclusions O
: O
In O
line O
with O
global O
research O
trends O
, O
further O
extended O
and O
advanced O
epigenetic O
studies O
would O
provide O
crucial O
information O
for O
the O
realization O
of O
comprehensive O
dental B-Disease
medicine I-Disease
and O
expand O
the O
scope O
of O
ongoing O
large-scale O
research O
projects O

In O
addition O
, O
we O
introduce O
a O
novel O
genotype-independent O
test O
to O
detect O
methylation O
imbalance O
between O
chromosomes O

About O
10% O
of O
the O
probes O
on O
the O
arrays O
were O
estimated O
to O
be O
useful O
for O
DNA O
methylation O
assay O
in O
the O
common O
marmoset O

The O
construction O
of O
the O
epigenetic O
clock O
involved O
the O
utilization O
of O
different O
machine-learning O
models O
, O
including O
linear O
models O
, O
deep O
neural O
networks O
( O
DNN O
) O
, O
and O
gradient-boosted O
decision O
trees O
( O
GBDT O
) O

260 O
: O
Genome O
architecture O
varies O
considerably O
among O
eukaryotes O
in O
terms O
of O
both O
size O
and O
structure O
( O
e O

e O

The O
second O
is O
primarily O
from O
the O
basic O
sciences O
, O
particularly O
molecular O
genetics O
, O
and O
regards O
epigenetics O
as O
a O
potentially O
important O
mechanism O
for O
organisms O
exposed O
to O
variable O
environments O
across O
multiple O
generations O

This O
has O
enhanced O
the O
ability O
to O
measure O
the O
biological O
age O
of O
humans O
and O
different O
organisms O
via O
their O
omics O
data O

, O
an O
indicator O
of O
the O
pathological O
process O
leading O
to O
disease B-Disease
) O
is O
unclear O

Zinc O
homeostasis O
is O
regulated O
by O
Zinc O
Transporters O
(ZnTs) O
, O
Zrt- O
and O
Irt-like O
proteins O
(ZIPs) O
, O
and O
the O
zinc O
storage O
protein O
metallothionein O
(MT) O

Future O
studies O
should O
focus O
on O
refined O
measurement O
and O
definition O
of O
prenatal O
stress O
and O
its O
timing O
, O
ideally O
also O
incorporating O
genomic O
as O
well O
as O
longitudinal O
information O

349 O
: O
Background O
: O
A O
common O
issue O
in O
CRISPR-Cas9 O
genome O
editing O
is O
off-target O
activity O
, O
which O
prevents O
the O
widespread O
use O
of O
CRISPR-Cas9 O
in O
medical O
applications O

This O
approach O
is O
outlined O
, O
showing O
a O
gradual O
, O
paradigmatic O
shift O
from O
the O
genecentric O
towards O
an O
epigenetic O
approach O
can O
be O
observed O
in O
the O
'scientific O
landscape O
' O
over O
the O
last O
20 O
years O

These O
new O
approaches O
improve O
the O
assessment O
of O
epigenetic O
diversity O
in O
ecological O
settings O
and O
may O
provide O
functional O
insights O

429: O
Lamarck O
was O
one O
of O
the O
first O
scientists O
who O
attempted O
to O
explain O
evolution O
, O
and O
he O
is O
especially O
well O
known O
for O
formulating O
the O
concept O
that O
acquired O
characteristics O
can O
be O
transmitted O
to O
future O
generations O
and O
may O
therefore O
steer O
evolution O

These O
mechanisms O
are O
critical O
components O
in O
the O
normal O
development O
and O
growth O
of O
cells O

This O
review O
summarizes O
the O
current O
evidences O
on O
the O
relationship O
between O
air O
pollution O
exposure O
, O
epigenetic O
alterations O
and O
cardiovascular O
impact O
, O
in O
view O
of O
present O
implications O
and O
future O
perspectives O


These O
methods O
have O
been O
used O
to O
generate O
base-resolution O
maps O
of O
5mC O
and O
its O
oxidation O
derivatives O
in O
genomic O
samples O

There O
are O
statistical O
challenges O
unique O
to O
DNA O
methylome O
data O
and O
also O
multiple O
features O
, O
which O
can O
be O
exploited O
to O
increase O
power O

Although O
the O
mechanisms O
are O
still O
largely O
unknown O
, O
especially O
in O
humans O
, O
the O
new O
research O
methods O
are O
now O
gradually O
available O
, O
and O
the O
animal O
models O
can O
provide O
more O
in-depth O
study O
of O
mechanisms O

236 O
: O
The O
discovery O
of O
animal O
cloning O
and O
subsequent O
development O
of O
cell O
reprogramming O
technology O
were O
quantum O
leaps O
as O
they O
led O
to O
the O
achievement O
of O
rejuvenation O
by O
cell O
reprogramming O
and O
the O
emerging O
view O
that O
aging O
is O
a O
reversible O
epigenetic O
process O

First O
, O
knowledge O
on O
the O
molecular O
processes O
involved O
in O
tumor B-Disease
progression O
contributes O
to O
molecularize O
medicine O
, O
extending O
genomic O
medicine O

It O
indeed O
provides O
new O
opportunities O
for O
diagnostic O
tools O
and O
innovative O
therapeutic O
targets O
in O
order O
to O
improve O
the O
prognosis O
of O
patients O
affected O
by O
these O
rare O
tumors B-Disease
, O
in O
particular O
in O
the O
context O
of O
metastatic O
diseases O
associated O
with O
SDHB O
mutations O

Genetic O
factors O
are O
not O
associated O
with O
distinct O
psychiatric B-Disease
disorders I-Disease
, O
but O
rather O
diverse O
clinical O
phenotypes O

Remarkably O
, O
nearly O
all O
neuronal O
nuclei O
that O
reside O
in O
an O
aged O
brain O
had O
permanently O
exited O
from O
the O
cell O
cycle O
during O
prenatal O
development O
, O
and O
DNA O
methylation O
and O
histone O
modifications O
and O
other O
molecular O
constituents O
of O
the O
epigenome O
are O
likely O
to O
play O
a O
critical O
role O
in O

Epigenetics O
may O
well O
constitute O
this O
missing O
link O
to O
include O
DNA O
methylation O
, O
histone O
changes O
, O
and O
microRNA O
which O
contribute O
to O
the O
epigenome O
characterizing O
specific O
diseases O

The O
reversal O
of O
DNA O
hypomethylation O
by O
inhibiting O
the O
polyamine O
recycling O
pathway O
was O
suggested O
as O
new O
epigenetic O
therapy O
in O
RA O

Emphasis O
is O
given O
in O
this O
article O
, O
through O
the O
use O
of O
case O
studies O
, O
to O
socially O
disadvantaged O
communities O
that O
are O
often O
under-represented O
in O
scientific O
literature O

In O
summary O
, O
EpiProfile O
2 O

At O
the O
moment O
, O
epigenetic O
biomarkers O
for O
RCC O
are O
not O
being O
used O
in O
clinical O
practice O
, O
but O
targeted O
epigenetic O
therapies O
are O
under O
investigation O

Furthermore O
, O
upcoming O
high-throughput O
epigenomic O
studies O
, O
which O
will O
add O
greatly O
to O
our O
knowledge O
concerning O
the O
impact O
of O
epigenetic O
modifications O
on O
pig O
immune O
response O
, O
are O
listed O
in O
this O
review O

There O
is O
a O
need O
for O
analytical O
methods O
that O
can O
more O
sensitively O
detect O
differential O
methylation O
profiles O
present O
in O
subsets O
of O
individuals O
from O
these O
heterogeneous O
, O
population-level O
datasets O

The O
mechanistic O
uncertainty O
of O
intraovarian O
PRP O
notwithstanding O
, O
at O
least O
two O
other O
major O
challenges O
confront O
this O
controversial O
intervention O

Head O
and O
neck O
cancers B-Disease
are O
a O
group O
of O
malignancies B-Disease
with O
diverse O
biological O
behaviors O
and O
a O
strong O
, O
well-established O
association O
with O
environmental O
effects O

We O
introduce O
a O
schematic O
, O
analytically O
solvable O
mathematical O
model O
to O
compare O
the O
adaptive O
value O
of O
different O
schemes O
of O
inheritance O

Although O
genetic O
data O
are O
often O
collected O
in O
epigenetic O
studies O
of O
large O
cohorts O
, O
these O
are O
typically O
not O
made O
publicly O
available O
, O
making O
the O
application O
of O
EPISTRUCTURE O
especially O
useful O
for O
anyone O
working O
on O
public O
data O

536 O
: O
Background O
: O
It O
has O
been O
estimated O
that O
a O
substantial O
portion O
of O
chronic O
and O
noncommunicable O
diseases O
can O
be O
caused O
or O
exacerbated O
by O
exposure O
to O
environmental O
chemicals O

We O
show O
that O
enzymatic O
cytosine O
conversion O
better O
preserves O
cfDNA O
fragmentation O
information O
than O
does O
bisulfite O
conversion O

We O
anticipate O
that O
the O
development O
of O
CRISPR O
based O
technology O
will O
continue O
to O
explore O
novel O
methods O

We O
propose O
that O
just O
as O
it O
has O
potential O
for O
regenerative O
medicine O
and O
disease B-Disease
modeling O
, O
cell O
reprogramming O
could O
also O
be O
a O
powerful O
tool O
for O
dissecting O
the O
role O
of O
the O
cancer B-Disease
epigenome O
in O
the O
development O
and O
maintenance O
of O
cancer B-Disease
cells O

To O
improve O
the O
pig O
's O
robustness O
and O
resilience O
against O
pathogens O
through O
selection O
, O
a O
better O
understanding O
of O
the O
genetic O
and O
epigenetic O
factors O
in O
the O
immune O
response O
is O
required O

However O
, O
very O
few O
studies O
have O
evaluated O
this O
from O
the O
perspective O
of O
epigenetics O

The O
advent O
and O
success O
of O
molecular O
biology O
have O
probably O
contributed O
to O
focusing O
biologists' O
attention O
on O
the O
"genetic" O
or O
the O
"non-genetic" O
over O
the O
"developmental" O

The O
laboratory O
is O
involved O
in O
the O
development O
and O
application O
of O
technologies O
to O
analyze O
DNA O
methylation O
, O
miRNAs O
and O
other O
epigenetic O
modifications O
quantitatively O
at O
high O
resolution O
at O
target O
loci O
and O
genome-wide O
using O
state-of-the-art O
sequencing O
technologies O
as O
well O
as O
the O
development O
of O
bioinformatic O
tools O
for O

This O
method O
has O
been O
successfully O
used O
to O
detect O
changes O
in O
DNA O
methylation O
either O
occurring O
naturally O
or O
induced O
by O
various O
toxicants O
and O
environmental O
factors O

Here O
, O
we O
resolve O
the O
DNA O
methylome O
across O
CpG O
, O
CHG O
, O
and O
CHH-methylation O
contexts O
in O
the O
loblolly O
pine O
tree O
( O
Pinus O
taeda O
) O
and O
construct O
epigenetic O
clocks O
capable O
of O
predicting O
ages O
in O
this O
species O
within O
6% O
of O
its O
maximum O
lifespan O

New O
datasuggest O
that O
not O
only O
is O
it O
ubiquitous O
, O
but O
both O
the O
generationand O
the O
transmission O
of O
epigenetic O
variations O
may O
be O
affectedby O
developmental O
conditions O

Using O
both O
genomic O
sequence O
and O
methylation O
information O
as O
the O
input O
, O
MAPLE O
predicts O
activity O
for O
each O
gene O
, O
which O
can O
be O
used O
to O
integrate O
with O
transcriptome O
data O
from O
the O
same O
cell O
types O

Here O
, O
we O
report O
that O
natural O
and O
D-galactose O
( O
D-gal O
) O
- O
induced O
aging O
kidneys O
display O
marked O
suppression O
of O
antiaging O
factor O
NRF2 O
( O
nuclear O
factor O
erythroid-derived O
2-like O
2 O
) O
and O
KLOTHO O
, O
accompanied O
by O
upregulations O
of O
DNA O
methyltransferase O
( O
DNMT O
) O

388 O
: O
Age O
is O
a O
fundamental O
aspect O
of O
animal O
ecology O
, O
but O
is O
difficult O
to O
determine O
in O
many O
species O

However O
, O
little O
is O
known O
about O
how O
DNA O
methylation O
status O
changes O
over O
time O
under O
ordinary O
environmental O
and O
clinical O
conditions O


The O
finding O
that O
fresh O
activated O
platelet O
releasate O
includes O
factors O
able O
to O
promote O
developmental O
signaling O
networks O
necessary O
to O
enable O
cell O
pluripotency O
tends O
to O
support O
this O
theory O

154 O
: O
Radiotherapy O
( O
RT O
) O
is O
one O
of O
the O
mainstay O
treatments O
for O
prostate B-Disease
cancer I-Disease
( O
PCa O
) O
, O
a O
highly O
prevalent O
neoplasm O
among O
males O
worldwide O

Recently O
, O
DNA O
methylation O
has O
attracted O
much O
attention O
due O
to O
the O
discovery O
of O
5-hydroxymethyl-cytosine O
and O
its O
role O
in O
epigenetic O
reprogramming O
and O
pluripotency O

Analysis O
results O
are O
returned O
to O
Google O
Cloud O
buckets O
for O
storage O
and O
visualization O
, O
removing O
the O
computational O
strain O
from O
local O
resources O

14 O
; O
95 O
% O
confidence O
interval O
(CI) O
= O
1 O

He O
has O
authored O
over O
100 O
peer-reviewed O
manuscripts O
, O
book O
chapters O
and O
review O
articles O
, O
and O
is O
on O
the O
editorial O
board O
of O
several O
journals O
in O
his O
field O

404 O
: O
Recent O
clinical O
studies O
document O
the O
power O
of O
immunotherapy O
in O
treating O
subsets O
of O
patients O
with O
advanced O
cancers B-Disease

MeDIP O
uses O
an O
antibody O
raised O
against O
5-methylcytosine O
to O
capture O
methylated O
fragments O
of O
DNA O
, O
which O
are O
subsequently O
sequenced O
to O
envisage O
the O
methylome O
landscape O

104 O
: O
DNA O
methylation O
is O
reconfigured O
during O
male O
reproduction O
in O
plants O
, O
but O
little O
is O
known O
regarding O
the O
mechanisms O
controlling O
these O
epigenetic O
dynamics O

However O
, O
three O
areas O
of O
development O
suggest O
where O
epigenetic O
data O
protection O
may O
prove O
problematic O

This O
review O
provides O
an O
overview O
of O
the O
most O
common O
methods O
of O
analysing O
DNA O
methylation O
in O
animals O
, O
when O
they O
are O
appropriate O
, O
what O
resolution O
of O
information O
they O
can O
provide O
and O
what O
their O
limitations O
are O

However O
, O
certain O
pro-angiogenic O
proteins O
tend O
to O
bypass O
the O
inhibition O

Family O
clusters O
of O
nonagenarian O
and O
centenarian O
siblings O
, O
who O
show O
both O
exceptional O
age-span O
and O
health-span O
, O
are O
likely O
to O
have O
inherited O
facilitatory O
gene O
groups O
, O
but O
also O
have O
nine O
decades O
of O
life O
experiences O
and O
behaviours O
which O
have O
interacted O
with O
their O
genetic O
profiles O

Mechanistically O
, O
we O
discuss O
the O
increasingly O
well-understood O
molecular O
pathways O
responsible O
for O
epigenetic O
inheritance O
, O
with O
a O
focus O
on O
the O
unusual O
features O
of O
the O
germline O
epigenome O

We O
conclude O
by O
offering O
two O
examples O
of O
modern O
state-of-the-art O
integrated O
multi-omics O
studies O
of O
epigenetics O
in O
disease B-Disease
pathogenesis O
, O
one O
which O
sought O
to O
capture O
shared O
mechanisms O
among O
multiple O
diseases O
, O
and O
another O
which O
used O
epigenetic O
big O
data O
to O
better O
understand O
the O
pathogenesis O
of O
a O

This O
chapter O
discusses O
the O
advantages O
and O
disadvantages O
of O
various O
methylome O
detection O
approaches O
to O
assess O
which O
is O
appropriate O
for O
the O
question O
at O
hand O

bio-data O

The O
knowledge O
upon O
which O
these O
claims O
are O
based O
is O
beginning O
to O
expand O

In O
this O
review O
, O
we O
summarize O
the O
basics O
of O
epigenome O
editing O
and O
cancer B-Disease
epigenetics O
, O
followed O
by O
the O
current O
examples O
of O
cancer B-Disease
induction O
and O
suppression O
with O
the O
transcriptional O
control O
and O
epigenome O
editing O
technologies O

In O
germ O
cells O
and O
the O
developing O
embryo O
, O
genome-wide O
epigenetic O
reprogramming O
drives O
the O
erasure O
and O
reestablishment O
of O
correct O
epigenetic O
patterns O
at O
critical O
developmental O
time O
periods O
and O
in O
specific O
cell O
types O

The O
latter O
underlines O
how O
complexity O
can O
be O
assembled O
differently O
across O
distinct O
configurations O
of O
experimental O
work O

In O
this O
review O
, O
we O
examine O
key O
questions O
concerning O
epigenetic O
mechanisms O
in O
regulating O
the O
expression O
of O
genes O
associated O
with O
brain O
aging O
and O
age-related O
cognitive O
decline O

This O
memory O
is O
induced O
in O
the O
hematopoietic O
niche O
and O
propagated O
to O
daughter O
cells O
, O
generating O
epigenetically O
and O
metabolically O
reprogrammed O
innate O
immune O
cells O
that O
are O
greatly O
enhanced O
in O
their O
capacity O
to O
resolve O
inflammation B-Disease

This O
results O
in O
substantial O
individual O
differences O
even O
between O
identical O
twins O

Over O
his O
entire O
life O
Darwin O
has O
modified O
and O
reassessed O
his O
views O
on O
habits O
as O
many O
times O
as O
required O
by O
evidence O
: O
his O
work O
on O
this O
notion O
may O
represent O
the O
paradigm O
of O
a O
habit O
of O
good O
scientific O
research O
methodology O

Overlapping O
genes O
in O
comparison O
2 O
affected O
paralogue O
genes O
involved O
in O
processes O
such O
as O
neural O
crest O
differentiation O
and O
ectoderm O
differentiation O

Epigenetic O
influences O
provide O
a O
fashionable O
contemporary O
explanation O
for O
such O
seemingly O
random O
processes O

481 O
: O
Human O
longevity O
is O
a O
complex O
trait O
and O
increasingly O
we O
understand O
that O
both O
genes O
and O
lifestyle O
interact O
in O
the O
longevity O
phenotype O

543 O
: O
Humans O
share O
96 O
% O
of O
our O
30,000 O
genes O
with O
Chimpanzees O

In O
addition O
to O
influencing O
how O
doctors O
treat O
diseases O
, O
discoveries O
about O
behavioral O
epigenetics O
are O
likely O
to O
alter O
how O
biologists O
think O
about O
evolution O
, O
because O
some O
epigenetic O
effects O
of O
experience O
appear O
to O
be O
transmissible O
from O
generation O
to O
generation O

We O
develop O
a O
new O
methodology O
conceived O
to O
extract O
the O
best O
information O
from O
such O
super-resolution O
data O
by O
exploiting O
the O
whole O
distribution O
of O
gyration O
radii O
, O
and O
to O
place O
these O
experimental O
results O
on O
a O
theoretical O
framework O

353 O
: O
DNA O
methylation O
analysis O
has O
become O
an O
integral O
part O
of O
biomedical O
research O

568 O
: O
Epigenetic O
changes O
are O
required O
for O
normal O
development O
, O
yet O
the O
nature O
and O
respective O
contribution O
of O
factors O
that O
drive O
epigenetic O
variation O
in O
humans O
remain O
to O
be O
fully O
characterized O

A O
few O
computational O
methods O
have O
been O
proposed O
for O
quantitative O
modeling O
of O
landscape O
; O
however O
, O
to O
model O
and O
visualize O
the O
landscape O
of O
a O
high O
dimensional O
gene O
regulatory O
system O
with O
realistic O
details O
is O
still O
challenging O

At O
last O
, O
future O
directions O
and O
limitations O
are O
highlighted O

Multiple O
cell O
surface O
and O
enzymatic O
markers O
have O
been O
characterized O
to O
identify O
CSCs O
within O
a O
heterogeneous O
tumor B-Disease
, O
and O
here O
we O
summarize O
ongoing O
preclinical O
and O
clinical O
efforts O
to O
therapeutically O
target O
these O
cells O
and O
improve O
patient O
outcomes O

For O
information O
on O
Kammerer's O
work O
he O
resorts O
to O
a O
popular O
science O
book O
( O
Kammerer O
, O
'24 O

We O
will O
also O
discuss O
the O
pathological O
implications O
of O
3D O
genome O
folding O

Whether O
directly O
or O
indirectly O
, O
arsenic O
modulates O
epigenetic O
gene O
regulation O
and O
our O
understanding O
of O
the O
direct O
effect O
of O
this O
modulation O
on O
chromatin O
structure O
is O
limited O

Conway's O
Game O
of O
Life O
has O
been O
widely O
used O
for O
this O
purpose O

Recent O
technological O
advances O
offer O
a O
better O
understanding O
of O
the O
underlying O
epigenetic O
alterations O
during O
carcinogenesis O
and O
provide O
insight O
into O
the O
discovery O
of O
putative O
epigenetic O
biomarkers O
for O
detection O
, O
prognosis O
, O
risk O
assessment O
, O
and O
disease B-Disease
monitoring O

Further O
, O
concordance O
rates O
in O
monozygotic O
twins O
are O
significantly O
higher O
compared O
to O
dizygotic O
sets O
while O
being O
significantly O
below O
50% O
for O
most O
autoimmune O
diseases O

DNA O
methylation O
is O
the O
most O
frequent O
epigenetic O
alteration O
observed O
in O
mammalian O
genomes O
, O
and O
generally O
it O
is O
negatively O
correlated O
with O
gene O
expression O

Epigenetics O
is O
the O
study O
of O
changes O
which O
occur O
in O
an O
organism O
due O
to O
changes O
in O
expression O
of O
the O
genetic O
code O
rather O
than O
changes O
to O
the O
genetic O
code O
itself O
; O
that O
is O
, O
epigenetic O
mechanisms O
impact O
upon O
the O
function O
of O
DNA O
without O
changing O
the O
DNA O
sequence O

However O
, O
even O
genome-wide O
association O
studies O
explain O
only O
a O
fraction O
of O
phenotypic O
variability O
not O
resolving O
the O
problem O
of O
" O
lost O
heritability O
" O

These O
mitotically O
stable O
and O
meiotically O
heritable O
changes O
are O
sensitive O
to O
environmental O
conditions O
especially O
during O
developmental O
periods O
, O
and O
they O
are O
essential O
to O
understanding O
how O
information O
in O
the O
DNA O
sequence O
is O
utilized O

We O
highlight O
the O
advantages O
of O
liquid O
biopsy O
based O
DNA-methylation O
profiling O
for O
noninvasive O
diagnosis O
of O
early O
stage O
cancers B-Disease
and O
discuss O
the O
advanced O
analytical O
approaches O
developed O
by O
commercial O
and O
academic O
partnerships O

Research O
has O
identified O
epigenetic O
mechanisms O
mediating O
between O
environmental O
and O
psychological O
factors O
that O
contribute O
to O
normal O
and O
abnormal O
behavioral O
development O

The O
concept O
of O
induced O
proximity O
has O
inspired O
the O
development O
of O
powerful O
tools O
for O
epigenetic O
research O

When O
comparing O
with O
other O
open-source O
target O
identification O
tools O
, O
it O
was O
found O
that O
only O
our O
tool O
was O
able O
to O
accurately O
predict O
all O
the O
targets O
corresponding O
to O
each O
compound O

Biological O
functions O
, O
such O
as O
epigenetic O
processes O
, O
are O
affected O
by O
all O
these O
causal O
factors O
and O
extend O
throughout O
the O
life O
course O

585 O
: O
The O
epigenetics O
community O
was O
an O
early O
adopter O
of O
next O
generation O
sequencing O
( O
NGS O
) O

com O
/ O
NetLand-NTU O
/ O
HopLand O

We O
studied O
the O
Arabidopsis O
thaliana O
ecotype O
Columbia O
plants O
exposed O
to O
cold O
stress O
for O
25 O
continuous O
generations O

Recent O
findings O
: O
Complementary O
approaches O
uncovered O
close O
links O
between O
circulating O
lipids O
and O
epigenetic O
mechanisms O
at O
multiple O
levels O

Finally O
, O
the O
authors O
outline O
the O
potential O
for O
misuse O
of O
this O
technology O
and O
suggest O
that O
well-informed O
policy O
could O
play O
a O
critical O
role O
in O
shaping O
the O
optimal O
implementation O
of O
epigenetic O
technologies O

org O
/ O
groups O
/ O
biolabs O
/ O
tools O
/ O
jbr O
- O
genome O
- O
browser O

Epigenetic O
processes O
act O
to O
dynamically O
control O
gene O
expression O
independently O
of O
DNA O
sequence O
variation O
and O
are O
known O
to O
regulate O
key O
neurobiological O
and O
cognitive O
processes O
in O
the O
brain O

495 O
: O
In O
mice O
, O
epiblast O
cells O
found O
both O
the O
germ-line O
and O
somatic O
lineages O
in O
the O
developing O
embryo O
